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1. 
WWOX: A TUMIOR SUPPRESSOR GENE 
MUTATED IN MULTIPLE CANCERS 
The present application claims priority to U.S. Provisional 
Patent Application Ser. No. 60/240,277 filed Oct. 13, 2000 5 
now abandoned. The entire text of the above-referenced 
disclosure is specifically incorporated by reference herein 
without disclaimer. 
The government may own rights in the present invention 
pursuant to grant number DAMD 17-94-J-4078 from the 
Breast Cancer Research Program sponsored by the Depart 
ment of the Defense, U.S. Army Medical Research and 




BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the fields of 
molecular biology, oncology and gene therapy. More par 
ticularly, it concerns the identification of a novel tumor 
suppressor gene, WWOX, which is mutated in several 
cancers. The invention provides methods of utilizing the 
tumor Suppressor gene as a cancer diagnostic tool. The 
invention also provides methods to identify patients with a 
higher Susceptibility to certain cancer types involving the 
status of the WWOX tumor suppressor. Furthermore, the 
invention provides methods for the treatment of cancers 
comprising administering a therapeutic nucleic acid and/or 
polypeptides based on the tumor suppressor gene. 
2. Description of Related Art 
Second only to heart disease, cancer is the leading cause 
of death in the United States, striking one in two men and 
one in three women (Landis, 1998). Normal tissue homeo 
Stasis is a highly regulated process of cell proliferation and 
cell death. The development of cancer is the culmination of 
complex, multistep biological processes, occurring through 
the accumulation of genetic alteration which typically cause 
an imbalance in the genes controlling either cell prolifera 
tion or cell death. Many if not all of these alterations involve 
specific cellular growth-controlling genes that are mutated. 
These genes typically fall into two categories: proto-onco 
genes and tumor Suppressor genes. Mutations in genes of 
either class generally lead to abnormal cell-growth and 
result in cancers. 
The function of tumor Suppressor genes is to antagonize 
cellular proliferation. When a tumor Suppressor gene is 
inactivated, for example by mutations such as deletions or 
point mutations, the cells regulatory machinery for control 
ling growth is upset. Several studies have shown that the 50 
neoplastic tendencies of Such mutated cells can be Sup 
pressed by the addition of a nonmutated (wild-type) version 
of the tumor Suppressor gene that expresses its gene product 
(Levine, 1995). For example, a point mutation in the p53 
tumor Suppressor protein results in the complete loss of 55 
wild-type p53 function (Vogelstein and Kinzler, 1992) and 
acquisition of 'dominant tumor promoting function. 
Currently, there are few effective options for the diagnosis 
and treatment of many common cancer types. The most 
conventional options of cancer treatment are Surgery, radia- 60 
tion therapy and chemotherapy. Typically, Surgical methods 
are used for the diagnosis (by Surgical biopsy) and treatment 
of cancer (Surgery to remove cancerous growths). However, 
if the cancer has metastasized and is widespread, Surgery is 
unlikely to result in a cure and an alternate approach must be 65 
taken. Radiation therapy, chemotherapy and immunotherapy 







1989; Ho et al., 1998). However, both radiation therapy and 
chemotherapy are associated with numerous side effects 
since normal cells are also affected and these include skin 
irritation, difficulty Swallowing, dry mouth, nausea, diar 
rhea, hair loss, mouth Sores, fatigue, bleeding to name a few. 
Immunotherapy, a rapidly evolving area in cancer research, 
is yet another option for the treatment of certain types of 
cancers which unfortunately has not been Sufficient to pre 
vent most tumor growths. 
Gene therapy is another emerging field in biomedical 
research with a focus on the treatment of disease by the 
introduction of therapeutic recombinant nucleic acids into 
Somatic cells of patients. Various clinical trials using gene 
therapies have been initiated and include the treatment of 
various cancers, AIDS, cystic fibrosis, adenosine deaminase 
deficiency, cardiovascular disease, Gaucher's disease, rheu 
matoid arthritis, and others. 
While there are some gene therapies for cancer treatments 
in clinical trials, not all cancer causing genes have been 
identified. As mutations in oncogenes and tumor-suppressor 
genes are the major causes for loss of cell-cycle control, 
there is a growing need to identify more genes of these two 
classes. Some examples of the tumor Suppressor genes 
targeted for anticancer genetherapies are p53 and retinoblas 
toma. However, not all cancers are due to mutations of these 
two genes. Given the diverse types of cancers and the large 
population affected by cancer there is need to identify more 
Such tumor Suppressor genes involved in cancer to find 
better and effective anticancer treatments. 
SUMMARY OF THE INVENTION 
The present invention seeks to overcome drawbacks 
inherent in the art by disclosing the cloning and character 
ization of a novel gene, mutated versions of which are 
expressed in cancer cells. The invention further provides 
nucleic acids, polypeptides, proteins encoded by this gene 
and antibodies towards various WWOX polypeptides and 
proteins. The invention also encompasses methods of mak 
ing and using such nucleic acids and the related polypep 
tides, proteins and antibodies. Furthermore, the invention 
provides methods for the diagnosis, detection, prognosis and 
treatment of cancers using one or more of the foregoing 
compositions. 
Thus, the invention describes the isolation of a novel gene 
named WWOX. The WWOX gene is identified to be a tumor 
Suppressor gene. Mutations of this gene are found to be 
expressed in the several tumor samples and in several 
cancer/tumor cell lines. Some of the mutations are alterna 
tively or abnormally spliced forms. For example, in some of 
the alternatively spliced forms the central exons of the wild 
type transcript are found deleted (usually exons 5, 6, 7 and 
8). Other mutations include hemizygous deletions of the 
WWOX locus that were identified in the vast majority of 
breast cancer lines analyzed (>80%). In addition, homozy 
gous deletions were also found in coding and non-coding 
regions of the gene (i.e. intronic regions). 
In one embodiment, the invention provides an isolated 
and purified polynucleotide comprising a nucleic acid 
sequence encoding a WWOX polypeptide. In another 
embodiment, the polynucleotide comprises a nucleic acid 
sequence encoding SEQ ID NO:2, SEQ ID NO:31, or SEQ 
ID NO:33. In yet another embodiment, the polynucleotide 
comprises SEQ ID NO:1, SEQ ID NO:30, or SEQ ID 
NO:32. It is contemplated that any other WWOX nucleic 
acid or protein sequence may be used in conjunction with 
this invention. 
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In one embodiment, the polynucleotide described above, 
comprises a nucleic acid sequence that encodes at least 90 
contiguous amino acid residues of SEQID NO:2. In another 
embodiment the polynucleotide comprises a nucleic acid 
sequence encoding at least 150 contiguous amino acid 
residues of SEQ ID NO:2. In yet another embodiment, the 
polynucleotide comprises at least 1.5 contiguous kilobases 
of SEQ ID NO:1. 
The invention also provides an expression vector com 
prising a nucleic acid sequence encoding a WWOX 
polypeptide. In one embodiment, the expression vector 
comprises the nucleic acid sequence encoding SEQ ID 
NO:2. In another embodiment, the expression vector com 
prises the nucleic acid sequence comprising SEQ ID NO:1. 
In yet other embodiments, the expression vector comprises 
the nucleic acid sequence comprising at least 1.5 contiguous 
kilobases of SEQ ID NO:1. In a related embodiment, the 
expression vector comprises a nucleic acid sequence encod 
ing at least 90 contiguous amino acids of SEQ ID NO:2. 
In further aspects of this embodiment of the invention, the 
expression vector further comprises a promoter operably 
linked to the WWOX-encoding nucleic acid sequence. In 
one related aspect, the promoter is heterologous. In another 
related aspect, the promoter is a constitutive promoter, a 
tissue-specific promoter, an inducible promoter, or a nonin 
ducible promoter. 
In one embodiment, the expression vector is a viral vector. 
In a specific aspect of this embodiment, the viral vector is a 
vaccinia virus, adenovirus, herpesvirus, retrovirus, cytome 
galovirus, or adeno-associated virus. 
The invention also provides a recombinant host cell 
comprising a nucleic acid sequence encoding a WWOX 
polypeptide. In a specific aspect of this embodiment, the 
polypeptide comprises SEQ ID NO:2. In another specific 
aspect of this embodiment the nucleic acid sequence com 
prises SEQ ID NO:1. 
The invention also provides several methods for preparing 
recombinant WWOX encoding polypeptides. Thus, in one 
embodiment a method of preparing recombinant WWOX is 
described that comprises: (a) transfecting a cell with a 
polynucleotide comprising a nucleic acid sequence encoding 
a WWOX polypeptide to produce a transformed host cell; 
and (b) maintaining the transformed host cell under biologi 
cal conditions sufficient for expression of the WWOX 
polypeptide in the host cell. In a specific aspect of this 
method the nucleic acid sequence encodes SEQID NO:2. In 
another specific aspect of this method the nucleic acid 
sequence comprises SEQID NO:1. In a related embodiment 
of the method, the polynucleotide is comprised in a vector. 
The invention also provides animal model studies which 
demonstrate the tumor suppressor properties of WWOX in 
vivo. In mice models of breast cancer, injection of vectors 
expressing WWOX supressed tumor growth in mice when 
compared to mice that were injected with control vectors. As 
the WWOX gene is a tumor suppressor gene with antican 
cer/antitumor properties, the inventors envision several 
therapeutic methods for anticancer therapies. Thus, the 
invention describes a method of treating a pre-cancer or 
cancer cell comprising providing to the cell an amount of a 
WWOX polypeptide effective to induce apoptosis in the cell. 
In one aspect of this method, the WWOX polypeptide is 
provided to the cell by administering an expression vector 
comprising a polynucleotide encoding a WWOX polypep 
tide under the transcriptional control of a promoter. In 
specific aspects of this method, the cell is a bladder, blood, 
bone, bone marrow, brain, breast, central nervous system, 













nasopharynx, neck, ovary, prostate, skin, stomach, or uterus 
cell. In other specific embodiments of this method, the 
expression vector comprises a viral vector. 
The invention also discloses a method of treating a subject 
having a hyperproliferative condition comprising contacting 
a cell within the Subject with an expression vector compris 
ing a polynucleotide encoding an WWOX polypeptide under 
the transcriptional control of a promoter, wherein expression 
of the WWOX polypeptide confers a therapeutic benefit on 
the Subject. The term contacting as used in this specifica 
tion also includes administering, delivering and/or provid 
ing. 
In one embodiment of the method, the cell is a cancer or 
pre-cancer cell. In a specific aspect of this embodiment, the 
cancer or pre-cancer cell is selected from a group consisting 
of a bladder, blood, bone, bone marrow, brain, breast, colon, 
esophagus, gastrointestine, head, kidney, liver, lung, 
nasopharynx, neck, ovary, prostate, skin, stomach, and 
uterus cell. In other aspects, the cancer or pre-cancer cell is 
derived from or is part of a solid tumor. In another embodi 
ment of the method, the cell is involved with restenosis, 
primary psoriasis, angiogenesis, rheumatoid arthritis, 
inflammatory bowel disease, psoriasis, eczema, secondary 
cataracts, or bronchial dysplasia. In some embodiments of 
the method, the contacting occurs in vitro. In other embodi 
ments, the contacting occurs in vivo. As described above the 
term contacting as used in this specification also includes 
administering, delivering, and/or providing. In one embodi 
ment of the method, the expression vector is delivered 
endoscopically, intravenously, intralesionally, percutane 
ously, or subcutaneously. In another embodiment, the 
expression vector is delivered by direct injection into the 
tumor. In yet other embodiments, the expression vector 
comprises a viral vector. In specific aspects of this embodi 
ment, the viral vector is a vaccinia virus, adenovirus, herp 
esvirus, retrovirus, cytomegalovirus, or adeno-associated 
virus. 
In one embodiment of this method, the contacting is 
performed at least twice. In other aspects of this embodi 
ment, the second contacting follows the first by a period of 
about one day to one year. 
The invention also contemplates methods for anticancer 
therapies wherein the therapies using WWOX encoding 
nucleic acids and or peptides are in combination or con 
junction with other anticancer therapies. Thus, in one aspect 
the method described above further comprises contacting the 
tumor with an anticancer therapy. This anticancer treatment 
can be any one or more of the following: chemotherapy, 
immunotherapy, Surgery, radiotherapy, gene therapy with a 
second therapeutic polynucleotide other than a polynucle 
otide encoding the WWOX polypeptide, or other biotherapy. 
In further embodiments, chemotherapy involving at least 
one DNA damaging agent is implemented in combination 
with administration of an WWOX encoding nucleic acid 
molecule. The DNA damaging agent may be gamma-irra 
diation, X-rays, UV-irradiation, microwaves, electronic 
emissions, adriamycin, 5-fluorouracil (5FU), etoposide (VP 
16), camptothecin, actinomycin-D, mitomycin C, cisplatin 
(CDDP), or hydrogen peroxide. In further embodiments, the 
DNA damaging agent is adriamycin. While in other embodi 
ments, the chemotherapy comprises a cisplatin (CDDP), 
carboplatin, procarbazine, mechlorethamine, cyclophospha 
mide, camptothecin, ifosfamide, melphalan, chlorambucil, 
bisulfan, nitroSurea, dactinomycin, daunorubicin, doxorubi 
cin, bleomycin, plicomycin, mitomycin, etoposide (VP16), 
tamoxifen, taxotere, taxol, transplatinum, 5-fluorouracil, 
Vincristin, vinblastin, or methotrexate or any analog or 
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derivative variant thereof. In one aspect of the invention, the 
chemotherapy comprises tamoxifen, while in another aspect 
is it comprises adriamycin. Further embodiments involve 
immunotherapy, such as Herceptin. In cases involving a 
cancerous tumor, a combination treatment may involve 
administration of a nucleic acid molecule encoding a 
WWOX polypeptide and tumor resection, which may occur 
before, after, or during the WWOX gene therapy adminis 
tration. If WWOX treatment occurs after tumor resection, 
the expression construct or vector encoding WWOX may be 
administered to the tumor bed. 
In yet other aspects of the method, the expression vector 
is contacted with the tumor prior to, at the same time as, or 
after contacting with the anticancer treatment. 
In one embodiment, the method is used when the endog 
enous WWOX polypeptide of the cancer cell is mutated. 
The invention also describes a method of treating a 
Subject having pre-cancer or cancer comprising contacting a 
pre-cancer or cancer cell within the Subject with an expres 
sion vector comprising a polynucleotide encoding WWOX 
polypeptide under the transcriptional control of a promoter, 
wherein expression of the WWOX polypeptide is at a level 
effective to kill the cell, thereby conferring a therapeutic 
benefit on the subject. 
The invention further discloses a method of treating 
cancer in a cancer patient, comprising administering to a 
tumor site therapeutically effective amounts of an expression 
vector and an anticancer agent, wherein the expression 
vector comprises a polynucleotide encoding an WWOX 
polypeptide under the transcriptional control of a promoter, 
and wherein expression of the WWOX polypeptide and 
anticancer agent results in treatment of the cancer. 
Yet another method described in the invention concerns 
arresting the cell cycle of a mammalian cancer cell com 
prising contacting the cell with an expression vector com 
prising a polynucleotide sequence encoding an WWOX 
polypeptide under the transcriptional control of a promoter, 
wherein expression of the WWOX polypeptide results in the 
cell cycle arrest of the cancer cell. 
The invention also discloses another method for treating 
microscopic residual cancer comprising the steps of: (i) 
identifying a patient having a resectable tumor; (ii) resecting 
the tumor; and (iii) contacting the tumor bed with an 
expression vector comprising a promoter functional in 
eukaryotic cells and a polynucleotide encoding an WWOX 
polypeptide, wherein the polynucleotide is under the tran 
Scriptional control of a promoter. 
The invention further describes a method for treating a 
Subject having a tumor comprising the steps of: (i) Surgically 
revealing the tumor, and (ii) contacting the tumor with an 
expression vector comprising a promoter functional in 
eukaryotic cells and a polynucleotide encoding an WWOX 
polypeptide, wherein the polynucleotide is under the tran 
Scriptional control of a promoter. 
Yet another method described herein comprises a method 
for treating a Subject having a tumor comprising the step of 
perfusing the tumor, over an extended period of time, with 
an expression vector comprising a promoter functional in 
eukaryotic cells and a polynucleotide encoding an WWOX 
polypeptide, wherein the polynucleotide is under the tran 
Scriptional control of a promoter. 
In addition the invention describes a method of treating a 
Subject having pre-cancer or cancer comprising administer 
ing a pre-cancer or cancer cell within the Subject a first 
expression vector comprising a polynucleotide encoding an 
WWOX polypeptide under the transcriptional control of a 













within the Subject a second expression vector comprising a 
polynucleotide encoding a wild-type tumor suppressor 
polypeptide under the transcriptional control of a promoter. 
In one aspect of this method, the first expression vector and 
the second expression vector are administered at the same 
time. 
The invention also provides a method of killing a human 
cell comprising contacting the cell with an expression vector 
comprising a polynucleotide sequence encoding an WWOX 
polypeptide under the transcriptional control of a promoter, 
wherein expression of the WWOX polypeptide results in the 
killing of the cell. 
A cancer includes diseases and conditions that are asso 
ciated with any sort of abnormal cell growth or abnormal 
growth regulation. This includes but is not limited to tumors, 
precancerous lesions, pre-cancer cells, carcinomas, malig 
nant cancers, microscopic residual cancers as some 
examples. 
Nucleic acid molecules of the present invention may 
contain sequences encoding a full-length, human WWOX 
gene, as disclosed in SEQ ID NO:1. In some embodiments 
of the invention, a nucleic acid molecule may encode fewer 
nucleotides than is depicted in SEQ ID NO:1, such that the 
molecule contains fewer than 1245 contiguous nucleotides 
from SEQ ID NO:1. In some aspects, a nucleic acid mol 
ecule may contain about 50, 60, 70, 80, 85, 86, 87, 88, 89, 
90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 
610, 617, 650, 675, 700, 750, 800, 850, 900, 950, 1000, 
1050, 1100, 1150, 1200, 1210, 1220, 1230, 1240 contiguous 
nucleotides from SEQ ID NO:1. In additional aspects, 
specific coding fragments for functional domains of WWOX 
include two WW-domain coding regions, one of these is 
from nucleotide +55 to +142 (87 contiguous nucleotides 
from SEQ ID NO:1) and the other is +175 to +264 (89 
contiguous nucleotides from SEQ ID NO:1) are contem 
plated. Furthermore, a short chain dehydrogenase domain 
encoded between nucleotides +373 and +990 (617 contigu 
ous nucleotides from SEQ ID NO: 1) are also contemplated 
as useful. 
Proteins of the present invention may contain amino acids 
sequences for the full-length human WWOX protein, as 
disclosed in SEQ ID NO:2. In some embodiments of the 
invention, shorter polypeptides and peptides may be used. 
Such polypeptides and peptides can contains fewer than 414 
contiguous amino acids of SEQ ID NO:2. In some aspects, 
these polypeptides and/or proteins may contain about 10, 20, 
30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 
170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 
290, 300, 310,320, 330, 340,350, 360,370, 380,390, 400, 
to about 410 contiguous amino acids of SEQ ID NO:2. 
Polypeptides with intermediate lengths are also contem 
plated as useful. In addition, polypeptides encoding specific 
functional regions of the WWOX protein are also contem 
plated. Thus, polypeptides containing about 29 contiguous 
amino acids of SEQ ID NO:2 encoding the two WW 
domains, one from amino acid number 18 to amino acid 
number 47 and another from amino acid number 59 to amino 
acid number 88 which are responsible for protein protein 
interactions are also contemplated. Additionally a polypep 
tides containing 205 contiguous amino acids of SEQ ID 
NO:2 encoding a catalytic part of WWOX with homology to 
a family of short chain dehydrogenases (SDR) protein from 
amino acid number 125 to amino acid number 330 is also 
contemplated. 
In embodiments describing expression constructs of 
WWOX suitable promoter and enhancer elements will be 
used. In some aspects the enhancers are 5' LTR enhancer 
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sequences from retroviral vectors. However, another 
enhancer sequence may be used. In certain embodiments, 
the promoter is a 5' LTR promoter sequence from retroviral 
vectors, CMV IE, dectin-1, dectin-2, human CD11c, F4780, 
SM22, RSV, SV40, Ad MLP, beta-actin, MHC class I or 
MHC class II promoter, however any other promoter that is 
useful to drive expression of the WWOX gene of the present 
invention, is believed to be applicable to the practice of the 
present invention. In other embodiments, a polyadenylation 
signal is operatively linked to a WWOX coding region. 
In certain embodiments, the nucleic acid is a viral vector, 
wherein the viral vector dose is from about 10, 10, 10, 
10°, 107, 10, 10, 10", 10'', 10", 10 pfu and higher. 
Alternatively, dosage may be expressed in units of viral 
particles (vp); thus, the numbers listed above in “pfu” units 
may be expressed in units of “vp' units or “viral particles.” 
It is contemplated that about 10 to about 10", about 10 to 
about 10', or 107 to about 10" viral particles may be 
administered to a patient. 
The methods of the present invention include dispersing 
expression constructs, vectors, and cassettes in pharmaco 
logically acceptable solution for administration to a patient. 
The pharmacologically acceptable solution can be a buffer, 
a solvent a diluent and may comprise a lipid. In one 
embodiment of the present invention, a nucleic acid mol 
ecule encoding a WWOX polypeptide is administered in a 
liposome. These nucleic acid molecules may be adminis 
tered to the patient intravenously, intraperitoneally, intratra 
cheally, intratumorally, intramuscularly, endoscopically, 
intralesionally, percutaneously, Subcutaneously, regionally, 
or by direct injection or perfusion. It is further contemplated 
that treatment methods may involve multiple administra 
tions. 
The nucleic acid of the present invention may be admin 
istered by injection. Other embodiments include the admin 
istering of the nucleic acid by multiple injections. In certain 
embodiments, the injection is performed local, regional or 
distal to a disease or tumor site. In some embodiments, the 
administering of nucleic acid is via continuous infusion, 
intratumoral injection, or intravenous injection. 
In another aspect, the invention provides methods for the 
detection and diagnosis of cancers. In a specific aspect, the 
type or subtype of cancer can be detected. One method 
comprises the generation of antibodies to different portions 
of the WWOX polypeptide and using these antibodies as 
biomarkers for the diagnosis of cancers. For example, some 
of the tumor specific alternatively spliced versions of 
WWOX have an open reading frame shift (such as the A5–8 
form) which encodes for a protein with a different and longer 
carboxy terminus end. Specific antibodies will be generated 
to detect these tumor specific WWOX's alternative protein 
forms. Such antibodies would be useful as they recognize 
and distinguish the abnormal forms of WWOX even in the 
presence of the normal forms of the WWOX protein in the 
same specimen. These methods also allow the identification 
of tumor specific WWOX proteins in a cell that is suspected 
to be cancerous. 
In addition, abnormal transcripts, such as the alternatively 
or abnormally spliced versions of WWOX, can also be 
identified on cINA samples synthesized from tumor 
samples RNA by means of RT-PCR and employing deletion 
specific primers. 
Yet another method comprises detection of changes in 
gene expression of the WWOX gene, such as increased or 
decreased gene expression, as an indicator of cancer. 
The invention also provides methods for the prognosis of 













method comprises identification of the mutated version of 
the WWOX protein expressed by a cancerous cell. This 
identifies the exact cancer Subtype and provides the prog 
nosis. 
Thus, the invention provides a method for detecting 
cancer comprising: (i) obtaining a sample; (ii) contacting the 
sample with an anti-WWOX antibody; and (iii) detecting the 
binding of the anti-WWOX-antibody to a WWOX polypep 
tide. A sample is defined herein as a cell, tissue, blood 
sample, cellular extract, biological fluid, serum/plasma, or a 
biopsy sample. The anti-WWOX antibody is specific for a 
mutated WWOX polypeptide. 
The invention also provides a method for detecting the 
Susceptibility of an individual to a certain cancer compris 
ing: (i) obtaining DNA from an individual; (ii) obtaining 
probes specific to WWOX; and (iii) identifying a change in 
the WWOX gene and/or gene products. The DNA can be 
cDNA or genomic DNA such as, chromosomal DNA. The 
identifying may comprise amplification Such as PCR-based 
amplification. The probes may in these embodiments encode 
nucleic acid primers. The change in the WWOX gene and/or 
gene products may be a mutation and/or an increase or 
decrease in the amount of a WWOX gene product. For 
example, alternatively or abnormally expressed WWOX 
transcripts were identified by PCR-based amplification in 
colonic adenocarcinoma cells, gastric adenocarcinoma cells, 
breast carcinoma cells and multiple myeloma cells. In the 
case of breast carcinomas, abnormal and alternatively 
expressed WWOX transcripts were also found to be 
expressed in primary breast tumor cells. 
In embodiments of the method involving chromosomal 
DNA, the identifying comprises the technique of fluorescent 
in situ hybridization (FISH). The FISH probes encode 
nucleic acids spanning the WWOX chromosomal locus. The 
probes further comprise one or more fluorescent detection 
moieties. These methods can detect the susceptibility of 
individuals to different types of cancers, for example, mul 
tiple myeloma Subtypes, breast cancers, colonic adenocar 
cinomas and gastric adenocarcinomas involving mutations 
in WWOX loci can be detected by these methods. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the speci 
fication may mean “one.” but it is also consistent with the 
meaning of “one or more.” “at least one.” and “one or more 
than one.” 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indi 
cating specific embodiments of the invention, are given by 
way of illustration only, since various changes and modifi 
cations within the spirit and scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of specific 
embodiments presented herein. 
FIGS. 1A, 1B, & 1C.. High-resolution physical map of the 
16q23.3–24.1 chromosomal region containing WWOX. 
(FIG. 1A) Sequence-tagged sites (STS) are ordered from 
centromere (left) to telomere (right). The relative distance 
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between sequence-tagged site markers is arbitrary. The 
nomenclature used for the STSs derived from the ends of 
specific BACs indicates first the BAC clone address fol 
lowed by S or T representing the SP6 or T7 (vector sequenc 
ing primers) end of the insert respectively. MM. 1 and JJN3 
indicate the relative position of translocation breakpoints 
observed in myelomas; t(14:16)(q32:q23). Based on the 
length of unordered contigs obtained from shotgun sequenc 
ing, the distance between markers 112B17S and 36O22T is 
2400 Kbp. (FIG. 1B). The isolated BACs and YACs are 
represented as horizontal lines; dashed vertical lines repre 
sent the position of STS markers in corresponding BACs 
and YACs. Size of clones are not to scale. There is only one 
gap in this BAC contig (between BACs 36O22 and 293D3). 
The homozygous deletion spanned from STS 249B4S to 
D16S3029 inclusive. (FIG. 1C) Black-filled rectangular 
blocks represent WWOX exons as numbered. The approxi 
mate position of each exon in each corresponding BAC 
clone is illustrated. 
FIGS. 2A & 2B. (FIG. 2A) Predicted amino acid sequence 
of WWOX reveals two WW domains and a short chain 
dehydrogenase domain. WW domains are boxed and con 
served tryptophans and prolines are shown in bold; note that 
in the second WW domain one tryptophan is replaced by a 
tyrosine (conservative change). The short chain dehydroge 
nase domain is underlined and the conserved residues 
YXXXK and S. characteristic of a substrate binding site, are 
highlighted; bases GXXXGXG, typical of a coenzyme bind 
ing site, are shown in bold italics (SEQID NO. 2). (FIG. 2B) 
Comparative alignment of the WW domains from WWOX 
vs. the Pfam WW domain prototypic amino acid sequence 
(SEQ ID NO. 69). In the consensus sequence, highly con 
served amino acids are shown in upper-case. The middle line 
illustrates how well the WWOX sequence compares with the 
WW consensus; satisfactory replacements are represented 
by +. Numbering corresponds to WWOX amino acid 
sequence (SEQ ID NO. 70). 
FIG. 3. Map of WWOX transcripts. 
FIG. 4. WWOX mRNA expression in breast cancer cell 
liness determined by real-time RT-PCR analysis. Levels of 
WWOX expression are represented as relative to those of 
the control gene B2-microglobulin. 
FIGS.5A, 5B & 5C. (FIG. 5A) Ability of WWOX to 
suppress anchorage independent growth of MDA-MB-435 
and T47D breast cancer cell lines transfected with expres 
sion vector carrying WWOX cDNA or transfected with 
control vector only in a soft agar growth assay. Comparative 
analysis on the number of colonies larger than 200 um in 
diameter. Colonies were stained by incubation with nitro 
blue tetrazolium, complete culture fields were photo 
graphed, colony counting and measurements were per 
formed using NIH Image analysis software. (FIG. 5B and 
FIG. C.) Suppression of tumorigenesis of MDA-MB-435 
breast cancer cells in nude mice by ectopically increased 
WWOX expression. Five animals per condition (i.e., cells 
transfected with vector alone or vector with the WWOX 
transgene) were injected bilaterally into the thoracic mam 
mary fat pads with 1x10 cells per site. Tumor growth was 
monitored for 7 weeks and caliper measurements were 
conducted once per week. (FIG. 5B) Comparative analysis 
on the rate of tumor growth from cells transfected with 
vector alone or vector with WWOX. Tumor volumes were 
calculated as described in the section entitled Example 4. 
Note the clear difference in tumor latency and rate of tumor 
growth. (FIG. 5C) The top two rows display the tumors 
formed by the MDA-MB-435/vector cells innude mice at the 













injection sites developed. The two bottom rows display the 
tumors that formed by MDA-MB-435 WWOX transfected 
cells at the end of the same observation period, 7 tumors out 
of 10 injection sites developed. Note the dramatic difference 
in size between both groups (P=0.00001). 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
The present invention describes the identification of a 
novel gene, human WWOX, which has an open reading 
frame of 1245bp and encodes a 414 amino-acid protein. The 
WWOX gene is composed of nine exons and was identified 
while mapping the chromosome region 16q23.3–24.1. The 
16q23.3–24.1 region is an area commonly affected by allelic 
losses in breast cancer. The inventors generated a detailed 
physical map of the genomic region spanning between 
sequence-tagged site markers D16S518 and D16S516 and 
used shotgun genomic sequencing as well as isolation and 
analysis of transcripts mapping to this chromosomal region. 
WWOX contains two WW domains coupled to a region 
with high homology to the short-chain dehydrogenase/re 
ductase family of enzymes. WW domains are generally 
involved in interactions with other proteins (see below). The 
highest normal expression of WWOX is seen in hormonally 
regulated tissues such as testis, ovary, and prostate. This 
expression pattern and the presence of a short-chain dehy 
drogenase/reductase domain and specific amino acid fea 
tures indicate a role for WWOX in steroid metabolism. 
A mutation screening showed that mutations of the 
WWOX gene yield mutated WWOX protein products in 
various tumor samples and tumor lines. Abnormal versions 
of the WWOX transcript were also detected in tumor lines. 
Some of these mutations are abnormally or alternatively 
spliced versions of WWOX. For example, deletion of exons 
6-8 (WWOX A6–8) was seen in cell lines MCF-7 and 
MDA-MB 453 (breast cancer cell lines); HCT116 (colon 
adenocarcinoma cell line); AGS (gastric adenocarcinoma 
cell line). Transcripts with deleted exons 5-8 (WWOX 
A5–8) were found in KMS11 a myeloma cell line. Other 
deletions were also found in following cell lines: JJN3 
(myeloma cell line); MDA-MB157 and MDA-MB435 
(breast cancer cell lines). In addition, expression studies 
show variable expression of WWOX in breast cancer cell 
lines as compared with normal breast cells and tissues. For 
example, some breast cancer cell lines show overexpression 
of WWOX transcripts while other breast cancer cell lines 
show little or no expression of WWOX. 
Some of the abnormally or alternatively spliced WWOX 
forms found in cancer cell lines exhibit intact WW-domain 
regions but have a deleted enzymatic domain thus, repre 
senting non-functional forms of the protein. Since the pro 
tein protein interaction domains are preserved in the 
abnormal forms these forms can act as dominant negative 
versions of the protein. In other words, the abnormal and 
enzymatically inactive forms compete with the wild type 
forms for binding with the WWOX binding partners. The 
kinetics of this alternative binding reaction may be preferred 
and thus the normal function of wild-type protein may be 
inhibited in cancer/tumor cells. 
Since cancer is caused by mutations in genes that are 
responsible for cell-cycle control and cell growth, mutations 
or aberrant expression patterns of genes in normal versus 
cancer cells indicate their involvement in regulating the 
cell-cycle and growth. Abnormally expressed genes, which 
includes expression of mutant products including abnor 
mally or alternatively spliced isoforms and changes in the 
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level of gene expression, are indicators of the cancerous 
phenotype. The present inventors envision that the detection 
of Such abnormal gene products in a biological sample 
obtained from a patient with a cancer can be effectively used 
for the detection and diagnosis of cancers. One can also 
obtain an indication on the specific type or Subtype of cancer 
based on the species of abnormal gene products expressed. 
Therefore, the present invention provides methods for the 
detection, diagnosis, prognosis and the treatment of cancers 
using the WWOX nucleic acid and protein sequences. 
Thus, the invention provides methods for identifying 
patients having abnormalities in the WWOX gene or its gene 
products. In some cases, the WWOX encoded proteins are 
mutated. In yet other cases, the amount of the expressed 
RNA and/or proteins are abnormal. For example, detecting 
an increase in gene expression of the WWOX gene is an 
indicator of cancer. 
The invention also provides methods in which antibodies 
are generated to different portions of some WWOX polypep 
tides and used as biomarkers for the diagnosis of cancers. 
The WWOX polypeptides and/or epitopes thereof are those 
that are expressed in cancers as a result of mutations. The 
invention also provides methods to identify individuals 
susceptible to WWOX-associated hyperproliferative condi 
tions. Such methods comprise generating fluorescent probes 
spanning the WWOX chromosomal locus to identify 
WWOX mutations. For example, fluorescent probes have 
been generated to identify multiple myeloma Subtypes in 
individuals. Kits for the detecting cancers as well as kits for 
detecting individuals susceptible to cancers are also con 
templated. 
The present invention also provides in vitro and in vivo 
data that demonstrate the tumor Supressor propoerties of 
WWOX. Ectopic expression of WWOX in breast cancer cell 
lines, mediated by transfecting recombinant retroviral con 
structs, inhibited the ability of the tumor cells to grow in soft 
agar. Reduced colony formation was observed in cancer 
cells expressing WWOX. In addition, in vivo studies using 
nude mice demonstrated that animals injected with vectors 
expressing WWOX had remarkably smaller tumors. For 
example, mice that were injected with a vector expressing 
WWOX had tumors with an average wet weight of 51+22 
mg in dramatic contrast to mice that were injected with a 
control vector that had tumors with an average wet weight 
of 821+295 mg. 
Therefore, the invention also provides methods for the 
treatment of cancer and hyperproliferative diseases by pro 
viding WWOX gene products. Nucleic acids encoding 
WWOX polypeptides and/or proteins can be provided as 
gene therapy to cells in need thereof as therapeutic and 
preventive treatments. 
A. Cancer and WWOX 
A variety of cancers including pre-cancers can be treated 
according to the methods of the present invention. Some of 
the cancer types contemplated for treatment in the present 
invention include breast, prostate, liver, myelomas, bladder, 
blood, bone, bone marrow, brain, colon, esophagus, gas 
trointestine, head, kidney, lung, nasopharynx, neck, ovary, 
skin, stomach, and uterus cancers are contemplated for 
treatment. 
Cancer has become one of the leading causes of death in 
the western world, second only behind heart disease. Current 
estimates project that one person in three in the U.S. will 
develop cancer, and that one person in five will die from 
cancer. Cancers can be viewed as altered cells that have lost 













genes that control cell cycle and normal cell growth. Muta 
tions in oncogenes therefore cause imbalances in cell cycle 
control and lead to cancers. 
The WWOX gene was identified by the present inventors 
while mapping the chromosomal region 16q23.3–24.1. This 
region is an area that is affected by allelic losses in breast, 
liver and prostate carcinomas and by translocations in mul 
tiple myeloma. Furthermore, various epithelial tumors have 
chromosomal and genomic abnormalities affecting chromo 
some 16q. Homozygous deletions have been identified in the 
chromosome 16q area in various tumor cell lines: the AGS 
gastric adenocarcinoma cell line, the HCT116 colon adeno 
carcinoma cell line, the PEO4 ovarian adenocarcinoma cell 
line and the WX330 small cell lung carcinoma cell line 
(Paige et al., 2000; Manglesdorf et al., 2000). The WWOX 
gene identified in the present invention spans this entire 
region and is larger than 1 Mb in size. Furthermore, WWOX 
also spans the common fragile site FRA16D. Thus, WWOX 
is a prime target for genetic abnormalities affecting the 
common fragile site in the 16q arm. WWOX has been 
identified by the present inventors as a tumor suppressor 
gene and several cancer cells and cell lines express alterna 
tively or abnormally spliced variants of the WWOX 
polypeptide. 
WWOX has also been demonstrated to have strong tumor 
Supressive properties in in vitro and in vivo studies. Inhibi 
tion of cancer cell growth and colony formation was seen in 
breast cancer cell lines that were transfected with recombi 
nant retroviral constructs that resulted in ectopic expression 
of WWOX. More importantly, in vivo studies using nude 
mice have demonstrated that animals injected with vectors 
expressing WWOX have significantly smaller tumors. For 
example, mice that were injected with a vector expressing 
WWOX had tumors with an average wet weight of 51+22 
mg in dramatic contrast to mice that were injected with a 
control vector that had tumors with an average wet weight 
of 821+295 mg. 
The present invention therefore provides methods that 
involve a WWOX polypeptide or a WWOX polypeptide 
encoding nucleic acid to treat patients with cancers where 
WWOX nucleic acids and/or proteins and/or polypeptides 
are involved, such that these patients are conferred a thera 
peutic benefit as a result of the treatment. By involvement, 
the WWOX encoding nucleic acid and/or protein and/or 
polypeptide may be mutated and/or abnormal and/or the 
overexpression of this gene and/or polypeptide may also 
suffice to cause the cancer. The term “therapeutic benefit 
used herein refers to anything that promotes or enhances the 
well-being of the patient with respect to the medical treat 
ment of the patients cancer. A list of nonexhaustive 
examples of this includes extension of the patients life by 
any period of time; decrease or delay in the neoplastic 
development of the disease; decrease in hyperproliferation; 
reduction in tumor growth; delay or prevention of 
metastases; reduction in the proliferation rate of a cancer cell 
or tumor cell; induction of apoptosis in any treated cell or in 
any cell affected by a treated cell; induction of cell killing: 
a decrease in cell growth; and/or a decrease in pain to the 
patient that can be attributed to the patients condition. 
In many contexts, it is not necessary that the cell be killed 
or induced to undergo normal cell death or "apoptosis.” 
Rather, to accomplish a meaningful treatment, all that is 
required is that the cancer/tumor growth be slowed to some 
degree. It may be that the cell's growth is completely 
blocked, however, or that some tumor regression is 
achieved. Clinical terms such as “remission' and “reduction 
of tumor also are contemplated given their normal usage. 
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B. Other Hyperproliferative Conditions and WWOX 
The present invention also provides methods for the 
treatment of hyperproliferative conditions other than cancer 
and preneoplastic conditions. The types of conditions that 
may be treated, according to the present invention, are 
limited only by the involvement of WWOX. By involve 
ment, it is not even a requirement that WWOX be mutated 
or abnormal. The overexpression, mislocalization, or abnor 
mal processing of this polypeptide may also suffice to cause 
a hyperproliferative state. The hyperproliferative conditions 
include conditions such as but not limited to restenosis, 
primary psoriasis, angiogenesis, rheumatoid arthritis, 
inflammatory bowel disease, psoriasis, eczema, secondary 
cataracts, or bronchial dysplasia. Thus, the administration of 
a WWOX polypeptide or a WWOX polypeptide encoding 
nucleic acid to treat patients with hyperproliferative condi 
tions confers a therapeutic benefit as a result of the treat 
ment. 
The term “therapeutic benefit” used herein refers to 
anything that promotes or enhances the well-being of the 
subject with respect to the medical treatment of his condi 
tion, which includes treatment of hyperproliferative condi 
tions. A list of nonexhaustive examples of this includes 
extension of the subjects life by any period of time, 
decrease in hyperproliferation, a decrease in pain or symp 
toms of the subject that can be attributed to the subjects 
condition. 
C. The WW Domain 
The WW domain is a small functional domain that is 
characterized by two tryptophan residues, one in the amino 
terminal portion of the WW domain and one in the carboxyl 
terminal portion, and is found in a large number of proteins 
from a variety of species including humans, nematodes, and 
yeast. WW domains are 30 to 40 amino acids in length, 
which make them much smaller than typical functional 
domains, most of which are from 50 to about 150 residues 
long. WW domains are often flanked by stretches of amino 
acids rich in histidine or cysteine and these stretches might 
be metal-binding sites. The center of WW domains is 
hydrophobic although the remainder of the domain bears a 
number of charged residues. These features are characteris 
tic of functional domains involved in protein protein inter 
actions (Bork and Sudol, 1994). 
Andre and Springael, 1994, proposed the following con 
sensus sequence for WW domains: 
where X represents any amino acid and bold letters 
represent highly conserved amino acids. They also 
proposed that WW domains led them to conclude that 
WW domains lack C.-helical content and possess a 
central B-strand region flanked by unstructured regions. 
Other studies predicta structure off-strands containing 
charged residues flanking a hydrophobic core com 
posed of four aromatic residues (Chen and Sudol, 1995, 
and references cited therein). 
The WW domain has been found in a wide variety of 
proteins of varying function. However, most proteins con 
taining WW domains are predominantly involved in either 
cell signaling and growth regulation or in the organization of 
the cytoskeleton. For example, the WW domain-containing 
protein dystrophin belongs to a family of cytoskeletal pro 
teins that includes C.-actinin and B-spectrin. Mutations in 
dystrophin are responsible for Duchenne and Becker mus 
cular dystrophies. The dystrophin gene gives rise to a family 













encodes a protein having four domains: (1) a globular, 
actin-binding region; (2) 24 spectrin-like repeats; (3) a 
cysteine-rich Ca' binding region; and (4) a carboxyl ter 
minal globular region. A short stretch of the dystrophin 
protein, after the spectrin-like repeats and before the Ca" 
binding region, B-dystroglycan. This suggests that WW 
domains may be involved in protein protein interactions 
(Bork and Sudol, 1994). 
Another example is YAP, a protein that was discovered by 
virtue of its binding to the SH3 domain of the proto 
oncogene Yes (Sudol, 1994). Murine YAP was found to have 
two WW domains and chicken and human YAP each have 
only a single WW domain (Sudol, et al., 1995). Chen and 
Sudol, 1995, screened a cDNA expression library with 
bacterially produced glutathione S-transferase fusion pro 
teins of the WW domain from YAP. They identified and 
isolated two proteins from the library (WBP-1 and WBP-2) 
that specifically bound the YAP WW domain. Comparison 
of the amino acid sequences of WBP-1 and WBP-2 revealed 
a homologous proline-rich region in each protein. The 
proline-rich regions contained the shared motif PPPPY. 
Chen and Sudol then showed that as few as ten residues 
containing this motif conferred upon a fusion protein the 
ability to specifically bind the YAP WW domain. This 
binding was highly specific; the motif bound to the YAP 
WW domain but not to the WW domain from dystrophin or 
to a panel of SH3 domains. 
Nedd4 is another protein which possesses three WW 
domains. In mouse, Nedd4 seems to play a role in embryonic 
development and the differentiation of the central nervous 
system (Kumar et al., 1992). 
Among other proteins having WW domains, the rat tran 
Scription factor FE65 possesses an amino terminal activation 
region that includes a WW domain (Bork and Sudol, 1994). 
A yeast protein, ess1, contains a WW domain and is thought 
to be involved in cytokinesis and/or cell separation (Hanes 
et al., 1989). The human protein kiaa93 has 4WW domains 
and may be the human version of mouse Nedd4 (Hoffman 
and Bucher, 1995). The human protein HUMORF1, 
although of unknown function, has a roughly 350 amino acid 
region, which is homologous to GTPase-activating proteins 
(Andre and Springael, 1994). 
D. WWOX Nucleic Acids and Uses Thereof 
One embodiment of the present invention is to transfer 
nucleic acids encoding a WWOX polypeptide to induce the 
destruction of cancers including precancers and/or hyper 
proliferative conditions. In one embodiment the nucleic 
acids encode a full-length, Substantially full-length, or func 
tional equivalent form of a WWOX protein. In other 
embodiments the WWOX is human WWOX. 
Thus, in some embodiments of the present invention, the 
treatment of cancer involves the administration of a thera 
peutic nucleic acid expression construct encoding a WWOX 
polypeptide to a cancer cell. It is contemplated that the 
cancer cells take up the construct and express the therapeutic 
polypeptide encoded by nucleic acid, thereby restoring a 
growth control to the cancer cells. 
Certain aspects of the present invention concern at least 
one WWOX nucleic acid molecule. In certain aspects, the 
WWOX nucleic acid comprises a wild-type or mutant 
WWOX nucleic acid. In particular aspects, the WWOX 
nucleic acid encodes for at least one transcribed nucleic acid. 
In particular aspects, the WWOX nucleic acid encodes at 
least one WWOX protein, polypeptide, or peptide, or bio 
logically functional equivalent thereof. In other aspects, the 
WWOX nucleic acid comprises at least one nucleic acid 
segment of SEQID NO:1, SEQID NO:30, SEQ ID NO:32, 
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or at least one biologically functional equivalent thereof. 
SEQ ID NO:30 and SEQ ID NO:32 represent alternatively 
spliced versions. In yet other aspects, the WWOX nucleic 
acid comprises a nucleic acid sequence which encodes at 
least 90 contiguous amino acid residues of SEQID NO:2. In 
still other aspects, the WWOX nucleic acid comprises a 
nucleic acid sequence encoding at least 150 contiguous 
amino acid residues of SEQ ID NO:2. Thus, the WWOX 
nucleic acid can comprise a nucleic acid sequence encoding 
90,91, 92,93, 94, 95, 96, 97,98, 99, 100, 101, 105, 110, 115, 
120, 125, 130, 135, 140, 145, 150, 160, 165, 170, 175, 180, 
185, 190, 200, 250, 300, 350, 400, 410, or 414 amino acids. 
In another aspect, the WWOX nucleic acid comprises at 
least 1.5 contiguous kilobases of SEQ ID NO:1. In some 
aspects the WWOX nucleic acid is a human WWOX nucleic 
acid. 
The present invention also concerns the isolation or 
creation of at least one recombinant construct or at least one 
recombinant host cell through the application of recombi 
nant nucleic acid technology known to those of skill in the 
art or as described herein. The recombinant constructor host 
cell may comprise at least one WWOX nucleic acid, and 
may express at least one WWOX protein, polypeptide, or 
peptide, or at least one biologically functional equivalent 
thereof. 
In some embodiments the invention refers to DNA 
sequences identified by Database Accession numbers: Gen 
Bank AF21 1943, AF212843, AF179633, AF395124, 
AF395 123. 
As used herein “wild-type' refers to the naturally occur 
ring sequence of a nucleic acid at a genetic locus in the 
genome of an organism, and sequences transcribed or trans 
lated from such a nucleic acid. Thus, the term “wild-type' 
also may refer to the amino acid sequence encoded by the 
nucleic acid. As a genetic locus may have more than one 
sequence or alleles in a population of individuals, the term 
“wild-type' encompasses all Such naturally occurring alle 
les. As used herein the term “polymorphic' means that 
variation exists (i.e., two or more alleles exist) at a genetic 
locus in the individuals of a population. As used herein, 
“mutant” refers to a change in the sequence of a nucleic acid 
or its encoded protein, polypeptide, or peptide that is the 
result of recombinant DNA technology. 
A nucleic acid may be made by any technique known to 
one of ordinary skill in the art. Non-limiting examples of 
synthetic nucleic acid, particularly a synthetic oligonucle 
otide, include a nucleic acid made by in vitro chemical 
synthesis using phosphotriester, phosphite orphosphoramid 
ite chemistry and Solid phase techniques such as described 
in EP 266.032, incorporated herein by reference, or via 
deoxynucleoside H-phosphonate intermediates as described 
by Froehler et al., 1986, and U.S. Pat. No. 5,705,629, each 
incorporated herein by reference. A non-limiting example of 
enzymatically produced nucleic acid include one produced 
by enzymes in amplification reactions such as PCRTM (see 
for example, U.S. Pat. No. 4,683.202 and U.S. Pat. No. 
4,683,195, each incorporated herein by reference), or the 
synthesis of oligonucleotides described in U.S. Pat. No. 
5,645,897, incorporated herein by reference. A non-limiting 
example of a biologically produced nucleic acid includes 
recombinant nucleic acid production in living cells, such as 
recombinant DNA vector production in bacteria (see for 
example, Sambrook et al. 1989, incorporated herein by 
reference). 
A nucleic acid may be purified on polyacrylamide gels, 













means known to one of ordinary skill in the art (see for 
example, Sambrook et al. 1989, incorporated herein by 
reference). 
The term “nucleic acid' will generally refer to at least one 
molecule or strand of DNA, RNA or a derivative or mimic 
thereof, comprising at least one nucleobase, such as, for 
example, a naturally occurring purine or pyrimidine base 
found in DNA (e.g., adenine “A” guanine “G, thymine “T.’ 
and cytosine “C”) or RNA (e.g. A, G, uracil “U” and C). The 
term “nucleic acid encompasses the terms "oligonucle 
otide' and “polynucleotide.” The term "oligonucleotide' 
refers to at least one molecule of between about 3 and about 
100 nucleobases in length. The term “polynucleotide' refers 
to at least one molecule of greater than about 100 nucleo 
bases in length. These definitions generally refer to at least 
one single-stranded molecule, but in specific embodiments 
will also encompass at least one additional Strand that is 
partially, Substantially or fully complementary to the at least 
one single-stranded molecule. Thus, a nucleic acid may 
encompass at least one double-stranded molecule or at least 
one triple-stranded molecule that comprises one or more 
complementary strand(s) or “complement(s) of a particular 
sequence comprising a strand of the molecule. 
In certain embodiments, a "gene' refers to a nucleic acid 
that is transcribed. As used herein, a 'gene segment is a 
nucleic acid segment of a gene. In certain aspects, the gene 
includes regulatory sequences involved in transcription, or 
message production or composition. In particular embodi 
ments, the gene comprises transcribed sequences that 
encode for a protein, polypeptide or peptide. In other par 
ticular aspects, the gene comprises a WWOX nucleic acid, 
and/or encodes a WWOX polypeptide or peptide-coding 
sequences. In keeping with the terminology described 
herein, an "isolated gene' may comprise transcribed nucleic 
acid(s), regulatory sequences, coding sequences, or the like, 
isolated Substantially away from other such sequences. Such 
as other naturally occurring genes, regulatory sequences, 
polypeptide or peptide encoding sequences, etc. In this 
respect, the term “gene' is used for simplicity to refer to a 
nucleic acid comprising a nucleotide sequence that is tran 
scribed, and the complement thereof. In particular aspects, 
the transcribed nucleotide sequence comprises at least one 
functional protein, polypeptide and/or peptide encoding 
unit. As will be understood by those in the art, this functional 
term “gene' includes both genomic sequences, RNA or 
cDNA sequences, or Smaller engineered nucleic acid seg 
ments, including nucleic acid segments of a non-transcribed 
part of a gene, including but not limited to the non-tran 
scribed promoter or enhancer regions of a gene. Smaller 
engineered gene nucleic acid segments may express, or may 
be adapted to express using nucleic acid manipulation 
technology, proteins, polypeptides, domains, peptides, 
fusion proteins, mutants and/or Such like. Thus, a “truncated 
gene' refers to a nucleic acid sequence that is missing a 
stretch of contiguous nucleic acid residues that encode a 
portion of the full-length WWOX polypeptide. For example, 
a truncated gene may not contain the nucleic acid sequence 
for the N-terminal region of the WWOX polypeptide. It is 
envisioned that the nucleic acid sequences of the present 
invention may contain fewer than 95% of the contiguous 
nucleic acid residues of SEQ ID NO:1, SEQ ID NO:30, or 
SEQ ID NO:32. Alternatively, these sequences may com 
prise fewer than 90%, 85%, 80%, 75%, or 70% of the 
contiguous nucleic acid residues of SEQ ID NO:1 SEQ ID 
NO:30, or SEQ ID NO:32. 
“Isolated substantially away from other coding 
sequences' means that the gene of interest, in this case the 
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WWOX gene, forms the significant part of the coding region 
of the nucleic acid, or that the nucleic acid does not contain 
large portions of naturally-occurring coding nucleic acids, 
Such as large chromosomal fragments, other functional 
genes, RNA or cDNA coding regions. Of course, this refers 
to the nucleic acid as originally isolated, and does not 
exclude genes or coding regions later added to the nucleic 
acid by recombinant nucleic acid technology. 
In certain embodiments, the nucleic acid is a nucleic acid 
segment. As used herein, the term “nucleic acid segment.” 
are Smaller fragments of a nucleic acid, such as for non 
limiting example, those that encode only part of the WWOX 
peptide or polypeptide sequence. Thus, a “nucleic acid 
segment may comprise any part of the WWOX gene 
sequence, of from about 2 nucleotides to the full-length of 
the WWOX peptide- or polypeptide-encoding region. In 
certain embodiments, the “nucleic acid segment encom 
passes the full-length WWOX gene sequence. In particular 
embodiments, the nucleic acid comprises any part of SEQ 
ID NO:1, SEQID NO:30, or SEQID NO:32, of from about 
2 nucleotides to the full-length of the sequence encoding 
SEQ ID NO:2, SEQID NO:31, or SEQ ID NO:33. 
Various nucleic acid segments may be designed based on 
a particular nucleic acid sequence, and may be of any length. 
By assigning numeric values to a sequence, for example, the 
first residue is 1, the second residue is 2, etc., an algorithm 
defining all nucleic acid segments can be created: 
in to n+y 
where n is an integer from 1 to the last number of the 
sequence and y is the length of the nucleic acid segment 
minus one, where n+y does not exceed the last number 
of the sequence. Thus, for a 10-mer, the nucleic acid 
segments correspond to bases 1 to 10, 2 to 11, 3 to 
12 . . . and/or so on. For a 15-mer, the nucleic acid 
segments correspond to bases 1 to 15, 2 to 16, 3 to 
17. . . and/or so on. For a 20-mer, the nucleic segments 
correspond to bases 1 to 20, 2 to 21, 3 to 22. . . and/or 
So on. In certain embodiments, the nucleic acid seg 
ment may be a probe or primer. 
The nucleic acid(s) of the present invention, regardless of 
the length of the sequence itself, may be combined with 
other nucleic acid sequences, including but not limited to, 
promoters, enhancers, polyadenylation signals, restriction 
enzyme sites, multiple cloning sites, coding segments, and 
the like, to create one or more nucleic acid construct(s). The 
overall length may vary considerably between nucleic acid 
constructs. Thus, a nucleic acid segment of almost any 
length may be employed, with the total length preferably 
being limited by the ease of preparation or use in the 
intended recombinant nucleic acid protocol. 
In a non-limiting example, one or more nucleic acid 
constructs may be prepared that include a contiguous stretch 
of nucleotides identical to or complementary to SEQ ID 
NO:1. Such a stretch of nucleotides, or a nucleic acid 
construct, may be or be about 10, about 15, about 20, about 
25, about 30, about 35, about 40, about 45, about 50, about 
55, about 60, about 65, about 70, about 75, about 80, about 
85, about 90, about 95, about 100, about 105, about 110, 
about 115, about 120, about 125, about 130, about 135, 
about 140, about 145, about 150, about 155, about 160, 
about 165, about 170, about 175, about 180, about 185, 
about 190, about 195, about 200, about 210, about 220, 
about 230, about 240, about 250, about 260, about 270, 
about 280, about 290, about 300, about 310, about 320, 
about 330, about 340, about 350, about 360, about 370, 





















about 840, about 850, about 860, 
about 880, about 890, about 900, about 910, about 920, 
about 930, about 940, about 950, about 960, about 970, 
about 980, about 990, about 1,000, about 1010, about 1020, 
about 1030, about 1040, about 1050, about 1060, about 
1070, about 1080, about 1090, about 1,100, about 1110, 
about 1120, about 1130, about 1140, about 1150, about 1160, 
about 1170, about 1180, about 1190, about 1200, 1210, 
about 1220, about 1230, about 1240, to about 1245 nucle 
otides in length, as well as constructs of greater size, up to 
and including chromosomal sizes (including all intermediate 
lengths and intermediate ranges), given the advent of nucleic 
acids constructs such as a yeast artificial chromosome are 
known to those of ordinary skill in the art. It will be readily 
understood that “intermediate lengths” and “intermediate 
ranges, as used herein, means any length or range including 
or between the given values (i.e., all integers including and 
between such values). 
It is further understood that a nucleic acid sequence 
encoding all or a portion of an WWOX polypeptide may be 
comprised of contiguous complementary or identical nucleic 
acid sequences of any of the lengths described above and 
from SEQ ID NO:1, SEQ ID NO:30, or SEQ ID NO:32. 
It is contemplated that the nucleic acid constructs of the 
present invention may encode a full-length WWOX or 
encode a truncated version of WWOX, such that the tran 
Script of the coding region represents the truncated version. 
The term “a sequence essentially as set forth in SEQ ID 
NO:1, or SEQID NO:30, or SEQID NO:32” or “a sequence 
essentially as set forth in SEQID NO:1, or SEQID NO:30, 
or SEQ ID NO:32” means that the sequence substantially 
corresponds to a portion of SEQ ID NO:1, or SEQ ID 
NO:30, or SEQ ID NO:32, and has relatively few amino 
acids that are not identical to, or biologically functionally 
equivalent to, the amino acids of SEQID NO:2, or SEQ ID 
NO:31, or SEQ ID NO:33. 
a. Oligonucleotide Probes and Primers 
Naturally, the present invention also encompasses DNA 
segments that are complementary, or essentially comple 
mentary, to the sequence set forth in SEQID NO:1, or SEQ 
ID NO:30, or SEQ ID NO:32. Nucleic acid sequences that 
are “complementary' are those that are capable of base 
pairing according to the standard Watson-Crick complemen 
tary rules. As used herein, the term "complementary 
sequences' means nucleic acid sequences that are substan 
tially complementary, as may be assessed by the same 
nucleotide comparison set forth above, or as defined as being 
capable of hybridizing to the nucleic acid segment of SEQ 
ID NO:1, or SEQ ID NO:30, or SEQ ID NO:32 under 
relatively stringent conditions such as those described 
herein. Such sequences may encode the entire WWOX 
protein or fragments thereof. 
The nucleic acid detection techniques and conditions 
described herein serve both to define the functionally 
equivalent nucleic acids of the invention, as outlined struc 
turally above, and to describe certain methods by which the 
cancer marker gene sequences and their equivalents may be 
used in practical terms to identify and characterize cancer 
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Hybridizing fragments should be of sufficient length to 
provide specific hybridization to a RNA or DNA tissue 
sample. The use of a hybridization probe of between about 
10–14 or 15–20 and about 100 nucleotides in length allows 
the formation of a duplex molecule that is both stable and 
selective. Molecules having complementary sequences over 
stretches greater than 20 bases in length are generally 
preferred, in order to increase stability and selectivity of the 
hybrid, and thereby improve the quality and degree of 
particular hybrid molecules obtained. 
Sequences of 17 bases long should occur only once in the 
human genome and, therefore, Suffice to specify a unique 
target sequence. Although shorter oligomers are easier to 
make and increase in vivo accessibility, numerous other 
factors are involved in determining the specificity of hybrid 
ization. Both binding affinity and sequence specificity of an 
oligonucleotide to its complementary target increases with 
increasing length. It is contemplated that exemplary oligo 
nucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 
25, 30, 35, 40, 45, 50, 55, 60, 65,70, 75, 80, 85,90, 95, 100 
or more base pairs will be used, although others are con 
templated. Longer polynucleotides encoding 250, 300, 500, 
600, 700, 800, 900, 1000, 1100, 1200 and longer are 
contemplated as well. Such oligonucleotides will find use, 
for example, as probes in Southern and Northern blots and 
as primers in amplification reactions. 
Accordingly, the nucleotide sequences of the invention 
may be used for their ability to selectively form duplex 
molecules with complementary stretches of genes or RNAs 
or to provide primers for amplification of DNA or RNA from 
tissues. Depending on the application envisioned, one will 
desire to employ varying conditions of hybridization to 
achieve varying degrees of selectivity of probe towards 
target Sequence. 
For applications requiring high selectivity, one will typi 
cally desire to employ relatively stringent conditions to form 
the hybrids, e.g., one will select relatively low salt and/or 
high temperature conditions, such as provided by about 0.02 
M to about 0.10 MNaCl at temperatures of about 50° C. to 
about 70° C. Such high stringency conditions tolerate little, 
if any, mismatch between the probe and the template or 
target Strand, and would be particularly suitable for isolating 
specific genes or detecting specific mRNA transcripts. It is 
generally appreciated that conditions can be rendered more 
stringent by the addition of increasing amounts of forma 
mide. 
For certain applications, for example, Substitution of 
amino acids by site-directed mutagenesis, it is appreciated 
that lower Stringency conditions are required. Under these 
conditions, hybridization may occur even though the 
sequences of probe and target Strand are not perfectly 
complementary, but are mismatched at one or more posi 
tions. Conditions may be rendered less stringent by increas 
ing salt concentration and decreasing temperature. For 
example, a medium stringency condition could be provided 
by about 0.1 to 0.25 MNaCl attemperatures of about 37° C. 
to about 55° C., while a low stringency condition could be 
provided by about 0.15 M to about 0.9 M salt, at tempera 
tures ranging from about 20° C. to about 55° C. Thus, 
hybridization conditions can be readily manipulated, and 
thus will generally be a method of choice depending on the 
desired results. 
In other embodiments, hybridization may be achieved 
under conditions of, for example, 50 mM Tris-HCl (pH 8.3), 
75 mM KC1, 3 mM MgCl, 10 mM dithiothreitol, at tem 
peratures between approximately 20° C. to about 37° C. 













approximately 10 mM Tris-HCl (pH 8.3), 50 mM KC1, 1.5 
uMMgCl2, attemperatures ranging from approximately 40° 
C. to about 72° C. 
One method of using probes and primers of the present 
invention is in the search for genes related to WWOX or, 
more particularly, homologs of WWOX from other species. 
Normally, the target DNA will be a genomic or cDNA 
library, although screening may involve analysis of RNA 
molecules. By varying the Stringency of hybridization, and 
the region of the probe, different degrees of homology may 
be discovered. 
Another way of exploiting probes and primers of the 
present invention is in site-directed, or site-specific 
mutagenesis. Site-specific mutagenesis is a technique useful 
in the preparation of individual peptides, or biologically 
functional equivalent proteins or peptides, through specific 
mutagenesis of the underlying DNA. The technique further 
provides a ready ability to prepare and test sequence vari 
ants, incorporating one or more of the foregoing consider 
ations, by introducing one or more nucleotide sequence 
changes into the DNA. Site-specific mutagenesis allows the 
production of mutants through the use of specific oligo 
nucleotide sequences which encode the DNA sequence of 
the desired mutation, as well as a sufficient number of 
adjacent nucleotides, to provide a primer sequence of Suf 
ficient size and sequence complexity to form a stable duplex 
on both sides of the deletion junction being traversed. 
Typically, a primer of about 17 to 25 nucleotides in length 
is preferred, with about 5 to 10 residues on both sides of the 
junction of the sequence being altered. 
The technique typically employs a bacteriophage vector 
that exists in both a single stranded and double stranded 
form. Typical vectors useful in site-directed mutagenesis 
include vectors such as the M13 phage. These phage vectors 
are commercially available and their use is generally well 
known to those skilled in the art. Double stranded plasmids 
are also routinely employed in site directed mutagenesis, 
which eliminates the step of transferring the gene of interest 
from a phage to a plasmid. 
In general, site-directed mutagenesis is performed by first 
obtaining a single-stranded vector, or melting of two strands 
of a double stranded vector which includes within its 
sequence a DNA sequence encoding the desired protein. An 
oligonucleotide primer bearing the desired mutated 
sequence is synthetically prepared. This primer is then 
annealed with the single-stranded DNA preparation, taking 
into account the degree of mismatch when selecting hybrid 
ization conditions, and Subjected to DNA polymerizing 
enzymes such as E. coli polymerase I Klenow fragment, in 
order to complete the synthesis of the mutation-bearing 
strand. Thus, a heteroduplex is formed wherein one strand 
encodes the original non-mutated sequence and the second 
strand bears the desired mutation. This heteroduplex vector 
is then used to transform appropriate cells, such as E. coli 
cells, and clones are selected that include recombinant 
vectors bearing the mutated sequence arrangement. 
The preparation of sequence variants of the selected gene 
using site-directed mutagenesis is provided as a means of 
producing potentially useful species and is not meant to be 
limiting, as there are other ways in which sequence variants 
of genes may be obtained. For example, recombinant vectors 
encoding the desired gene may be treated with mutagenic 
agents. Such as hydroxylamine, to obtain sequence variants. 
In certain embodiments, it will be advantageous to 
employ nucleic acid sequences of the present invention in 
combination with an appropriate means, such as a label, for 
determining hybridization. A wide variety of appropriate 
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indicator means are known in the art, including fluorescent, 
radioactive, enzymatic or other ligands, such as avidin/ 
biotin, which are capable of being detected. 
In certain embodiments, one may desire to employ a 
fluorescent label, electroluminescence or an enzyme tag 5 
Such as urease, alkaline phosphatase or peroxidase, instead 
of radioactive or other environmentally undesirable 
reagents. In the case of enzyme tags, calorimetric indicator 
Substrates are known which can be employed to provide a 
detection means visible to the human eye or spectrophoto- 10 
metrically, to identify specific hybridization with comple 
mentary nucleic acid-containing samples. 
In general, it is envisioned that the hybridization probes 
described herein will be useful both as reagents in solution 
hybridization, as in PCRTM, for detection of expression of 
corresponding genes, as well as in embodiments employing 
a Solid phase. In embodiments involving a solid phase, the 
test DNA (or RNA) is adsorbed or otherwise affixed to a 
selected matrix or Surface. This fixed, single-stranded 
nucleic acid is then subjected to hybridization with selected 
probes under desired conditions. 
The selected conditions will depend on the particular 
circumstances based on the particular criteria required (de 
pending, for example, on the G+C content, type of target 
nucleic acid, Source of nucleic acid, size of hybridization 
probe, etc.). Following washing of the hybridized surface to 
remove non-specifically bound probe molecules, hybridiza 
tion is detected, or even quantified, by means of the label. 
b. Vectors and Regulatory Signals 
15 
30 
Vectors of the present invention are designed, primarily, 
to transform cancer cells with a therapeutic WWOX gene 
under the control of regulated eukaryotic promoters (i.e., 
constitutive, inducible, repressable, tissue-specific). Also, 
the vectors may contain a selectable marker if, for no other 35 
reason, to facilitate their manipulation in vitro. However, 
selectable markers may play an important role in producing 
recombinant cells. 
Tables 1 and 2, below, list a variety of regulatory signals 
for use according to the present invention. 40 
TABLE 1. 
Inducible Elements 
Element Inducer References 45 
MT II Phorbol Ester (TFA) Palmiter et al., 1982; Haslinger and 
Heavy metals Karin (R), 1985; Searle et al., 1985; 
Stuart et al., 1985: Imagawa et al., 
1987: Karin , 1987; Angel et al., 
1987b; McNeal et al., 1989 50 
MMTV (mouse Glucocorticoids Huang et al., 1981; Lee et al., 
mammary tu- 1981; Majors and Varmus, 1983; 
mor virus) Chandler et al., 1983; Lee et al., 
1984: Fonta et al., 1985: Sakai 
et al., 1986 
B-Interferon poly(rI)X Tavernier et al., 1983 55 
poly(rc) 
Adeno- E1A Imperiale and Nevins, 1984 
virus 5 E2 
Collagenase Phorbol Ester (TPA) Angel et al., 1987a 
Stromelysin Phorbol Ester (TPA) Angel et al., 1987b 
SV40 Phorbol Ester (TFA) Angel et al., 1987b 60 
Murine MX Interferon, New- Hug et al., 1988 
Gene castle Disease Virus 
GRP78 Gene A231.87 Resendez et al., 1988 
C-2-Macro- IL-6 Kunz et al., 1989 
globulin 
Vimentin Serum Rittling et al., 1989 
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E1A, SV40 Large T Taylor et al., 1989; Taylor and 
Antigen Kingston, 1990a,b 
Phorbol Ester-TPA Mordacq and Linzer, 1989 
PMA Hensel et al., 1989 
Thyroid Hormone Chatterjee et al., 1989 
TABLE 2 
Other Promoter Enhancer Elements 
References 
Banerji et al., 1983; Gilles et al., 1983; Grosschedl and 
Baltimore, 1985; Atchinson and Perry, 1986, 1987: Imler 
et al., 1987; Weinberger et al., 1988; Kiledjian et al., 
1988; Porton et al., 1990 
Queen and Baltimore, 1983; Picard and Schaffner, 1984 
Luria et al., 1987, Winoto and Baltimore, 1989; Redondo 
et al., 1990 
Sullivan and Peterlin, 1987 
Goodbourn et al., 1986; Fujita et al., 1987: Goodbourn 
and Maniatis, 1985 
Greene et al., 1989 
Greene et al., 1989; Lin et al., 1990 
Koch et al., 1989 
Sherman et al., 1989 
Kawamoto et al., 1988; Ng et al., 1989 
Jaynes et al., 1988; Horlick and Benfield, 1989; Johnson 
et al., 1989a 
Costa et al., 1988 
Omitz et al., 1987 
Karin et al., 1987: Culotta and Hamer, 1989 
Pinkert et al., 1987; Angel et al., 1987 
Pinkert et al., 1987, Tronche et al., 1989, 1990 
Godbout et al., 1988; Campere and Tilghman, 1989 
Bodine and Ley, 1987; Perez-Stable and Constantini, 
990 
Trudel and Constantini, 1987 
Cohen et al., 1987 
Triesman, 1986; Deschamps et al., 1985 
Edlund et al., 1985 
Hirsch et al., 1990 
Latimer et al., 1990 
Hwang et al., 1990 
Ripe et al., 1989 
Chang et al., 1989 
Larsen et al., 1986 
Edbrooke et al., 1989 
Yutzey et al., 1989 
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TABLE 2-continued 
Other Promoter Enhancer Elements 
Promoter? 
Enhancer References 
Platelet- Pech et al., 1989 
Derived 
Growth Factor 
Duchenne Klamut et al., 1990 
Muscular 
Dystrophy 
SV40 Banerji et al., 1981; Moreau et al., 1981; Sleigh and 
Lockett, 1985: Firak and Subramanian, 1986; Herr and 
Clarke, 1986: Imbra and Karin, 1986: Kadesch and Berg, 
986: Wang and Calame, 1986: Ondek et al., 1987; Kuhl 
et al., 1987 Schaffner et al., 1988 
Polyoma Swartzendruber and Lehman, 1975; Vasseur et al., 1980: 
Katinka et al., 1980, 1981; Tyndell et al., 1981; Dandolo 
et al., 1983; deVilliers et al., 1984: Hen et al., 1986: 
Satake et al., 1988; Campbell and Villarreal, 1988 
Retroviruses Kriegler and Botchan, 1982, 1983; Levinson et al., 1982; 
Kriegler et al., 1983, 1984a,b, 1988; Bosze et al., 1986: 
Miksicek et al., 1986: Celander and Haseltine, 1987: 
Thiesen et al., 1988: Celander et al., 1988: Chol et al., 
988: Reisman and Rotter, 1989 
Papilloma Campo et al., 1983: Lusky et al., 1983: Spandidos and 
Virus Wilkie, 1983: Spalholz et al., 1985; Lusky and Botchan, 
986; Cripe et al., 1987: Gloss et al., 1987: Hirochika 
et al., 1987, Stephens and Hentschel, 1987: Glue et al., 
988 
Hepatitis Bulla and Siddiqui, 1986; Jameel and Siddiqui, 1986: 
B Virus Shaul and Ben-Levy, 1987: Spandau and Lee, 1988 
Human Im- Muesing et al., 1987; Hauber and Cullan, 1988; 
munodefic- akobovits et al., 1988: Feng and Holland, 1988: Takebe 
iency Virus et al., 1988: Rowen et al., 1988: Berkhout et al., 1989: 
Laspia et al., 1989: Sharp and Marciniak, 1989; 
Braddock et al., 1989 
Cytomegalo- Weber et al., 1984: Boshart et al., 1985; Foecking and 
virus Hofstetter, 1986 
Gibbon Ape Holbrook et al., 1987: Quinn et al., 1989 
Leukemia 
Virus 
The promoters and enhancers that control the transcrip 
tion of protein encoding genes in eukaryotic cells are 
composed of multiple genetic elements. The cellular 
machinery is able to gather and integrate the regulatory 
information conveyed by each element, allowing different 
genes to evolve distinct, often complex patterns of transcrip 
tional regulation. A promoter used in the context of the 
present invention includes constitutive, inducible, and tis 
Sue-specific promoters. 
The term “promoter' will be used here to refer to a group 
of transcriptional control modules that are clustered around 
the initiation site for RNA polymerase II. Much of the 
thinking about how promoters are organized derives from 
analyses of several viral promoters, including those for the 
HSV thymidine kinase (tk) and SV40 early transcription 
units. These studies, augmented by more recent work, have 
shown that promoters are composed of discrete functional 
modules, each consisting of approximately 7–20 bp of DNA, 
and containing one or more recognition sites for transcrip 
tional activator proteins. 
At least one module in each promoter functions to posi 
tion the start site for RNA synthesis. The best known 
example of this is the TATA box, but in some promoters 
lacking a TATA box, Such as the promoter for the mamma 
lian terminal deoxynucleotidyl transferase gene and the 
promoter for the SV40 late genes, a discrete element over 
lying the start site itself helps to fix the place of initiation. 
Additional promoter elements regulate the frequency of 
transcriptional initiation. Typically, these are located in the 












number of promoters have recently been shown to contain 
functional elements downstream of the start site as well. The 
spacing between elements is flexible, so that promoter 
function is preserved when elements are inverted or moved 
relative to one another. In the tk promoter, the spacing 
between elements can be increased to 50 bp apart before 
activity begins to decline. Depending on the promoter, it 
appears that individual elements can function either co 
operatively or independently to activate transcription. 
Enhancers were originally detected as genetic elements 
that increased transcription from a promoter located at a 
distant position on the same molecule of DNA. This ability 
to act over a large distance had little precedent in classic 
studies of prokaryotic transcriptional regulation. Subsequent 
work showed that regions of DNA with enhancer activity are 
organized much like promoters. That is, they are composed 
of many individual elements, each of which binds to one or 
more transcriptional proteins. 
The basic distinction between enhancers and promoters is 
operational. An enhancer region as a whole must be able to 
stimulate transcription at a distance; this need not be true of 
a promoter region or its component elements. On the other 
hand, a promoter must have one or more elements that direct 
initiation of RNA synthesis at a particular site and in a 
particular orientation, whereas enhancers lack these speci 
ficities. Aside from this operational distinction, enhancers 
and promoters are very similar entities. 
Promoters and enhancers have the same general function 
of activating transcription in the cell. They are often over 
lapping and contiguous, often seeming to have a very similar 
modular organization. Taken together, these considerations 
Suggest that enhancers and promoters are homologous enti 
ties and that the transcriptional activator proteins bound to 
these sequences may interact with the cellular transcriptional 
machinery in fundamentally the same way. 
One promoter that may be used in the present invention is 
the cytomegalovirus (CMV) promoter. This promoter is 
commercially available from Invitrogen in the vector pcD 
NAIII, which is preferred for use in the present invention. 
Also contemplated as useful in the present invention are the 
dectin-1 and dectin-2 promoters. Additional viral promoters, 
cellular promoters/enhancers and inducible promoters/en 
hancers that could be used in combination with the present 
invention are listed in Tables 2 and 3. Additionally any 
promoter/enhancer combination (as per the Eukaryotic Pro 
moter Data Base EPDB) could also be used to drive expres 
sion of structural genes encoding oligosaccharide processing 
enzymes, protein folding accessory proteins, selectable 
marker proteins or a heterologous protein of interest. Alter 
natively, a tissue-specific promoter for cancer gene therapy 
(Table 3) or the targeting of tumors (Table 4) may be 
employed with the nucleic acid molecules of the present 
invention. 
TABLE 3 
Candidate tissue-specific promoters for cancer gene therapy 
Normal cells in which 
promoter is active 
Cancers in which 





Most colorectal carcin- Colonic mucosa; gastric 
omas; 50% of lung mucosa; lung epithelia; 
carcinomas; 40–50% eccrine Sweat glands; 
of gastric carcinomas; cells in testes 
most pancreatic carcin 
omas; many breast 
carcinomas 
25 
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Cancers in which 
promoter is active 
Normal cells in which 
promoter is active 
Most prostate Prostate epithelium 
carcinomas 
Majority of non-Small Neurons; lymphocytes; 
cell lung cancers mast cells; eosinophils 
Many lung adeno- Type II pneumocytes; 
carcinomas Clara 
Most small cell Neuroendocrine cells 
lung cancers in lung 
Most adenocarcinomas Glandular epithelial 
(originating from cells in breast, 
any tissue) and in respiratory 
gastrointestinal, and, 
genitourinary tracts 
Most hepatocellular Hepatocytes (under 
carcinomas; possibly certain conditions); 
many testicular testis 
C8CS 
Most hepatocellular Hepatocytes 
carcinomas 
Most melanomas Melanocytes; astrocytes; 
Schwann cells; 
SOle (OS 








Head and neck 
cancers) 
Many squamous cell 





Myelin basic Many gliomas 
protein (MBP) 
Testis-specific Possibly many 
angiotensin-converting testicular cancers 
enzyme (Testis 
specific ACE) 























Cancers in which 
Promoter is active 
Almost all cancers 
Many colorectal carcinomas; 
many melanomas; possibly 
many other cancers 
Most melanomas; many pan 
creatic carcinomas; most 
astrocytomas; keratinocytes; 
possibly many other cancers 
Most lung carcinomas (both 
Small cell and non-Small cell); 
most epithelial colorectal 
carcinomas 
Many melanomas; some non 
Small cell lung carcinomas; 
Some breast carcinomas 
Normal cells in which 







cells in immunoprivileged 
tissues; some cells in lungs, 
ovaries, liver, and prostate 
Proliferating cells (only 
Some cell-types): mammary 
















Candidate promoters for use with a tissue-specific targeting of tumors 
Cancers in which Normal cells in which 
Promoter Promoter is active Promoter is active 
VEGF 70% of all cancers (constitutive Cells at sites of 
overexpression in many cancers) neovascularization (but 
unlike in tumors, expres 
Sion is transient, less 
strong, and never 
constitutive) 
bFGF Presumably many different cells at sites of ischemia 
cancers, since bFGF expression (but unlike tumors, 
is induced by ischemic expression is transient, less 
conditions strong, and never 
constitutive) 
COX-2 Most colorectal carcinomas; Cells at sites of 
many lung carcinomas; possibly inflammation 
many other cancers 
IL-10 Most colorectal carcinomas; Leukocytes 
many lung carcinomas; many 
squamous cell carcinomas of 
head and neck; possibly 
many other cancers 
GRP78, Presumably many different Cells at sites of ischemia 
BP cancers, since GRP7S 
expression is induced by 
tumor-specific conditions 
CAirG Induced by ionization radiation, Cells exposed to ionizing 
elements so conceivably most tumors radiation; leukocytes 
from upon irradiation 
Egr-1 
A signal that may prove useful is a polyadenylation signal 
(hGH, BGH, SV40). The use of internal ribo some binding 
sites (IRES) elements are used to create multigene, or 
polycistronic, messages. IRES elements are able to bypass 
the ribosome scanning model of 5'-methylated cap-depen 
dent translation and begin translation at internal sites (Pel 
letier and Sonenberg, 1988). IRES elements from two mem 
bers of the picornavirus family (polio and 
encephalomyocarditis) have been described (Pelletier and 
Sonenberg, 1988), as well as an IRES from a mammalian 
message (Maceak and Sarnow, 1991). IRES elements can 
be linked to heterologous open reading frames. Multiple 
open reading frames can be transcribed together, each sepa 
rated by an IRES, creating polycistronic messages. By virtue 
of the IRES element, each open reading frame is accessible 
to ribosomes for efficient translation. Multiple genes can be 
efficiently expressed using a single promoter/enhancer to 
transcribe a single message. 
In any event, it will be understood that promoters are 
DNA elements which when positioned functionally 
upstream of a gene leads to the expression of that gene. Most 
transgene constructs of the present invention are function 
ally positioned downstream of a promoter element. 
C. Gene Transfer 
i. Viral Transformation 
a) Adenoviral Infection 
One method for delivery of the recombinant DNA 
involves the use of an adenovirus expression vector. 
Although adenovirus vectors are known to have a low 
capacity for integration into genomic DNA, this feature is 
counterbalanced by the high efficiency of gene transfer 
afforded by these vectors. “Adenovirus expression vector” is 
meant to include those constructs containing adenovirus 
sequences Sufficient to (a) Support packaging of the con 
struct and (b) to ultimately express a recombinant gene 
construct that has been cloned therein. 
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The vector comprises a genetically engineered form of 
adenovirus. Knowledge of the genetic organization or aden 
ovirus, a 36 kb, linear, double-stranded DNA virus, allows 
substitution of large pieces of adenoviral DNA with foreign 
sequences up to 7 kb (Grunhaus and et al., 1992). In contrast 
to retrovirus, the adenoviral infection of host cells does not 
result in chromosomal integration because adenoviral DNA 
can replicate in an episomal manner without potential geno 
toxicity. Also, adenoviruses are structurally stable, and no 
genome rearrangement has been detected after extensive 
amplification. 
Adenovirus is particularly Suitable for use as a gene 
transfer vector because of its mid-sized genome, ease of 
manipulation, high titer, wide target-cell range and high 
infectivity. Both ends of the viral genome contain 100–200 
base pair inverted repeats (ITRs), which are cis elements 
necessary for viral DNA replication and packaging. The 
early (E) and late (L) regions of the genome contain different 
transcription units that are divided by the onset of viral DNA 
replication. The E1 region (E1A and E1 B) encodes proteins 
responsible for the regulation of transcription of the viral 
genome and a few cellular genes. The expression of the E2 
region (E2A and E2B) results in the synthesis of the proteins 
for viral DNA replication. These proteins are involved in 
DNA replication, late gene expression and host cell shut-off 
(Renan, 1990). The products of the late genes, including the 
majority of the viral capsid proteins, are expressed only after 
significant processing of a single primary transcript issued 
by the major late promoter (MLP). The MLP (located at 
16.8 m.u.) is particularly efficient during the late phase of 
infection, and all the mRNAs issued from this promoter 
possess a 5'-tripartite leader (TPL) sequence which makes 
them preferred mRNAs for translation. 
Recombinant adenovirus is generated from homologous 
recombination between shuttle vector and provirus vector. 
Due to the possible recombination between two proviral 
vectors, wild-type adenovirus may be generated from this 
process. Therefore, it is critical to isolate a single clone of 
virus from an individual plaque and examine its genomic 
Structure. 
In nature, adenovirus can package approximately 105% of 
the wild-type genome (Ghosh-Choudhury et al., 1987), 
providing capacity for about 2 extra kb of DNA. Helper cell 
lines derived from human cells such as human embryonic 
kidney cells, muscle cells, hematopoietic cells or other 
human embryonic mesenchymal or epithelial cells may be 
used to make the construct. Alternatively, the helper cells 
may be derived from the cells of other mammalian species 
that are permissive for human adenovirus. Such cells 
include, e.g., Vero cells or other monkey embryonic mes 
enchymal or epithelial cells. 
The adenovirus vector may be replication defective, or at 
least conditionally defective, the nature of the adenovirus 
vector is not believed to be crucial to the successful practice 
of the invention. The adenovirus may be of any of the 42 
different known serotypes or Subgroups A-F. 
Adenovirus growth and manipulation is known to those of 
skill in the art, and exhibits broad host range in vitro and in 
vivo. This group of viruses can be obtained in high titers, 
e.g., 10° 10' plaque-forming units per ml, and they are 
highly infective. The life cycle of adenovirus does not 
require integration into the host cell genome. The foreign 
genes delivered by adenovirus vectors are episomal and, 
therefore, have low genotoxicity to host cells. No side effects 
have been reported in studies of vaccination with wild-type 
adenovirus (Top et al., 1971), demonstrating their safety and 













Adenovirus vectors have been used in eukaryotic gene 
expression (Levrero et al., 1991; Gomez-Foix et al., 1992) 
and vaccine development (Grunhaus et al., 1992; Graham 
and Prevec, 1992). Animal studies have suggested that 
recombinant adenovirus could be used for gene therapy 
(Stratford-Perricaudet and Perricaudet, 1991; Stratford-Per 
ricaudet et al., 1990; Rich et al., 1993). Studies in admin 
istering recombinant adenovirus to different tissues include 
trachea instillation (Rosenfeld et al., 1991; Rosenfeld et al., 
1992), muscle injection (Ragot et al., 1993), peripheral 
intravenous injections (Herz and Gerard, 1993) and stereo 
tactic inoculation into the brain (Le Gal La Salle et al., 
1993). 
b) Retroviral Infection 
A preferred method for delivery of the recombinant DNA 
in the present invention involves the use of an retroviral 
expression vector. The retroviruses are a group of single 
stranded RNA viruses characterized by an ability to convert 
their RNA to double-stranded DNA in infected cells by a 
process of reverse-transcription (Coffin, 1990). The resulting 
DNA then stably integrates into cellular chromosomes as a 
provirus and directs synthesis of viral proteins. The integra 
tion results in the retention of the viral gene sequences in the 
recipient cell and its descendants. The retroviral genome 
contains three genes, gag, pol, and env that code for capsid 
proteins, polymerase enzyme, and envelope components, 
respectively. A sequence found upstream from the gag gene 
contains a signal for packaging of the genome into virions. 
Two long terminal repeat (LTR) sequences are present at the 
5' and 3' ends of the viral genome. These contain strong 
promoter and enhancer sequences and are also required for 
integration in the host cell genome (Coffin, 1990). 
In order to construct a retroviral vector, a nucleic acid 
encoding a gene of interest is inserted into the viral genome 
in the place of certain viral sequences to produce a virus that 
is replication-defective. In order to produce virions, a pack 
aging cell line containing the gag, pol, and enV genes but 
without the LTR and packaging components is constructed 
(Mann et al., 1983). When a recombinant plasmid containing 
a cDNA, together with the retroviral LTR and packaging 
sequences is introduced into this cell line (by calcium 
phosphate precipitation for example), the packaging 
sequence allows the RNA transcript of the recombinant 
plasmid to be packaged into viral particles, which are then 
secreted into the culture media (Nicolas and Rubenstein, 
1988: Temin, 1986; Mann et al., 1983). The media contain 
ing the recombinant retroviruses is then collected, optionally 
concentrated, and used for gene transfer. Retroviral vectors 
are able to infect a broad variety of cell types. However, 
integration and stable expression require the division of host 
cells (Paskind et al., 1975). 
Concern with the use of defective retrovirus vectors is the 
potential appearance of wild-type replication-competent 
virus in the packaging cells. This can result from recombi 
nation events in which the intact sequence from the recom 
binant virus inserts upstream from the gag, pol, env 
sequence integrated in the host cell genome. However, 
packaging cell lines are available that should greatly 
decrease the likelihood of recombination (Markowitz et 
1988: Hersdorffer et al., 1990). 
c) AAV Infection 
Adeno-associated virus (AAV) is an attractive vector 
system for use in the present invention as it has a high 
frequency of integration and it can infect nondividing cells, 
thus making it useful for delivery of genes into mammalian 
cells in tissue culture (Muzyczka, 1992). AAV has a broad 
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host range for infectivity (Tratschin, et al., 1984; Laughlin, 
et al., 1986; Lebkowski, et al., 1988; McLaughlin, et al., 
1988), which means it is applicable for use with the present 
invention. Details concerning the generation and use of 
rAAV vectors are described in U.S. Pat. No. 5,139,941 and 
U.S. Pat. No. 4,797.368, each incorporated herein by refer 
CCC. 
Studies demonstrating the use of AAV in gene delivery 
include LaFace et al. (1988); Zhou et al. (1993); Flotte et al. 
(1993); and Walsh et al. (1994). Recombinant AAV vectors 
have been used successfully for in vitro and in vivo trans 
duction of marker genes (Lebkowski et al., 1988; Samulski 
et al., 1989: Shelling and Smith, 1994: Yoder et al., 1994: 
Zhou et al., 1994; Hermonat and Muzyczka, 1984; Tratschin 
et al., 1985; McLaughlin et al., 1988) and genes involved in 
human diseases (Flotte et al., 1992: Ohi et al., 1990; Walsh 
et al., 1994: Wei et al., 1994). Recently, an AAV vector has 
been approved for phase I human trials for the treatment of 
cystic fibrosis. 
AAV is a dependent parvovirus in that it requires coin 
fection with another virus (either adenovirus or a member of 
the herpes virus family) to undergo a productive infection in 
cultured cells (Muzyczka, 1992). In the absence of coinfec 
tion with helper virus, the wild-type AAV genome integrates 
through its ends into human chromosome 19 where it resides 
in a latent state as a provirus (Kotin et al., 1990; Samulski 
et al., 1991). ra AV, however, is not restricted to chromo 
some 19 for integration unless the AAV Rep protein is also 
expressed (Shelling and Smith, 1994). When a cell carrying 
an AAV provirus is superinfected with a helper virus, the 
AAV genome is “rescued from the chromosome or from a 
recombinant plasmid, and a normal productive infection is 
established (Samulski et al., 1989; McLaughlin et al., 1988: 
Kotin et al., 1990; Muzyczka, 1992). 
Typically, recombinant AAV (ra AV) virus is made by 
cotransfecting a plasmid containing the gene of interest 
flanked by the two AAV terminal repeats (McLaughlin et al., 
1988; Samulski et al., 1989; each incorporated herein by 
reference) and an expression plasmid containing the wild 
type AAV coding sequences without the terminal repeats, for 
example p|M45 (McCarty et al., 1991; incorporated herein 
by reference). The cells are also infected or transfected with 
adenovirus or plasmids carrying the adenovirus genes 
required for AAV helper function. ra AV virus stocks made 
in Such fashion are contaminated with adenovirus which 
must be physically separated from the rAAV particles (for 
example, by cesium chloride density centrifugation). Alter 
natively, adenovirus vectors containing the AAV coding 
regions or cell lines containing the AAV coding regions and 
Some or all of the adenovirus helper genes could be used 
(Yang et al., 1994; Clarket al., 1995). Cell lines carrying the 
rAAV DNA as an integrated provirus can also be used 
(Flotte et al., 1995). 
d) Other Viral Vectors 
Other viral vectors may be employed as constructs in the 
present invention. Vectors derived from viruses such as 
vaccinia virus (Ridgeway, 1988: Baichwal and Sugden, 
1986; Coupar et al., 1988) and herpesviruses may be 
employed. They offer several attractive features for various 
mammalian cells (Friedmann, 1989; Ridgeway, 1988: 
Baichwal and Sugden, 1986; Coupar et al., 1988; Horwich 
et al., 1990). 
A molecularly cloned strain of Venezuelan equine 
encephalitis (VEE) virus has been genetically refined as a 
replication competent vaccine vector for the expression of 
heterologous viral proteins (Davis et al., 1996). Studies have 














responses and has been suggested that VEE may be an 
extremely useful vector for immunizations (Caley et al., 
1997). It is contemplated in the present invention, that VEE 
virus may be useful in targeting dendritic cells. 
With the recent recognition of defective hepatitis B 
viruses, new insight was gained into the structure-function 
relationship of different viral sequences. In vitro studies 
showed that the virus could retain the ability for helper 
dependent packaging and reverse transcription despite the 
deletion of up to 80% of its genome (Horwich et al., 1990). 
This suggested that large portions of the genome could be 
replaced with foreign genetic material. 
In still further embodiments of the present invention, the 
nucleic acid encoding human WWOX is housed within an 
infective virus that has been engineered to express a specific 
binding ligand. The virus particle will thus bind specifically 
to the cognate receptors of the target cell and deliver the 
contents to the cell. A novel approach designed to allow 
specific targeting of retrovirus vectors was recently devel 
oped based on the chemical modification of a retrovirus by 
the chemical addition of lactose residues to the viral enve 
lope. Such modifications permit specific infection of cancer 
and/or hyperproliferative cells via specific receptors present 
on these cells. 
For example, targeting of recombinant retroviruses was 
designed in which biotinylated antibodies against a retrovi 
ral envelope protein and against a specific cell receptor were 
used. The antibodies were coupled via the biotin compo 
nents by using streptavidin (Roux et al., 1989). Using 
antibodies against major histocompatibility complex class I 
and class II antigens, they demonstrated the infection of a 
variety of human cells that bore those surface antigens with 
an ecotropic virus in vitro (Roux et al., 1989). 
ii. Non-Viral Delivery 
In addition to viral delivery of the nucleic acid encoding 
full length or truncated WWOX protein, the following are 
additional methods of recombinant gene delivery to a given 
host cell and are thus considered in the present invention. 
a) Electroporation 
In certain preferred embodiments of the present invention, 
the gene construct is introduced into target hyperprolifera 
tive cells via electroporation. Electroporation involves the 
exposure of cells (or tissues) and DNA (or a DNA complex) 
to a high-voltage electric discharge. 
Transfection of eukaryotic cells using electroporation has 
been quite successful. Mouse pre-B lymphocytes have been 
transfected with human kappa-immunoglobulin genes (Pot 
ter et al., 1984), and rat hepatocytes have been transfected 
with the chloramphenicol acetyltransferase gene (Tur-Kaspa 
et al., 1986) in this manner. 
It is contemplated that electroporation conditions for 
hyperproliferative cells from different sources may be opti 
mized. One may particularly wish to optimize such param 
eters as the Voltage, the capacitance, the time and the 
electroporation media composition. The execution of other 
routine adjustments will be known to those of skill in the art. 
b) Particle Bombardment 
Another embodiment of the invention for transferring a 
naked DNA construct into cells involves particle bombard 
ment. This method depends on the ability to accelerate 
DNA-coated microprojectiles to a high velocity allowing 
them to pierce cell membranes and enter cells without 
killing them (Klein et 1987). The microprojectiles used have 
consisted of biologically inert Substances such as tungsten, 
platinum, or gold beads. 
It is contemplated that in Some instances DNA precipita 
tion onto metal particles would not be necessary for DNA 
US 7,060,811 B2 
31 
delivery to a recipient cell using particle bombardment. It is 
contemplated that particles may contain DNA rather than be 
coated with DNA. Hence it is proposed that DNA-coated 
particles may increase the level of DNA delivery via particle 
bombardment but are not, in and of themselves, necessary. 
Several devices for accelerating small particles have been 
developed. One such device relies on a high Voltage dis 
charge to generate an electrical current, which in turn 
provides the motive force (Yang et al., 1990). Another 
method involves the use of a Biolistic Particle Delivery 
System, which can be used to propel particles coated with 
DNA through a screen, such as stainless steel or Nytex 
screen, onto a filter Surface covered with cells in Suspension. 
The screen disperses the particles so that they are not 
delivered to the recipient cells in large aggregates. It is 
believed that a screen intervening between the projectile 
apparatus and the cells to be bombarded reduces the size of 
projectile aggregates and may contribute to a higher fre 
quency of transformation by reducing the damage inflicted 
on the recipient cells by projectiles that are too large. 
For the bombardment, cells in suspension are preferably 
concentrated on filters, or alternatively on solid culture 
medium. The cells to be bombarded are positioned at an 
appropriate distance below the macroprojectile stopping 
plate. If desired, one or more screens are also positioned 
between the acceleration device and the cells to be bom 
barded. 
In bombardment transformation, one may optimize the 
prebombardment culturing conditions and the bombardment 
parameters to yield the maximum numbers of stable trans 
formants. Both the physical and biological parameters for 
bombardment are important in this technology. Physical 
factors are those that involve manipulating the DNA/micro 
projectile precipitate or those that affect the flight and 
Velocity or either the macro- or microprojectiles. Biological 
factors include all steps involved in manipulation of cells 
before and immediately after bombardment, the osmotic 
adjustment of target cells to help alleviate the trauma asso 
ciated with bombardment, and also the nature of the trans 
forming DNA, such as linearized DNA or intact supercoiled 
plasmids. Recently, results from a clinical trial evaluating 
utility of this delivery system for vaccination was published. 
The study was designed to determine the safety and immu 
nogenicity in Volunteers of a DNA vaccine consisting of a 
plasmid encoding hepatitis B surface antigen delivered by 
the PowderJect XR1 gene delivery system into human skin 
(Tacket et al., 1999). 
Accordingly, it is contemplated that one may wish to 
adjust various bombardment parameters in Small scale stud 
ies to fully optimize the conditions. One may particularly 
wish to adjust physical parameters such as gap distance, 
flight distance, tissue distance and helium pressure. One also 
may optimize the trauma reduction factors by modifying 
conditions which influence the physiological state of the 
recipient cells and which may therefore influence transfor 
mation and integration efficiencies. For example, the 
osmotic state, tissue hydration and the Subculture stage or 
cell cycle of the recipient cells may be adjusted for optimum 
transformation. The execution of other routine adjustments 
will be known to those of skill in the art. 
c) Calcium Phosphate Co-Precipitation or DEAE-Dextran 
Treatment 
In other embodiments of the present invention, the trans 
genic construct is introduced to the cells using calcium 
phosphate co-precipitation. Mouse primordial germ cells 
have been transfected with the SV40 large T antigen, with 














have been transfected with adenovirus 5 DNA (Graham and 
Van Der Eb, 1973) using this technique. Also in this manner, 
mouse L(A9), mouse C127, CHO, CV-1, BHK, NIH3T3 and 
HeLa cells were transfected with a neomycin marker gene 
(Chen and Okayama, 1987), and rathepatocytes were trans 
fected with a variety of marker genes (Rippe et al., 1990). 
In another embodiment, the expression construct is deliv 
ered into the cell using DEAE-dextran followed by poly 
ethylene glycol. In this manner, reporter plasmids were 
introduced into mouse myeloma and erythroleukemia cells 
(Gopal, 1985). 
d) Direct Microinjection or Sonication Loading 
Further embodiments of the present invention include the 
introduction of the nucleic acid construct by direct micro 
injection or Sonication loading. Direct microinjection has 
been used to introduce nucleic acid constructs into Xenopus 
oocytes (Harland and Weintraub, 1985), and LTK fibro 
blasts have been transfected with the thymidine kinase gene 
by sonication loading (Fechheimer et al., 1987). 
e) Lipid-Mediated Transformation 
In a further embodiment of the invention, the gene con 
struct may be entrapped in a liposome or lipid formulation. 
Liposomes are vesicular structures characterized by a phos 
pholipid bilayer membrane and an inner aqueous medium. 
Multilamellar liposomes have multiple lipid layers separated 
by aqueous medium. They form spontaneously when phos 
pholipids are Suspended in an excess of aqueous solution. 
The lipid components undergo self-rearrangement before the 
formation of closed structures and entrap water and dis 
solved solutes between the lipid bilayers (Ghosh and Bach 
hawat, 1991). Also contemplated is a gene construct com 
plexed with Lipofectamine (Gibco BRL). 
Lipid-mediated nucleic acid delivery and expression of 
foreign DNA in vitro has been very successful (Nicolau and 
Sene, 1982: Fraley et al., 1979; Nicolau et al., 1987). Wong 
et al. (1980) demonstrated the feasibility of lipid-mediated 
delivery and expression of foreign DNA in cultured chick 
embryo, HeLa and hepatoma cells. 
Lipid based non-viral formulations provide an alternative 
to adenoviral gene therapies. Although many cell culture 
studies have documented lipid based non-viral gene transfer, 
systemic gene delivery via lipid based formulations has been 
limited. A major limitation of non-viral lipid based gene 
delivery is the toxicity of the cationic lipids that comprise 
the non-viral delivery vehicle. The in vivo toxicity of 
liposomes partially explains the discrepancy between in 
vitro and in vivo gene transfer results. Another factor 
contributing to this contradictory data is the difference in 
lipid vehicle stability in the presence and absence of serum 
proteins. The interaction between lipid vehicles and serum 
proteins has a dramatic impact on the stability characteristics 
of lipid vehicles (Yang and Huang, 1997). Cationic lipids 
attract and bind negatively charged serum proteins. Lipid 
vehicles associated with serum proteins are either dissolved 
or taken up by macrophages leading to their removal from 
circulation. Current in vivo lipid delivery methods use 
Subcutaneous, intradermal, intratumoral, or intracranial 
injection to avoid the toxicity and Stability problems asso 
ciated with cationic lipids in the circulation. The interaction 
of lipid vehicles and plasma proteins is responsible for the 
disparity between the efficiency of in vitro (Felgner et al., 
1987) and in vivo gene transfer (Zhu et al., 1993; Solodinet 
al., 1995: Thierry et al., 1995: Tsukamoto et al., 1995: 
Aksentijevich et al., 1996). 
The production of lipid formulations often is accom 
plished by Sonication or serial extrusion of liposomal mix 
tures after (I) reverse phase evaporation (II) dehydration 
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rehydration (III) detergent dialysis and (IV) thin film 
hydration. Once manufactured, lipid structures can be used 
to encapsulate compounds that are toxic (chemotherapeu 
tics) or labile (nucleic acids) when in circulation. Lipid 
encapsulation has resulted in a lower toxicity and a longer 
serum half-life for such compounds (Gabizon et al., 1996). 
Numerous disease treatments are using lipid based gene 
transfer strategies to enhance conventional or establish novel 
therapies, in particular therapies for treating cancers. 
In certain embodiments of the invention, the lipid vehicle 
may be complexed with a hemagglutinating virus (HVJ). 
This has been shown to facilitate fusion with the cell 
membrane and promote cell entry of lipid-encapsulated 
DNA (Kaneda et al., 1989). In other embodiments, the lipid 
vehicle may be complexed or employed in conjunction with 
nuclear non-histone chromosomal proteins (HMG-1) (Kato 
et al., 1991). In yet further embodiments, the lipid vehicle 
may be complexed or employed in conjunction with both 
HVJ and HMG-1. 
E. WWOX Protein, Polypeptides, and Peptides 
The invention contemplates the use of a WWOX polypep 
tide in the treatment of cancers. In some embodiments a 
full-length or a substantially full-length WWOX polypep 
tide may be used. The term “full-length” refers to a WWOX 
polypeptide that contains at least the 414 amino acids 
encoded by the WWOX cDNA. The term “substantially 
full-length” in the context of WWOX refers to a WWOX 
polypeptide that contains at least 80% of the contiguous 
amino acids of the full-length WWOX polypeptide. How 
ever, it is also contemplated that WWOX polypeptides 
containing at least about 85%, 90%, and 95% of SEQ ID 
NO:2, or SEQID NO:31, or SEQID NO:33, are within the 
scope of the invention as “substantially full-length” 
WWOX. In other embodiments the WWOX polypeptide 
comprises at least 90 contiguous amino acid residues of SEQ 
ID NO:2. In still other aspects, the WWOX polypeptide 
comprises at least 150 contiguous amino acid residues of 
SEQ ID NO:2 
Some embodiments contemplate the attachment of a 
heterologous signal sequence to the WWOX polypeptide to 
make it secreted. 
The term “biologically functional equivalent” is well 
understood in the art and is further defined in detail herein. 
Accordingly, a sequence that has between about 70% and 
about 80%; or more preferably, between about 81% and 
about 90%; or even more preferably, between about 91% 
and about 99% of amino acids that are identical or func 
tionally equivalent to the amino acids of SEQ ID NO:2, or 
SEQ ID NO:31, or SEQ ID NO:33, will be a sequence that 
is “essentially as set forth in SEQ ID NO:2, or SEQ ID 
NO:31, or SEQID NO:33” provided the biological activity 
of the protein, polypeptide, or peptide is maintained. 
The term “functionally equivalent codon’ is used herein 
to refer to codons that encode the same amino acid, such as 
the six codons for arginine and serine, and also refers to 
codons that encode biologically equivalent amino acids (see 
Table 5). 
Excepting intronic and flanking regions, and allowing for 
the degeneracy of the genetic code, nucleic acid sequences 
that have between about 70% and about 79%; or more 
preferably, between about 80% and about 89%; or even 
more particularly, between about 90% and about 99%; of 
nucleotides that are identical to the nucleotides of SEQ ID 
NO:1, or SEQID NO:30, or SEQID NO:32, will be nucleic 
acid sequences that are “essentially as set forth in SEQ ID 
NO:1, or SEQID NO:30, or SEQID NO:32. It will also be 














nucleic acid and amino acid sequences of SEQID NO:1, or 
SEQ ID NO:30, or SEQ ID NO:32, and SEQ ID NO:2, or 
SEQ ID NO:31, or SEQ ID NO:33, respectively. Recombi 
nant vectors and isolated nucleic acid segments may there 
fore variously include these coding regions themselves, 
coding regions bearing selected alterations or modifications 
in the basic coding region, and they may encode larger 
polypeptides or peptides that nevertheless include Such 
coding regions or may encode biologically functional 
equivalent proteins, polypeptide or peptides that have vari 
ant amino acids sequences. 
The nucleic acids of the present invention encompass 
biologically functional equivalent WWOX proteins, 
polypeptides, or peptides. Such sequences may arise as a 
consequence of codon redundancy or functional equivalency 
that are known to occur naturally within nucleic acid 
sequences or the proteins, polypeptides or peptides thus 
encoded. Alternatively, functionally equivalent proteins, 
polypeptides or peptides may be created via the application 
of recombinant DNA technology, in which changes in the 
protein, polypeptide or peptide structure may be engineered, 
based on considerations of the properties of the amino acids 
being exchanged. Recombinant changes may be introduced, 
for example, through the application of site-directed 
mutagenesis techniques as discussed herein below, e.g., to 
introduce improvements or alterations to the antigenicity of 
the protein, polypeptide or peptide, or to test mutants in 
order to examine WWOX protein, polypeptide, or peptide 
activity at the molecular level. 
Fusion proteins, polypeptides or peptides may be pre 
pared, e.g., where the WWOX coding regions are aligned 
within the same expression unit with other proteins, 
polypeptides or peptides having desired functions. Non 
limiting examples of Such desired functions of expression 
sequences include purification or immunodetection purposes 
for the added expression sequences, e.g., proteinaceous 
compositions that may be purified by affinity chromatogra 
phy or the enzyme labeling of coding regions, respectively. 
TABLE 5 
CODON TABLE 
Amino Acids Codons 
Alanine Ala A GCAGCC GCG GCU 
Cysteine Cys C UGC UGU 
Aspartic acid Asp D GAC GAU 
Glutamic acid Glu E GAA GAG 
Phenylalanine Phe F UUCUUU 
Glycine Gly G. GGA GGC GGG GGU 
Histidine His H CAC CAU 
Isoleucine Ile I AUAAUCAUU 
Lysine Lys K AAAAAG 
Leucine Leu L UUAUUG CUACUC CUG CUU 
Methionine Met M AUG 
Asparagine ASn N AACAAU 
Proline Pro P CCACCC CCG CCU 
Glutamine Gln Q CAA CAG 
Arginine Arg R AGA AGG CGA CGC CGG CGU 
Serine Ser S AGC AGU UCAUCC UCG UCU 
Threonine Thr T ACA ACC ACG ACU 
Valine Wall W. GUAGUC GUG GUU 
Tryptophan Trp W UGG 
Tyrosine Tyr Y UAC UAU 
It also will be understood that amino acid and nucleic acid 
sequences may include additional residues, such as addi 
tional N- or C-terminal amino acids or 5' or 3' sequences, 
and yet still be essentially as set forth in one of the sequences 
disclosed herein, so long as the sequence meets the criteria 
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set forth above, including the maintenance of biological 
protein activity where protein expression is concerned. The 
addition of terminal sequences particularly applies to nucleic 
acid sequences that may, for example, include various 
non-coding sequences flanking either of the 5' or 3' portions 
of the coding region or may include various internal 
sequences, i.e., introns, which are known to occur within 
genes. 
The following is a discussion based upon changing of the 
amino acids of a protein to create an equivalent, or even an 
improved, second-generation molecule. For example, cer 
tain amino acids may be substituted for other amino acids in 
a protein structure without appreciable loss of interactive 
binding capacity with structures such as, for example, anti 
gen-binding regions of antibodies or binding sites on Sub 
strate molecules. Since it is the interactive capacity and 
nature of a protein that defines that protein's biological 
functional activity, certain amino acid substitutions can be 
made in a protein sequence, and in its underlying DNA 
coding sequence, and nevertheless produce a protein with 
like properties. It is thus contemplated by the inventors that 
various changes may be made in the DNA sequences of 
genes without appreciable loss of their biological utility or 
activity, as discussed below. Table 5 shows the codons that 
encode particular amino acids. 
In making Such changes, the hydropathic index of amino 
acids may be considered. The importance of the hydropathic 
amino acid index in conferring interactive biologic function 
on a protein is generally understood in the art (Kyte & 
Doolittle, 1982). It is accepted that the relative hydropathic 
character of the amino acid contributes to the secondary 
structure of the resultant protein, which in turn defines the 
interaction of the protein with other molecules, for example, 
enzymes, Substrates, receptors, DNA, antibodies, antigens, 
and the like. 
It also is understood in the art that the substitution of like 
amino acids can be made effectively on the basis of hydro 
philicity. U.S. Pat. No. 4,554,101, incorporated herein by 
reference, states that the greatest local average hydrophilic 
ity of a protein, as governed by the hydrophilicity of its 
adjacent amino acids, correlates with a biological property 
of the protein. As detailed in U.S. Pat. No. 4,554,101, the 
following hydrophilicity values have been assigned to amino 
acid residues: arginine (+3.0); lysine (+3.0); aspartate 
(+3.0t1); glutamate (+3.0t1); serine (+0.3); asparagine 
(+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); pro 
line (-0.5+1); alanine (-0.5); histidine *-0.5); cysteine 
(-1,0); methionine (-1.3); valine (-1.5); leucine (-1.8); 
isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); 
tryptophan (-3.4). 
It is understood that an amino acid can be substituted for 
another having a similar hydrophilicity value and still pro 
duce a biologically equivalent and immunologically equiva 
lent protein. In Such changes, the Substitution of amino acids 
whose hydrophilicity values are within +2 is preferred, those 
that are within +1 are particularly preferred, and those within 
+0.5 are even more particularly preferred. 
As outlined above, amino acid Substitutions generally are 
based on the relative similarity of the amino acid side-chain 
substituents, for example, their hydrophobicity, hydrophi 
licity, charge, size, and the like. Exemplary Substitutions that 
take into consideration the various foregoing characteristics 
are well known to those of skill in the art and include: 
arginine and lysine; glutamate and aspartate; serine and 














Another embodiment for the preparation of polypeptides 
according to the invention is the use of peptide mimetics. 
Mimetics are peptide-containing molecules that mimic ele 
ments of protein secondary structure. The underlying ratio 
male behind the use of peptide mimetics is that the peptide 
backbone of proteins exists chiefly to orient amino acid side 
chains in Such a way as to facilitate molecular interactions, 
Such as those of antibody and antigen. A peptide mimetic is 
expected to permit molecular interactions similar to the 
natural molecule. These principles may be used, in conjunc 
tion with the principles outline above, to engineer second 
generation molecules having many of the natural properties 
of WWOX, but with altered and even improved character 
istics. 
(a) Fusion Proteins 
A specialized kind of insertional variant is the fusion 
protein. This molecule generally has all or a substantial 
portion of the native molecule, linked at the N- or C-termi 
nus, to all or a portion of a second polypeptide. For example, 
fusions typically employ leader sequences from other spe 
cies to permit the recombinant expression of a protein in a 
heterologous host. Another useful fusion includes the addi 
tion of an immunologically active domain, such as an 
antibody epitope, to facilitate purification of the fusion 
protein. Inclusion of a cleavage site at or near the fusion 
junction will facilitate removal of the extraneous polypep 
tide after purification. Other useful fusions include linking 
of functional domains, such as active sites from enzymes 
Such as a hydrolase, glycosylation domains, cellular target 
ing signals or transmembrane regions. 
(b) Protein Purification 
It may be desirable to purify WWOX or variants thereof. 
Protein purification techniques are well known to those of 
skill in the art. These techniques involve, at one level, the 
crude fractionation of the cellular milieu to polypeptide and 
non-polypeptide fractions. Having separated the polypeptide 
from other proteins, the polypeptide of interest may be 
further purified using chromatographic and electrophoretic 
techniques to achieve partial or complete purification (or 
purification to homogeneity). Analytical methods particu 
larly Suited to the preparation of a pure peptide are ion 
exchange chromatography, exclusion chromatography; 
polyacrylamide gel electrophoresis; isoelectric focusing. A 
particularly efficient method of purifying peptides is fast 
protein liquid chromatography or even HPLC. 
Certain aspects of the present invention concern the 
purification, and in particular embodiments, the Substantial 
purification, of an encoded protein or peptide. The term 
“purified protein or peptide' as used herein, is intended to 
refer to a composition, isolatable from other components, 
wherein the protein or peptide is purified to any degree 
relative to its naturally-obtainable state. A purified protein or 
peptide therefore also refers to a protein or peptide, free 
from the environment in which it may naturally occur. 
Generally, “purified will refer to a protein or peptide 
composition that has been Subjected to fractionation to 
remove various other components, and which composition 
substantially retains its expressed biological activity. Where 
the term “substantially purified' is used, this designation 
will refer to a composition in which the protein or peptide 
forms the major component of the composition, Such as 
constituting about 50%, about 60%, about 70%, about 80%, 
about 90%, about 95% or more of the proteins in the 
composition. 
Various methods for quantifying the degree of purification 
of the protein or peptide will be known to those of skill in 
the art in light of the present disclosure. These include, for 
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example, determining the specific activity of an active 
fraction, or assessing the amount of polypeptides within a 
fraction by SDS/PAGE analysis. A preferred method for 
assessing the purity of a fraction is to calculate the specific 
activity of the fraction, to compare it to the specific activity 
of the initial extract, and to thus calculate the degree of 
purity, herein assessed by a “-fold purification number.” The 
actual units used to represent the amount of activity will, of 
course, be dependent upon the particular assay technique 
chosen to follow the purification and whether or not the 
expressed protein or peptide exhibits a detectable activity. 
Various techniques Suitable for use in protein purification 
will be well known to those of skill in the art. These include, 
for example, precipitation with ammonium Sulphate, PEG, 
antibodies and the like or by heat denaturation, followed by 
centrifugation; chromatography steps such as ion exchange, 
gel filtration, reverse phase, hydroxylapatite and affinity 
chromatography; isoelectric focusing; gel electrophoresis; 
and combinations of Such and other techniques. As is 
generally known in the art, it is believed that the order of 
conducting the various purification steps may be changed, or 
that certain steps may be omitted, and still result in a Suitable 
method for the preparation of a substantially purified protein 
or peptide. 
There is no general requirement that the protein or peptide 
always be provided in their most purified state. Indeed, it is 
contemplated that less substantially purified products will 
have utility in certain embodiments. Partial purification may 
be accomplished by using fewer purification steps in com 
bination, or by utilizing different forms of the same general 
purification scheme. For example, it is appreciated that a 
cation-exchange column chromatography performed utiliz 
ing an HPLC apparatus will generally result in a greater 
“-fold' purification than the same technique utilizing a low 
pressure chromatography system. Methods exhibiting a 
lower degree of relative purification may have advantages in 
total recovery of protein product, or in maintaining the 
activity of an expressed protein. 
It is known that the migration of a polypeptide can vary, 
sometimes significantly, with different conditions of SDS/ 
PAGE (Capaldi et al., 1977). It will therefore be appreciated 
that under differing electrophoresis conditions, the apparent 
molecular weights of purified or partially purified expression 
products may vary. 
High Performance Liquid Chromatography (HPLC) is 
characterized by a very rapid separation with extraordinary 
resolution of peaks. This is achieved by the use of very fine 
particles and high pressure to maintain an adequate flow 
rate. Separation can be accomplished in a matter of minutes, 
or at most an hour. Moreover, only a very small volume of 
the sample is needed because the particles are so Small and 
close-packed that the void volume is a very small fraction of 
the bed volume. Also, the concentration of the sample need 
not be very great because the bands are so narrow that there 
is very little dilution of the sample. 
Gel chromatography, or molecular sieve chromatography, 
is a special type of partition chromatography that is based on 
molecular size. The theory behind gel chromatography is 
that the column, which is prepared with tiny particles of an 
inert Substance that contain Small pores, separates larger 
molecules from Smaller molecules as they pass through or 
around the pores, depending on their size. As long as the 
material of which the particles are made does not adsorb the 
molecules, the sole factor determining rate of flow is the 
size. Hence, molecules are eluted from the column in 
decreasing size, so long as the shape is relatively constant. 













ecules of different size because separation is independent of 
all other factors such as pH, ionic strength, temperature, etc. 
There also is virtually no adsorption, less Zone spreading and 
the elution volume is related in a simple matter to molecular 
weight. 
Affinity Chromatography is a chromatographic procedure 
that relies on the specific affinity between a substance to be 
isolated and a molecule that it can specifically bind to. This 
is a receptor-ligand type interaction. The column material is 
synthesized by covalently coupling one of the binding 
partners to an insoluble matrix. The column material is then 
able to specifically adsorb the substance from the solution. 
Elution occurs by changing the conditions to those in which 
binding will not occur (e.g., alter pH, ionic strength, and 
temperature). 
A particular type of affinity chromatography useful in the 
purification of carbohydrate containing compounds is lectin 
affinity chromatography. Lectins are a class of Substances 
that bind to a variety of polysaccharides and glycoproteins. 
Lectins are usually coupled to agarose by cyanogen bro 
mide. Conconavalin A coupled to Sepharose was the first 
material of this sort to be used and has been widely used in 
the isolation of polysaccharides and glycoproteins other 
lectins that have been include lentil lectin, wheat germ 
agglutinin which has been useful in the purification of 
N-acetyl glucosaminyl residues and Helix pomatia lectin. 
Lectins themselves are purified using affinity chromatogra 
phy with carbohydrate ligands. Lactose has been used to 
purify lectins from castor bean and peanuts; maltose has 
been useful in extracting lectins from lentils and jack bean: 
N-acetyl-D-galactosamine is used for purifying lectins from 
soybean: N-acetylglucosaminyl binds to lectins from wheat 
germ; D-galactosamine has been used in obtaining lectins 
from clams and L-fucose will bind to lectins from lotus. 
The matrix should be a substance that itself does not 
adsorb molecules to any significant extent and that has a 
broad range of chemical, physical and thermal stability. The 
ligand should be coupled in Such a way as to not affect its 
binding properties. The ligand also should provide relatively 
tight binding. And it should be possible to elute the sub 
stance without destroying the sample or the ligand. One of 
the most common forms of affinity chromatography is 
immunoaffinity chromatography. The generation of antibod 
ies that would be suitable for use in accord with the present 
invention is discussed below. 
F. Antibodies 
a. Antibody Generation 
A “WWOX-antigen' is defined herein as mutated 
WWOX peptide(s) or polypeptide(s) and/or those WWOX 
polypeptides or proteins that are expressed in higher con 
centrations that are expressed in cancers or hyperprolifera 
tive states involving WWOX. Polyclonal or monoclonal 
antibodies specific for such WWOX-antigens have utilities 
in several applications. These include the production of 
diagnostic kits for use in detecting and diagnosing cancer. 
An additional use is to link such antibodies to therapeutic 
agents, such as chemotherapeutic agents, and to administer 
the antibodies to individuals with cancer, thereby selectively 
targeting the cancer cells for destruction. 
Means for preparing and characterizing antibodies are 
well known in the art (See, e.g., Antibodies: A Laboratory 
Manual, Cold Spring Harbor Laboratory, 1988; incorporated 
herein by reference). Antibodies to WWOX peptides or 
protein may be generated using such standard techniques. 
Briefly, a polyclonal antibody is prepared by immunizing 
an animal with an immunogenic composition in accordance 
with the present invention and collecting antisera from that 
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immunized animal. A wide range of animal species can be 
used for the production of antisera Such as, a rabbit, a mouse, 
a rat, a hamster, a guinea pig or a goat. 
As is well known in the art, a given composition may vary 
in its immunogenicity. It is often necessary therefore to 
boost the host immune system, as may be achieved by 
coupling a peptide or polypeptide immunogen to a carrier. 
Exemplary and preferred carriers are keyhole limpet 
hemocyanin (KLH) and bovine serum albumin (BSA). 
Other albumins such as ovalbumin, mouse serum albuminor 
rabbit serum albumin can also be used as carriers. Means for 
conjugating a polypeptide to a carrier protein are well 
known in the art and include glutaraldehyde, m-maleimido 
bencoyl-N-hydroxysuccinimide ester, carbodiimyde and 
bis-biazotized benzidine. 
As also is well known in the art, the immunogenicity of 
a particular immunogen composition can be enhanced by the 
use of non-specific stimulators of the immune response, 
known as adjuvants. Exemplary and preferred adjuvants 
include complete Freund's adjuvant (a non-specific stimu 
lator of the immune response containing killed Mycobacte 
rium tuberculosis), incomplete Freund's adjuvants and alu 
minum hydroxide adjuvant. 
A variety of routes can be used to administer the immu 
nogen (Subcutaneous, intramuscular, intradermal, intrave 
nous and intraperitoneal). The production of polyclonal 
antibodies may be monitored by sampling blood of the 
immunized animal at various points following immuniza 
tion. 
A second, booster injection, also may be given. The 
process of boosting and tittering is repeated until a suitable 
titer is achieved. When a desired level of immunogenicity is 
obtained, the immunized animal can be bled and the serum 
isolated and stored, and/or the animal can be used to 
generate MAbs. 
For production of rabbit polyclonal antibodies, the animal 
can be bled through an ear vein or alternatively by cardiac 
puncture. The procured blood is allowed to coagulate and 
then centrifuged to separate serum components from whole 
cells and blood clots. The serum may be used as is for 
various applications or else the desired antibody fraction 
may be purified by well-known methods, such as affinity 
chromatography using another antibody or a peptide bound 
to a solid matrix or protein A followed by antigen (peptide) 
affinity column for purification. 
MAbs may be readily prepared through use of well 
known techniques, such as those exemplified in U.S. Pat. 
No. 4,196,265, incorporated herein by reference. Typically, 
this technique involves immunizing a Suitable animal with a 
selected immunogen composition, e.g., a purified or partially 
purified WWOX protein, polypeptide or peptide. The immu 
nizing composition is administered in a manner effective to 
stimulate antibody producing cells. Rodents such as mice 
and rats are preferred animals, however, the use of rabbit, 
sheep, goat, monkey cells also is possible. The use of rats 
may provide certain advantages (Goding, 1986, pp. 60–61), 
but mice are preferred, with the BALB/c mouse being most 
preferred as this is most routinely used and generally gives 
a higher percentage of stable fusions. 
The animals are injected with antigen, generally as 
described above. The antigen may be coupled to carrier 
molecules such as keyhole limpet hemocyanin if necessary. 
The antigen would typically be mixed with adjuvant, Such as 
Freund's complete or incomplete adjuvant. Booster injec 














Following immunization, Somatic cells with the potential 
for producing antibodies, specifically B lymphocytes (B 
cells), are selected for use in the MAb generating protocol. 
These cells may be obtained from biopsied spleens or lymph 
nodes. The antibody-producing B lymphocytes from the 
immunized animal are then fused with cells of an immortal 
myeloma cell, generally one of the same species as the 
animal that was immunized. Myeloma cell lines suited for 
use in hybridoma-producing fusion procedures preferably 
are non-antibody-producing, have high fusion efficiency, 
and enzyme deficiencies that render then incapable of grow 
ing in certain selective media which support the growth of 
only the desired fused cells (hybridomas). 
Selection of the hybridoma secreting the Mab of choice is 
performed by culturing the cells in selective media Such as 
HAT and individual clonal supernatants are tested (after 
about two to three weeks) for the desired reactivity. The 
assay should be sensitive, simple and rapid, such as radio 
immunoassays, enzyme immunoassays, cytotoxicity assays, 
plaque assays, dot immunobinding assays, and the like. The 
selected hybridomas would then be serially diluted and 
cloned into individual antibody-producing cell lines, which 
clones can then be propagated indefinitely to provide MAbs. 
It also is contemplated that a molecular cloning approach 
may be used to generate monoclonals. For this, combinato 
rial immunoglobulin phagemid libraries are prepared from 
RNA isolated from the spleen of the immunized animal, and 
phagemids expressing appropriate antibodies are selected by 
panning using cells expressing the antigen and control cells 
e.g., normal-versus-tumor cells. The advantages of this 
approach over conventional hybridoma techniques are that 
approximately 10 times as many antibodies can be pro 
duced and screened in a single round, and that new speci 
ficities are generated by H and L chain combination which 
further increases the chance of finding appropriate antibod 
1CS 
Humanized monoclonal antibodies are antibodies of ani 
mal origin that have been modified using genetic engineer 
ing techniques to replace constant region and/or variable 
region framework sequences with human sequences, while 
retaining the original antigen specificity. Such antibodies are 
commonly derived from rodent antibodies with specificity 
against human antigens. Such antibodies are generally useful 
for in vivo therapeutic applications. This strategy reduces 
the host response to the foreign antibody and allows selec 
tion of the human effector functions. 
The techniques for producing humanized immunoglobu 
lins are well known to those of skill in the art. For example 
U.S. Pat. No. 5,693,762 discloses methods for producing, 
and compositions of humanized immunoglobulins having 
one or more complementarity determining regions (CDR's). 
When combined into an intact antibody, the humanized 
immunoglobulins are Substantially non-immunogenic in 
humans and retain Substantially the same affinity as the 
donor immunoglobulin to the antigen, such as a protein or 
other compound containing an epitope. 
Other U.S. patents, each incorporated herein by reference, 
that teach the production of antibodies useful in the present 
invention include U.S. Pat. No. 5,565,332, which describes 
the production of chimeric antibodies using a combinatorial 
approach; U.S. Pat. No. 4,816,567 which describes recom 
binant immunoglobin preparations and U.S. Pat. No. 4,867, 
973 which describes antibody-therapeutic agent conjugates. 
b. Antibody Conjugates 
Antibody conjugates in which a WWOX antibody is 
linked to a detectable label or a cytotoxic agent form further 
aspects of the invention. Diagnostic antibody conjugates 
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may be used both in vitro diagnostics, as in a variety of 
immunoassays, and in Vivo diagnostics, such as in imaging 
technology. 
Certain antibody conjugates include those intended pri 
marily for use in vitro, where the antibody is linked to a 
secondary binding ligand or to an enzyme (an enzyme tag) 
that will generate a colored product upon contact with a 
chromogenic Substrate. Examples of Suitable enzymes 
include urease, alkaline phosphatase, (horseradish) hydro 
gen peroxidase and glucose oxidase. Preferred secondary 
binding ligands are biotin and avidin or streptavidin com 
pounds. The use of such labels is well known to those of skill 
in the art in light and is described, for example, in U.S. Pat. 
Nos. 3,817,837; 3,850,752; 3,939,350; 3,996.345; 4,277, 
437; 4,275,149 and 4.366,241; each incorporated herein by 
reference. 
c. Antibodies for use In Vitro also may be Radiolabeled 
Antibody Conjugates 
In using an antibody-based molecule as an in vivo diag 
nostic agent to provide an image of for example, breast, 
gastric, colon, pancreas, renal, ovarian, lung, prostate, 
hepatic, and lung cancer or respective metastases, magnetic 
resonance imaging. X-ray imaging, computerized emission 
tomography and Such technologies may be employed. In the 
antibody-imaging constructs of the invention, the antibody 
portion used will generally bind to a WWOX polypeptide, 
used as a cancer marker, and the imaging agent will be an 
agent detectable upon imaging. Such as a paramagnetic, 
radioactive or fluorescent agent. 
Many appropriate imaging agents are known in the art, as 
are methods for their attachment to antibodies (see, e.g., 
U.S. Pat. Nos. 5,021,236 and 4,472,509, both incorporated 
herein by reference). Certain attachment methods involve 
the use of a metal chelate complex employing, for example, 
an organic chelating agent Such a DTPA attached to the 
antibody (U.S. Pat. No. 4,472,509). Monoclonal antibodies 
also may be reacted with an enzyme in the presence of a 
coupling agent such as glutaraldehyde or periodate. Conju 
gates with fluorescein markers are prepared in the presence 
of these coupling agents or by reaction with an isothiocy 
anate. 
In the case of paramagnetic ions, one might mention by 
way of example ions such as chromium (III), manganese 
(II), iron (III), iron (II), cobalt(II), nickel (II), copper (II), 
neodymium (III), Samarium (III), ytterbium (III), gado 
linium (III), vanadium (II), terbium (III), dysprosium (III), 
holmium (III) and erbium (III), with gadolinium being 
particularly preferred. 
Ions useful in other contexts, such as X-ray imaging, 
include but are not limited to lanthanum (III), gold (III), lead 
(II), and especially bismuth (III). 
In the case of radioactive isotopes for therapeutic and/or 
diagnostic application, one might mention astatine', 'car 
bon, chromium, chlorine, cobalt, cobalt, copper7, 
'Eu, gallium', hydrogen, iodine', iodine', iodine'', 
indium'', iron, phosphorus, rhenium, rhenium', 
selenium, sulphur, technicium’" and yttrium''. 'I is 
often being preferred for use in certain embodiments, and 
technicium and indium'' are also often preferred due to 
their low energy and Suitability for long range detection. 
Radioactively labeled monoclonal antibodies of the 
present invention may be produced according to well-known 
methods in the art. For instance, monoclonal antibodies can 
be iodinated by contact with sodium or potassium iodide and 
a chemical oxidizing agent such as sodium hypochlorite, or 
an enzymatic oxidizing agent, such as lactoperoxidase. 













labeled with technetium-” by ligand exchange process, for 
example, by reducing pertechnate with Stannous solution, 
chelating the reduced technetium onto a Sephadex column 
and applying the antibody to this column or by direct 
labeling techniques, e.g., by incubating pertechnate, a reduc 
ing agent Such as SNC1, a buffer Solution Such as sodium 
potassium phthalate Solution, and the antibody. 
Intermediary functional groups which are often used to 
bind radioisotopes which exist as metallic ions to antibody 
are diethylenetriaminepentaacetic acid (DTPA) and ethylene 
diaminetetracetic acid (EDTA). 
Fluorescent labels include rhodamine, fluorescein isothio 
cyanate and renographin. 
d. Immunotoxins 
The invention further provides immunotoxins in which an 
antibody that binds to a mutated WWOX peptide or 
polypeptide that is expressed in a cancer or hyperprolifera 
tive state, i.e., a WWOX-antigen, is linked to a cytotoxic 
agent. Immunotoxin technology is fairly well-advanced and 
known to those of skill in the art. Immunotoxins are agents 
in which the antibody component is linked to another agent, 
particularly a cytotoxic or otherwise anticellular agent, hav 
ing the ability to kill or suppress the growth or cell division 
of cells. 
As used herein, the terms “toxin' and “toxic moiety' are 
employed to refer to any cytotoxic or otherwise anticellular 
agent that has such a killing or Suppressive property. Toxins 
are thus pharmacologic agents that can be conjugated to an 
antibody and delivered in an active form to a cell, wherein 
they will exert a significant deleterious effect. 
The preparation of immunotoxins is, in general, well 
known in the art (see, e.g., U.S. Pat. No. 4.340,535, incor 
porated herein by reference). It also is known that while IgG 
based immunotoxins will typically exhibit better binding 
capability and slower blood clearance than their Fab' coun 
terparts, Fab' fragment-based immunotoxins will generally 
exhibit better tissue penetrating capability as compared to 
IgG based immunotoxins. 
Exemplary anticellular agents include chemotherapeutic 
agents, radioisotopes as well as cytotoxins. Example of 
chemotherapeutic agents are hormones such as steroids; 
antimetabolites such as cytosine arabinoside, fluorouracil, 
methotrexate or aminopterin; anthracycline; mitomycin C: 
Vinca alkaloids; demecolcine; etoposide; mithramycin; or 
alkylating agents such as chlorambucil or melphalan. 
Preferred immunotoxins often include a plant-, fungal- or 
bacterial-derived toxin, Such as an Achain toxin, a ribosome 
inactivating protein, C.-sarcin, aspergillin, restirictocin, a 
ribonuclease, diphtheria toxin or pseudomonas exotoxin, to 
mention just a few examples. The use of toxin-antibody 
constructs is well known in the art of immunotoxins, as is 
their attachment to antibodies. Of course, combinations of 
the various toxins could also be coupled to one antibody 
molecule, thereby accommodating variable or even 
enhanced cytotoxicity. 
One type of toxin for attachment to antibodies is ricin, 
with deglycosylated ricin A chain being particularly pre 
ferred. As used herein, the term “ricin' is intended to refer 
to ricin prepared from both natural Sources and by recom 
binant means. Various recombinant or genetically engi 
neered forms of the ricin molecule are known to those of 
skill in the art, all of which may be employed in accordance 
with the present invention. 
Linking or coupling one or more toxin moieties to an 
antibody may be achieved by a variety of mechanisms, for 
example, covalent binding, affinity binding, intercalation, 
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coordinate binding and complexation. Covalent binding 
methods use chemical cross-linkers, natural peptides or 
disulfide bonds. 
The covalent binding can be achieved either by direct 
condensation of existing side chains or by the incorporation 
of external bridging molecules. Many bivalent or polyvalent 
agents are useful in coupling protein molecules to other 
proteins, peptides or amine functions. Examples of coupling 
agents are carbodiimides, diisocyanates, glutaraldehyde, 
diazobenzenes, and hexamethylene diamines. This list is not 
intended to be exhaustive of the various coupling agents 
known in the art but, rather, is exemplary of the more 
common coupling agents that may be used. 
Once conjugated, it will be important to purify the con 
jugate so as to remove contaminants such as unconjugated A 
chain or antibody. It is important to remove unconjugated A 
chain because of the possibility of increased toxicity. More 
over, it is important to remove unconjugated antibody to 
avoid the possibility of competition for the antigen between 
conjugated and unconjugated species. In any event, a num 
ber of purification techniques have been found to provide 
conjugates to a sufficient degree of purity to render them 
clinically useful. 
In general, the most preferred technique will incorporate 
the use of Blue-Sepharose with a gel filtration or gel 
permeation step. Blue-Sepharose is a column matrix com 
posed of Cibacron Blue 3GA and agarose, which has been 
found to be useful in the purification of immunoconjugates. 
The use of Blue-Sepharose combines the properties of ion 
exchange with Achain binding to provide good separation of 
conjugated from unconjugated binding. The Blue-Sepharose 
allows the elimination of the free (non conjugated) antibody 
from the conjugate preparation. To eliminate the free (un 
conjugated) toxin (e.g., dgA) a molecular exclusion chro 
matography step may be used using either conventional gel 
filtration procedure or high performance liquid chromatog 
raphy. 
After a sufficiently purified conjugate has been prepared, 
one will generally desire to prepare it into a pharmaceutical 
composition that may be administered parenterally. This is 
done by using for the last purification step a medium with a 
Suitable pharmaceutical composition. Such formulations 
will typically include pharmaceutical buffers, along with 
excipients, stabilizing agents and Such like. The pharmaceu 
tically acceptable compositions will be sterile, non-immu 
nogenic and non-pyrogenic. Details of their preparation are 
well known in the art and are further described herein. It will 
be appreciated that endotoxin contamination should be kept 
minimally at a safe level, for example, less that 0.5 ng/mg 
protein. 
Suitable pharmaceutical compositions in accordance with 
the invention will generally comprise from about 10 to about 
100 mg of the desired conjugate admixed with an acceptable 
pharmaceutical diluent or excipient, Such as a sterile aque 
ous Solution, to give a final concentration of about 0.25 to 
about 2.5 mg/ml with respect to the conjugate. 
G. Immunological Detection 
a. Immunoassays 
The anti-WWOX antibodies, directed to WWOX pro 
teins, and/or polypeptides expressed in cancers, are useful in 
various diagnostic and prognostic applications connected 
with the detection and analysis of cancer. The WWOX 
proteins, and/or polypeptides include mutated versions of 
WWOX as well as those WWOX forms that are expressed 
in higher concentrations in cancers and hyperproliferative 













In still further embodiments, the present invention thus 
concerns immunodetection methods for binding, purifying, 
removing, quantifying or otherwise generally detecting bio 
logical components. The encoded proteins or peptides of the 
present invention may be employed to detect antibodies 
having reactivity therewith, or, alternatively, antibodies pre 
pared in accordance with the present invention, may be 
employed to detect the presence of the WWOX proteins 
including mutated, altered and increased levels. 
The steps of various useful immunodetection methods 
have been described in the Scientific literature. Such as, e.g., 
Nakamura et al. (1987; incorporated herein by reference). 
Immunoassays, in their most simple and direct sense, are 
binding assays. Certain preferred immunoassays are the 
various types of enzyme linked immunosorbent assays (ELI 
SAS), radioimmunoassays (RIA) and immunobead capture 
assay. Immunohistochemical detection using tissue sections 
also is particularly useful. However, it will be readily 
appreciated that detection is not limited to such techniques, 
and Western blotting, dot blotting, FACS analyses, and the 
like also may be used in connection with the present 
invention. 
In general, immunobinding methods include obtaining a 
sample Suspected of containing a protein, peptide or anti 
body, and contacting the sample with an antibody or protein 
or peptide in accordance with the present invention, as the 
case may be, under conditions effective to allow the forma 
tion of immunocomplexes. 
The immunobinding methods of this invention include 
methods for detecting or quantifying the amount of a reac 
tive component in a sample, which methods require the 
detection or quantitation of any immune complexes formed 
during the binding process. Here, one would obtain a sample 
suspected of containing a WWOX-antigen as defined above, 
or a corresponding antibody, and contact the sample with an 
antibody or encoded protein or peptide, as the case may be, 
and then detect or quantify the amount of immune com 
plexes formed under the specific conditions. 
In terms of antigen detection, the biological sample ana 
lyzed may be any sample that is suspected of containing a 
cancer involving WWOX such as a breast, gastric, colon, 
pancreas, myeloma, renal, ovarian, lung, prostate, hepatic, 
lung, lymph node, brain, uterus or bone marrow tissue 
section or specimen, a homogenized tissue extract, an iso 
lated cell, a cell membrane preparation, separated or purified 
forms of any of the above protein-containing compositions, 
or even any biological fluid that comes into contact with 
cancer tissues, including blood, lymphatic fluid, seminal 
fluid and urine. 
Contacting the chosen biological sample with the protein, 
peptide or antibody under conditions effective and for a 
period of time sufficient to allow the formation of immune 
complexes (primary immune complexes) is generally a 
matter of simply adding the composition to the sample and 
incubating the mixture for a period of time long enough for 
the antibodies to form immune complexes with, i.e., to bind 
to, any antigens present, such as WWOX encoded antigens. 
After this time, the sample-antibody composition, such as a 
tissue section, ELISA plate, dot blot or Western blot, will 
generally be washed to remove any non-specifically bound 
antibody species, allowing only those antibodies specifically 
bound within the primary immune complexes to be detected. 
In general, the detection of immunocomplex formation is 
well known in the art and may be achieved through the 
application of numerous approaches. These methods are 
generally based upon the detection of a label or marker, Such 
as any radioactive, fluorescent, biological or enzymatic tags 
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or labels of standard use in the art. U.S. Patents concerning 
the use of such labels include U.S. Pat. Nos. 3,817,837; 
3.850,752; 3,939,350; 3,996.345; 4,277,437; 4,275,149 and 
4.366,241, each incorporated herein by reference. Of course, 
one may find additional advantages through the use of a 
secondary binding ligand Such as a second antibody or a 
biotin/avidin ligand binding arrangement, as is known in the 
art. 
The encoded protein, peptide or corresponding antibody 
employed in the detection may itself be linked to a detect 
able label, wherein one would then simply detect this label, 
thereby allowing the amount of the primary immune com 
plexes in the composition to be determined. 
Alternatively, the first added component that becomes 
bound within the primary immune complexes may be 
detected by means of a second binding ligand that has 
binding affinity for the encoded protein, peptide or corre 
sponding antibody. In these cases, the second binding ligand 
may be linked to a detectable label. The second binding 
ligand is itself often an antibody, which may thus be termed 
a 'secondary antibody. The primary immune complexes are 
contacted with the labeled, secondary binding ligand, or 
antibody, under conditions effective and for a period of time 
sufficient to allow the formation of secondary immune 
complexes. The secondary immune complexes are then 
generally washed to remove any non-specifically bound 
labeled secondary antibodies or ligands, and the remaining 
label in the secondary immune complexes is then detected. 
Further methods include the detection of primary immune 
complexes by a two step approach. A second binding ligand, 
Such as an antibody, that has binding affinity for the encoded 
protein, peptide or corresponding antibody is used to form 
secondary immune complexes, as described above. After 
washing, the secondary immune complexes are contacted 
with a third binding ligand or antibody that has binding 
affinity for the second antibody, again under conditions 
effective and for a period of time sufficient to allow the 
formation of immune complexes (tertiary immune com 
plexes). The third ligand or antibody is linked to a detectable 
label, allowing detection of the tertiary immune complexes 
thus formed. This system may provide for signal amplifica 
tion if this is desired. 
The immunodetection methods of the present invention 
have evident utility in the diagnosis of cancer. Here, a 
biological or clinical sample Suspected of containing either 
the encoded protein or peptide or corresponding antibody is 
used. However, these embodiments also have applications to 
non-clinical samples, such as in the titering of antigen or 
antibody samples, in the selection of hybridomas, and the 
like. 
b. ELISAS 
As noted, it is contemplated that the WWOX proteins or 









example, ELISAS can be used to detect the presence of 55 
mutated/abnormal versions of WWOX proteins in cancer 
cells, using antibodies specific for those abnormal WWOX 
proteins. Thus, one can detect cancer in a cell and it may be 
further possible to detect the specific sub-type of the cancer 
depending on which abnormal WWOX protein is expressed. 
In one exemplary ELISA, antibodies binding to the 
encoded proteins of the invention are immobilized onto a 
selected Surface exhibiting protein affinity, Such as a well in 
a polystyrene microtiter plate. Then, a test composition 
Suspected of containing the cancer disease marker antigen, 
e.g., a WWOX protein/polypeptide expressed in cancer 




binding and washing to remove non-specifically bound 
immunocomplexes, the bound antigen may be detected. 
Detection is generally achieved by the addition of a 
second antibody specific for the target protein, that is linked 
to a detectable label. This type of ELISA is a simple 
“sandwich ELISA'. Detection also may be achieved by the 
addition of a second antibody, followed by the addition of a 
third antibody that has binding affinity for the second 
antibody, with the third antibody being linked to a detectable 
label. 
In another exemplary ELISA, the samples suspected of 
containing a WWOX polypeptide?protein are immobilized 
onto the well surface and then contacted with the antibodies 
of the invention. After binding and washing to remove 
non-specifically bound immunecomplexes, the bound anti 
body is detected. Where the initial antibodies are linked to 
a detectable label, the immunecomplexes may be detected 
directly. Again, the immunecomplexes may be detected 
using a second antibody that has binding affinity for the first 
antibody, with the second antibody being linked to a detect 
able label. 
Another ELISA in which the a WWOX polypeptide/ 
protein is immobilized, involves the use of antibody com 
petition in the detection. In this ELISA, labeled antibodies 
are added to the wells, allowed to bind to the WWOX 
antigen, and detected by means of their label. The amount of 
marker antigen in an unknown sample is then determined by 
mixing the sample with the labeled antibodies before or 
during incubation with coated wells. The presence of marker 
antigen in the sample acts to reduce the amount of antibody 
available for binding to the well and thus reduces the 
ultimate signal. This is appropriate for detecting antibodies 
in an unknown sample, where the unlabeled antibodies bind 
to the antigen-coated wells and also reduces the amount of 
antigen available to bind the labeled antibodies. 
Irrespective of the format employed, ELISAs have certain 
features in common, such as coating, incubating or binding, 
washing to remove non-specifically bound species, and 
detecting the bound immunecomplexes. These are described 
as follows: 
In coating a plate with either antigen or antibody, one will 
generally incubate the wells of the plate with a solution of 
the antigen or antibody, either overnight or for a specified 
period of hours. The wells of the plate will then be washed 
to remove incompletely adsorbed material. Any remaining 
available surfaces of the wells are then "coated with a 
nonspecific protein that is antigenically neutral with regard 
to the test antisera. These include bovine serum albumin 
(BSA), casein and solutions of milk powder. The coating 
allows for blocking of nonspecific adsorption sites on the 
immobilizing Surface and thus reduces the background 
caused by nonspecific binding of antisera onto the Surface. 
In ELISAs, it is probably more customary to use a 
secondary or tertiary detection means rather than a direct 
procedure. Thus, after binding of a protein or antibody to the 
well, coating with a non-reactive material to reduce back 
ground, and washing to remove unbound material, the 
immobilizing Surface is contacted with the control human 
cancer and/or clinical or biological sample to be tested under 
conditions effective to allow immunecomplex (antigenfan 
tibody) formation. Detection of the immunecomplex then 
requires a labeled secondary binding ligand or antibody, or 
a secondary binding ligand or antibody in conjunction with 
a labeled tertiary antibody or third binding ligand. 
“Under conditions effective to allow immunecomplex 
(antigen/antibody) formation” means that the conditions 
preferably include diluting the antigens and antibodies with 
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solutions such as BSA. bovine gamma globulin (BGG) and 
phosphate buffered saline (PBS)/Tween. These added agents 
also tend to assist in the reduction of nonspecific back 
ground. 
The "suitable' conditions also mean that the incubation is 
at a temperature and for a period of time sufficient to allow 
effective binding. Incubation steps are typically from about 
1 to 2 to 4h, at temperatures preferably on the order of 25° 
to 27°C., or may be overnight at about 4°C. or so. 
Following all incubation steps in an ELISA, the contacted 
Surface is washed so as to remove non-complexed material. 
A preferred washing procedure includes washing with a 
solution such as PBS/Tween, or borate buffer. Following the 
formation of specific immunecomplexes between the test 
sample and the originally bound material, and Subsequent 
washing, the occurrence of even minute amounts of immu 
necomplexes may be determined. 
To provide a detecting means, the second or third anti 
body will have an associated label to allow detection. 
Preferably, this will be an enzyme that will generate color 
development upon incubating with an appropriate chro 
mogenic Substrate. Thus, for example, one will desire to 
contact and incubate the first or second immunecomplex 
with a urease, glucose oxidase, alkaline phosphatase or 
hydrogen peroxidase-conjugated antibody for a period of 
time and under conditions that favor the development of 
further immunecomplex formation (e.g., incubation for 2 h 
at room temperature in a PBS-containing solution Such as 
PBS-Tween). 
After incubation with the labeled antibody, and subse 
quent to washing to remove unbound material, the amount 
of label is quantified, e.g., by incubation with a chromogenic 
Substrate such as urea and bromocresol purple or 2,2'-azido 
di-(3-ethyl-benzthiazoline-6-sulfonic acid ABTS and 
H2O, in the case of peroxidase as the enzyme label. 
Quantitation is then achieved by measuring the degree of 
color generation, e.g., using a visible spectra spectropho 
tOmeter. 
In other embodiments, solution-phase competition ELISA 
is also contemplated. Solution phase ELISA involves attach 
ment of a WWOX polypeptide?protein to a bead, for 
example a magnetic bead. The bead is then incubated with 
sera from human and animal origin. After a suitable incu 
bation period to allow for specific interactions to occur, the 
beads are washed. The specific type of antibody is the 
detected with an antibody indicator conjugate. The beads are 
washed and Sorted. This complex is the read on an appro 
priate instrument (fluorescent, electroluminescent, spectro 
photometer, depending on the conjugating moiety). The 
level of antibody binding can thus by quantitated and is 
directly related to the amount of signal present. 
c. Immunohistochemistry 
The antibodies to the WWOX-antigens as defined above 
also may be used in conjunction with both fresh-frozen and 
formalin-fixed, paraffin-embedded tissue blocks prepared 
from study by immunohistochemistry (IHC). For example, 
each tissue block consists of 50 mg of residual “pulverized' 
tumor. The method of preparing tissue blocks from these 
particulate specimens has been Successfully used in previous 
IHC studies of various prognostic factors, e.g., in breast, and 
is well known to those of skill in the art (Brown et al., 1990; 
Abbondanzo et al., 1990; Allred et al., 1990). 
Briefly, frozen-sections may be prepared by rehydrating 
50 ng of frozen “pulverized' tumor at room temperature in 
phosphate buffered saline (PBS) in small plastic capsules: 
pelleting the particles by centrifugation; resuspending them 














Sule and pelleting again by centrifugation: Snap-freezing in 
-70° C. isopentane; cutting the plastic capsule and removing 
the frozen cylinder of tissue; securing the tissue cylinder on 
a cryostat microtome chuck; and cutting 25–50 serial sec 
tions containing an average of about 500 remarkably intact 
tumor cells. 
Permanent-sections may be prepared by a similar method 
involving rehydration of the 50 mg sample in a plastic 
microfuge tube; pelleting; resuspending in 10% formalin for 
4h fixation; washing/pelleting; resuspending in warm 2.5% 
agar, pelleting; cooling in ice water to harden the agar, 
removing the tissue?agar block from the tube; infiltrating and 
embedding the block in paraffin; and cutting up to 50 serial 
permanent sections. 
d. FACS Analyses 
Fluorescent activated cell sorting, flow cytometry or flow 
microfluorometry provides the means of scanning individual 
cells for the presence of an antigen, such as a WWOX 
polypeptide?protein. The method employs instrumentation 
that is capable of activating, and detecting the excitation 
emissions of labeled cells in a liquid medium. 
FACS is unique in its ability to provide a rapid, reliable, 
quantitative, and multiparameter analysis on either living or 
fixed cells. The cancer antibodies of the present invention 
provide a useful tool for the analysis and quantitation of 
antigenic cancer markers of individual cells. 
Cells would generally be obtained by biopsy, single cell 
suspension in blood or culture. FACS analyses would prob 
ably be most useful when desiring to analyze a number of 
cancer antigens at a given time, e.g., to follow an antigen 
profile during disease progression. 
e. In Vivo Imaging 
The invention also provides in Vivo methods of imaging 
cancer using antibody conjugates. The term “in vivo imag 
ing refers to any non-invasive method that permits the 
detection of a labeled antibody, or fragment thereof, that 
specifically binds to cancer cells located in the body of an 
animal or human Subject. 
The imaging methods generally involve administering to 
an animal or subject an imaging-effective amount of a 
detectably-labeled cancer-specific antibody or fragment 
thereof (in a pharmaceutically effective carrier). Such as a 
WWOX antibody, and then detecting the binding of the 
labeled antibody to the cancerous tissue. The detectable 
label is preferably a spin-labeled molecule or a radioactive 
isotope that is detectable by non-invasive methods. 
An "imaging effective amount is an amount of a detect 
ably-labeled antibody, or fragment thereof, that when 
administered is sufficient to enable later detection of binding 
of the antibody or fragment to cancer tissue. The effective 
amount of the antibody-marker conjugate is allowed Sufi 
cient time to come into contact with reactive antigens that be 
present within the tissues of the patient, and the patient is 
then exposed to a detection device to identify the detectable 
marker. 
Antibody conjugates or constructs for imaging thus have 
the ability to provide an image of the tumor, for example, 
through magnetic resonance imaging, X-ray imaging, com 
puterized emission tomography and the like. Elements par 
ticularly useful in Magnetic Resonance Imaging (“MRI) 
include the nuclear magnetic spin-resonance isotopes ''Gd, 
Mn., 'Dy, ‘Cr, and Fe, with gadolinium often being 
preferred. Radioactive substances, such as technicium" or 
indium'', that may be detected using a gamma scintillation 
camera or detector, also may be used. Further examples of 
metallic ions suitable for use in this invention are ‘I, ''I, 
13 II, 7Ru, 67Cu, 7Ga, 125I, Ga, 7As, 897, and ''T1. 
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A factor to consider in selecting a radionuclide for in vivo 
diagnosis is that the half-life of a nuclide belong enough so 
that it is still detectable at the time of maximum uptake by 
the target, but short enough so that deleterious radiation 
upon the host, as well as background, is minimized. Ideally, 
a radionuclide used for in vivo imaging will lack a particu 
late emission, but produce a large number of photons in a 
140–2000 keV range, which may be readily detected by 
conventional gamma cameras. 
A radionuclide may be bound to an antibody either 
directly or indirectly by using an intermediary functional 
group. Intermediary functional groups which are often used 
to bind radioisotopes which exist as metallic ions to anti 
body are diethylenetriaminepentaacetic acid (DTPA) and 
ethylene diaminetetracetic acid (EDTA). 
Administration of the labeled antibody may be local or 
systemic and accomplished intravenously, intra-arterially, 
via the spinal fluid or the like. Administration also may be 
intradermal or intracavitary, depending upon the body site 
under examination. After a sufficient time has lapsed for the 
labeled antibody or fragment to bind to the diseased tissue, 
in this case cancer tissue, for example 30 min to 48 h, the 
area of the Subject under investigation is then examined by 
the imaging technique. MRI, SPECT, planar scintillation 
imaging and other emerging imaging techniques may all be 
used. 
The distribution of the bound radioactive isotope and its 
increase or decrease with time is monitored and recorded. 
By comparing the results with data obtained from studies of 
clinically normal individuals, the presence and extent of the 
diseased tissue can be determined. 
The exact imaging protocol will necessarily vary depend 
ing upon factors specific to the patient, and depending upon 
the body site under examination, method of administration, 
type of label used and the like. The determination of specific 
procedures is, however, routine to the skilled artisan. 
Although dosages for imaging embodiments are dependent 
upon the age and weight of patient, a one time dose of about 
0.1 to about 20 mg, more preferably, about 1.0 to about 2.0 
mg of antibody-conjugate per patient is contemplated to be 
useful. 
H. Combination Cancer Therapies 
A wide variety of cancer therapies, known to one of skill 
in the art, may be used in combination with the anticancer 
peptides and nucleotides of the present invention. Thus, in 
order to increase the effectiveness of the anticancer therapy 
using a WWOX polypeptide, or expression construct coding 
therefor, it may be desirable to combine these compositions 
with other agents effective in the treatment of cancer Such as 
but not limited to those described below. 
For example, one can use radiation therapy followed by 
gene therapy with the WWOX-encoding nucleic acids. 
Alternatively, one can use the WWOX-based anti-cancer 
therapy in conduction with Surgery and/or chemotherapy, 
and/or immunotherapy, and/or other genetherapy, and/or 
local heat therapy. Thus, one can use one or several of the 
standard cancer therapies existing in the art in addition with 
the WWOX-based therapies of the present invention. All 
other non-WWOX based cancer therapies are refereed to 
herein as other cancer therapies. 
The other cancer therapy may precede or follow the 
WWOX-based therapy by intervals ranging from minutes to 
days to weeks. In embodiments where the other cancer 
therapy and the WWOX-based therapy are administered 
together, one would generally ensure that a significant 
period of time did not expire between the time of each 













administer to a patient both modalities within about 12–24 
hours of each other and, more preferably, within about 6–12 
hours of each other, with a delay time of only about 12 hours 
being most preferred. In some situations, it may be desirable 
to extend the time period for treatment significantly, how 
ever, where several days (2, 3, 4, 5, 6 or 7) to several weeks 
(1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective 
administrations. 
It also is conceivable that more than one administration of 
either the other cancer therapy and the WWOX-based 
therapy will be required to achieve complete cancer cure. 
Various combinations may be employed, where the other 
cancer therapy is “A” and the WWOX-based therapy treat 
ment is “B”, as exemplified below: 
A/B/AB/A/B B/BFAA/A/B B/A/A A/B/B B/B/BFAB/B/ 
A/B 
A/A/B/B A/B/A/B A/B/BFA B/B/A/AB/A/B/AB/A/A/B 
BFBFBFA 
A/A/A/B B/AIA/A A/B/A/AA/A/B/A A/B/BFB B/A/B/B 
B/BFAAB 
Other combinations also are contemplated. 
In addition, the WWOX-based therapy can be adminis 
tered to a patient in conjunction with other therapeutic 
methods such as for example standard AIDS treatments. The 
exact dosages and regimens can be suitable altered by those 
of ordinary skill in the art. 
a) Radiotherapeutic Agents 
Radiotherapeutic agents and factors include radiation and 
waves that induce DNA damage for example, Y-irradiation, 
X-rays, UV-irradiation, microwaves, electronic emissions, 
radioisotopes, and the like. Therapy may be achieved by 
irradiating the localized tumor site with the above described 
forms of radiations. 
Dosage ranges for X-rays range from daily doses of 50 to 
200 roentgens for prolonged periods of time (3 to 4 weeks), 
to single doses of 2000 to 6000 roentgens. Dosage ranges for 
radioisotopes vary widely, and depend on the half-life of the 
isotope, the strength and type of radiation emitted, and the 
uptake by the neoplastic cells. 
b) Surgery 
Approximately 60% of persons with cancer will undergo 
Surgery of Some type, which includes preventative, diagnos 
tic or staging, curative and palliative Surgery. Curative 
Surgery includes resection in which all or part of cancerous 
tissue is physically removed, excised, and/or destroyed. 
Tumor resection refers to physical removal of at least part of 
a tumor. In addition to tumor resection, treatment by Surgery 
includes laser Surgery, cryoSurgery, electroSurgery, and 
microscopically controlled Surgery (Mohs Surgery). It is 
further contemplated that the present invention may be used 
in conjunction with removal of Superficial cancers, precan 
cers, or incidental amounts of normal tissue. 
Upon excision of part of all of cancerous cells, tissue, or 
tumor, a cavity may be formed in the body. Treatment may 
be accomplished by perfusion, direct injection or local 
application of the area with an additional anti-cancer 
therapy, such as with WWOX nucleic acids or peptides. 
Such treatment may be repeated, for example, every 1, 2, 3, 
4, 5, 6, or 7 days, or every 1,2,3,4, and 5 weeks or every 1, 
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments 
may be of varying dosages as well. 
c) Chemotherapeutic Agents 
Agents that affect DNA function are defined as chemo 
therapeutic agents, for example, agents that directly cross 
link DNA, agents that intercalate into DNA, and agents that 
lead to chromosomal and mitotic aberrations by affecting 
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nucleic acid synthesis. Some examples of chemotherapeutic 
agents include antibiotic chemotherapeutics such as, DOXo 
rubicin, Daunorubicin, Mitomycin (also known as mutamy 
cin and/or mitomycin-C). Actinomycin D (Dactinomycin), 
Bleomycin, Plicomycin. Plant alkaloids such as Taxol. Vin 
cristine, Vinblastine. Miscellaneous agents such as Cispl 
atin, VP16, Tumor Necrosis Factor. Alkylating Agents such 
as, Carmustine, Melphalan (also known as alkeran, L-phe 
nylalanine mustard, phenylalanine mustard, L-PAM, or 
L-sarcolysin, is a phenylalanine derivative of nitrogen mus 
tard), Cyclophosphamide, Chlorambucil, Busulfan (also 
known as myleran), Lomustine. And other agents for 
example, Cisplatin (CDDP), Carboplatin, Procarbazine, 
Mechlorethamine, Camptothecin, Ifosfamide, Nitrosurea, 
Etoposide (VP16), Tamoxifen, Raloxifene, Estrogen Recep 
tor Binding Agents, Gemcitabien, Navelbine, Farnesyl-pro 
tein transferase inhibitors, Transplatinum, 5-Fluorouracil, 
and Methotrexate, Temazolomide (an aqueous form of 
DTIC), or any analog or derivative variant of the foregoing. 
d) Immunotherapy 
Immunotherapeutics, generally, rely on the use of immune 
effector cells and molecules to target and destroy cancer 
cells. The immune effector may be, for example, an antibody 
specific for Some marker on the Surface of a tumor cell. 
Common tumor markers include carcinoembryonic antigen, 
prostate specific antigen, urinary tumor associated antigen, 
fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sia 
lyl Lewis Antigen, MucA. MuchB, PLAP, estrogen receptor, 
laminin receptor, erb B and p155. The antibody alone may 
serve as an effector of therapy or it may recruit other cells 
to actually effect cell killing. The antibody also may be 
conjugated to a drug or toxin (chemotherapeutic, radionu 
clide, ricin A chain, cholera toxin, pertussis toxin, etc.) and 
serve merely as a targeting agent. Alternatively, the effector 
may be a lymphocyte carrying a surface molecule that 
interacts, either directly or indirectly, with a tumor cell 
target. Various effector cells include cytotoxic T cells and 
NK cells. WWOX gene transfer to cancer cells causes cell 
















enged by reticuloendothelial cells including dendritic cells 
and macrophages and presented to the immune system to 
generate anti-tumor immunity (Rovere et al., 1999; Stein 
man et al., 1999). Immune stimulating molecules may be 
provided as immune therapy: for example, cytokines such as 
IL-2, IL-4, IL-12, GM-CSF, gamma-IFN. chemokines such 
as MIP-1, MCP-1, IL-8 and growth factors such as FLT3 
ligand. Combining immune stimulating molecules, either as 
proteins or using gene delivery in combination with WWOX 
will enhance anti-tumor effects. This one may use (i) Passive 
Immunotherapy which includes: injection of antibodies 
alone; injection of antibodies coupled to toxins or chemo 
therapeutic agents; injection of antibodies coupled to radio 
active isotopes; injection of anti-idiotype antibodies; and 
finally, purging of tumor cells in bone marrow; and/or (ii) 
Active Immunotherapy wherein an antigenic peptide, 
polypeptide or protein, or an autologous or allogenic tumor 
cell composition or "vaccine' is administered, generally 
with a distinct bacterial adjuvant (Ravindranath & Morton, 
1991) and/or (iii) Adoptive Immunotherapy wherein the 
patient’s circulating lymphocytes, or tumor infiltrated lym 
phocytes, are isolated in vitro, activated by lymphokines 
Such as IL-2 or transduced with genes for tumor necrosis, 
and readministered (Rosenberg et al., 1988: 1989). 
(e) Gene Therapy 
In yet another embodiment, the other treatment is a 
secondary gene therapy in which a second therapeutic 
polynucleotide is administered before, after, or at the same 
time a first therapeutic polynucleotide encoding a WWOX 
polypeptide. Delivery of a vector encoding a WWOX 
polypeptide in conjuction with a second vector encoding one 
of the following gene products will have a combined anti 
hyperproliferative effect on target tissues. Alternatively, a 
single vector encoding both genes may be used. A variety of 
proteins are encompassed within the invention, some of 
which are described below. Table 6 lists various genes that 
may be targeted for gene therapy of some form in combi 
nation with the present invention. 
TABLE 6 
Oncogenes 
Source Human Disease Function 
FGF family member 
Transfection 
MMTV promoter FGF family member 
Insertion 
MMTV promoter Factor-like 
Insertion 
Simian sarcoma virus PDGF B 
Receptor Tyrosine Kinases 
Avian erythroblastosis Amplified, deleted EGF, TGF-Of 
virus; ALV promoter squamous cell Amphiregulin 
insertion; amplified 
human tumors 
Transfected from rat 
Glioblastomas 
SM feline sarcoma 
virus 
HZ feline sarcoma 
virus 
Transfection from 
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Sporadic thyroid can 
cer; familial medullary 
thyroid cancer; 
multiple endocrine 








Orphan receptor Tyr 
Kinase 










Mul.V (murine leu 
kemia virus) promoter 
insertion 
Avian Rous sarcoma 
Virus 




SERTHR, PROTEIN KINASES 
AKT8 murine retro 
virus 
Maloney murine SV 
Promoter insertion 
Mouse 
3611 murine SV: MH2 
avian SV 
























Interact with RB RNA 
polymerase, CRK, 
CBL 
Src family: T cell 
signaling; interacts 
CD4-CD8 T cells 
Membrane-associated 
Tyr kinase with 
signaling function; 
activated by receptor 
kinases 
Src family; signaling 
Regulated by PI(3)K?: 
regulate 70-kd S6 k? 
GVBD: cystostatic 
actor: MAP kinase 
kinase 
Signaling in RAS 
Pathway 




interacts with catenins 
2 transmembrane 
domain; signals 
hrough Gli homogue 
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1 transcription factor 
with c-JUN 
Zinc finger; cubitus 
interruptus homologue 
is in hedgehog 
signaling pathway; 
inhibitory link PTC 
and hedgehog 
Gene fusions high 
mobility group 
HMGI-C (XT-hook) 
and transcription factor 
LIM or acidic domain 
Transcription factor 
AP-1 with FOS 
Gene fusion of DNA 
binding and methyl 
transferase MLL with 
ELI RNA pol II 
elongation factor 
DNA binding 
DNA binding with 


































Mismatch repair; MutL 
Homologue 
Mismatch repair; MutS 
Homologue 
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Gene Source Human Disease Function 
PMS1 HNPCC Mismatch repair; MutL 
Homologue 
PMS2 HNPCC Mismatch repair; MutL 
Homologue 
NK4;MTS1 Adjacent INK-4B at Candidate MTS1 p16 CDK inhibitor 
9p21; CDK complexes suppressor and MLM 
melanoma gene 
NK4B, MTS2 Candidate suppressor p15 CDK inhibitor 
MDM-2 Amplified Sarcoma Negative regulator p53 
S3 Association with SV40 Mutated >50% human Transcription factor; 
T antigen tumors, including checkpoint control; 
hereditary Li-Fraumeni apoptosis 
syndrome 
PRAD1 BCL1 Translocation with Parathyroid adenoma; Cyclin D 
Parathyroid hormone B-CLL 
or IgG 
RB Hereditary Retinoblastoma: Interact cyclinicodk; 
Retinoblastoma: Osteosarcoma; breast regulate E2F 
Association with many cancer; other sporadic transcription factor 
DNA virus tumor C8CES 
Antigens 
XPA Xeroderma Excision repair; photo 
pigmentOSum; skin 
cancer predisposition 
(i) Inducers of Cellular Proliferation 
The proteins that induce cellular proliferation further fall 
into various categories dependent on function. The com 
monality of all of these proteins is their ability to regulate 
cellular proliferation. For example, a form of PDGF, the sis 
oncogene, is a secreted growth factor. 
The proteins FMS, ErbA, ErbB and neu are growth factor 
receptors. Mutations to these receptors result in loss of 
regulatable function. For example, a point mutation affecting 
the transmembrane domain of the Neu receptor protein 
results in the neu oncogene. The erbA oncogene is derived 
from the intracellular receptor for thyroid hormone. The 
modified oncogenic ErbA receptor is believed to compete 
with the endogenous thyroid hormone receptor, causing 
uncontrolled growth. 
The largest class of oncogenes includes the signal trans 
ducing proteins (e.g., Src, Abl and Ras). The protein Src is 
a cytoplasmic protein-tyrosine kinase, and its transformation 
from proto-oncogene to oncogene in some cases, results via 
mutations at tyrosine residue 527. In contrast, transforma 
tion of GTPase protein ras from proto-oncogene to onco 
gene, in one example, results from a valine to glycine 
mutation at amino acid 12 in the sequence, reducing ras 
GTPase activity. 
The proteins Jun, Fos and Myc are proteins that directly 
exert their effects on nuclear functions as transcription 
factors. 
(ii) Inhibitors of Cellular Proliferation 
The tumor Suppressor oncogenes function to inhibit 
excessive cellular proliferation. The inactivation of these 
genes destroys their inhibitory activity, resulting in unregu 
lated proliferation. The tumor suppressors p53, p16 and 
C-CAM are described below. 
High levels of mutant p53 have been found in many cells 
transformed by chemical carcinogenesis, ultraviolet radia 
tion, and several viruses. The p53 gene is a frequent target 
of mutational inactivation in a wide variety of human tumors 
and is already documented to be the most frequently mutated 











393-amino acid phosphoprotein that can form complexes 
with host proteins such as large-T antigen and E1B. The 
protein is found in normal tissues and cells, but at concen 
trations which are minute by comparison with transformed 
cells or tumor tissue 
Wild-type p53 is recognized as an important growth 
regulator in many cell types. Missense mutations are com 
mon for the p53 gene and are essential for the transforming 
ability of the oncogene. A single genetic change prompted 
by point mutations can create carcinogenic p53. Unlike 
other oncogenes, however, p53 point mutations are known to 
occur in at least 30 distinct codons, often creating dominant 
alleles that produce shifts in cell phenotype without a 
reduction to homozygosity. Additionally, many of these 
dominant negative alleles appear to be tolerated in the 
organism and passed on in the germ line. Various mutant 
alleles appear to range from minimally dysfunctional to 
strongly penetrant, dominant negative alleles (Weinberg, 
1991). 
Another inhibitor of cellular proliferation is p16. The 
major transitions of the eukaryotic cell cycle are triggered by 
cyclin-dependent kinases, or CDKs. One CDK, cyclin 
dependent kinase 4 (CDK4), regulates progression through 
the G. The activity of this enzyme may be to phosphorylate 
Rb at late G. The activity of CDK4 is controlled by an 
activating Subunit, D-type cyclin, and by an inhibitory 
subunit, the p16' has been biochemically characterized as 
a protein that specifically binds to and inhibits CDK4, and 
thus may regulate Rb phosphorylation (Serrano et al., 1993; 
Serrano et al., 1995). Since the p16' protein is a CDK4 
inhibitor (Serrano, 1993), deletion of this gene may increase 
the activity of CDK4, resulting in hyperphosphorylation of 
the Rb protein. p16 also is known to regulate the function of 
CDK6. 
p16' belongs to a newly described class of CDK 
inhibitory proteins that also includes p16°, p 19, p21''", 
and p27''. The p16'Y' gene maps to 9p21, a chromosome 
region frequently deleted in many tumor types. Homozy 
gous deletions and mutations of the p16' gene are fre 
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quent in human tumor cell lines. This evidence Suggests that 
the p16'Y' gene is a tumor suppressor gene. This interpre 
tation has been challenged, however, by the observation that 
the frequency of the p16' gene alterations is much lower 
in primary uncultured tumors than in cultured cell lines 
(Caldas et al., 1994; Cheng et al., 1994; Hussussian et al., 
1994; Kamb et al., 1994: Nobori et al., 1995: Orlow et al., 
1994). Restoration of wild-type p16'' function by trans 
fection with a plasmid expression vector reduced colony 
formation by Some human cancer cell lines (Okamoto, 
1994). 
Other genes that may be employed as secondary gene 
therapies in conduction with the genetherapy of the present 
invention include Rb, APC, DCC, NF-1, NF-2, WT-1, 
MEN-I, MEN-II, Zac1, p73, VHL, MMAC1/PTEN, 
DBCCR-1, FCC, rsk-3, p27, p27/p16 fusions, p21/p27 
fusions, anti-thrombotic genes (e.g., COX-1, TFPI), PGS, 
Dp, E2F, ras, myc, neu, raf erb, fms, trk, ret, gsp, hst, abl. 
E1A, p300, genes involved in angiogenesis (e.g., VEGF, 
FGF, thrombospondin, BAI-1. GDAIF, or their receptors) 
and MCC. 
(iii) Regulators of Programmed Cell Death 
Apoptosis, or programmed cell death, is an essential 
process for normal embryonic development, maintaining 
homeostasis in adult tissues, and Suppressing carcinogenesis 
(Kerr et al., 1972). The Bcl-2 family of proteins and ICE-like 
proteases have been demonstrated to be important regulators 
and effectors of apoptosis in other systems. The Bcl-2 
protein, discovered in association with follicular lymphoma, 
plays a prominent role in controlling apoptosis and enhanc 
ing cell Survival in response to diverse apoptotic stimuli 
(Bakhshi et al., 1985; Cleary and Sklar, 1985; Cleary et al., 
1986: Tsujimoto et al., 1985; Tsujimoto and Croce, 1986). 
The evolutionarily conserved Bcl-2 protein now is recog 
nized to be a member of a family of related proteins, which 
can be categorized as death agonists or death antagonists. 
Subsequent to its discovery, it was shown that Bcl-2 acts 
to suppress cell death triggered by a variety of stimuli. Also, 
it now is apparent that there is a family of Bcl-2 cell death 
regulatory proteins which share in common structural and 
sequence homologies. These different family members have 
been shown to either possess similar functions to Bcl-2 (e.g., 
Bcl, Bcl-, Bcls, Mcl-1, A1, Bfl-1) or counteract Bcl-2 
function and promote cell death (e.g., Bax, Bak, Bik, Bim, 
Bid, Bad, Harakiri). 
(f) Other Agents 
It is contemplated that other agents may be used in 
combination with the present invention to improve the 
therapeutic efficacy of treatment. These additional agents 
include immunomodulatory agents, agents that affect the 
upregulation of cell Surface receptors and GAP junctions, 
cytostatic and differentiation agents, inhibitors of cell ade 
hesion, agents that increase the sensitivity of the hyperpro 
liferative cells to apoptotic inducers, or other biological 
agents. Immunomodulatory agents include tumor necrosis 
factor, interferon alpha, beta, and gamma; IL-2 and other 
cytokines; F42K and other cytokine analogs; or MIP-1, 
MIP-1beta, MCP-1, RANTES, and other chemokines. In 
other embodiments, cytostatic or differentiation agents can 
be used in combination with the present invention to 
improve the anti-hyerproliferative efficacy of the treatments. 
Another form of therapy for use in conjunction with 
chemotherapy, radiation therapy or biological therapy 
includes hyperthermia, which is a procedure in which a 
patient's tissue is exposed to high temperatures (up to 106° 
F.). External or internal heating devices may be involved in 













mia. Local hyperthermia involves the application of heat to 
a small area, such as a tumor. Heat may be generated 
externally with high-frequency waves targeting a tumor 
from a device outside the body. Internal heat may involve a 
sterile probe including thin, heated wires or hollow tubes 
filled with warm water, implanted microwave antennae, or 
radiofrequency electrodes. 
A patient's organ or a limb is heated for regional therapy, 
which is accomplished using devices that produce high 
energy, Such as magnets. Alternatively, some of the patients 
blood may be removed and heated before being perfused 
into an area that will be internally heated. Whole-body 
heating may also be implemented in cases where cancer has 
spread throughout the body. Warm-water blankets, hot wax, 
inductive coils, and thermal chambers may be used for this 
purpose. 
Hormonal therapy may also be used in conjunction with 
the present invention or in combination with any other 
cancer therapy previously described. The use of hormones 
may be employed in the treatment of certain cancers such as 
breast, prostate, ovarian, or cervical cancer to lower the level 
or block the effects of certain hormones such as testosterone 
or estrogen. This treatment is often used in combination with 
at least one other cancer therapy as a treatment option or to 
reduce the risk of metastases. 
I. WWOX-Based Therapies and Pharmaceuticals 
a. Protein Therapy of WWOX 
Another therapy approach is the provision, to a subject, of 
WWOX polypeptide, active fragments, synthetic peptides, 
mimetics or other analogs thereof. The protein may be 
produced by recombinant expression means or, if Small 
enough, generated by an automated peptide synthesizer. 
Formulations would be selected based on the route of 
administration and purpose including but not limited to 
liposomal formulations and classic pharmaceutical prepara 
tions. 
b. Genetic-Based Therapies with WWOX 
One of the therapeutic embodiments contemplated by the 
present inventors is the intervention, at the molecular level, 
in the events involved in the tumorigenesis of Some cancers. 
Specifically, the present inventors intend to provide, to a 
cancer cell, an expression construct capable of providing a 
WWOX polypeptide to that cell. Because the sequence 
homology between the human, mouse, rat, rabbit, murine, 
primate and dog genes, any of these nucleic acids could be 
used in human therapy, as could any of the gene sequence 
variants which would encode the same, or a biologically 
equivalent polypeptide. The lengthy discussion above of 
expression vectors and the genetic elements employed 
therein is incorporated into this section by reference. Par 
ticularly preferred expression vectors are viral vectors. 
Those of skill in the art are well aware of how to apply 
gene delivery to in vivo and ex vivo situations. For viral 
vectors, one generally will prepare a viral vector stock. 
Depending on the kind of virus and the titer attainable, one 
will deliver 1 to 100, 10 to 50, 100–1000, or up to 1x10, 
1x10, 1x10, 1x107, 1x10, 1x10, 1x10', 1x10'', or 
1x10 infectious particles to the patient. Similar figures may 
be extrapolated for liposomal or other non-viral formula 
tions by comparing relative uptake efficiencies. Formulation 
as a pharmaceutically acceptable composition is discussed 
below. 
Various routes are contemplated for various tumor types. 
The section below on routes contains an extensive list of 
possible routes. For practically any tumor, systemic delivery 
is contemplated. This will prove especially important for 
attacking microscopic or metastatic cancer. Where discrete 
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tumor mass, or solid tumor, may be identified, a variety of 
direct, local and regional approaches may be taken. For 
example, the tumor may be directly injected with the expres 
sion vector. A tumor bed may be treated prior to, during or 
after resection. Following resection, one generally will 
deliver the vector by a catheter left in place following 
Surgery. One may utilize the tumor vasculature to introduce 
the vector into the tumor by injecting a Supporting vein or 
artery. A more distal blood supply route also may be utilized. 
The method of treating cancer includes treatment of a 
tumor as well as treatment of the region near or around the 
tumor. In this application, the term “residual tumor site' 
indicates an area that is adjacent to a tumor. This area may 
include body cavities in which the tumor lies, as well as cells 
and tissue that are next to the tumor. 
In a different embodiment, ex vivo gene therapy is con 
templated. This approach is particularly Suited, although not 
limited, to treatment of bone marrow associated cancers. In 
an ex vivo embodiment, cells from the patient are removed 
and maintained outside the body for at least some period of 
time. During this period, a therapy is delivered, after which 
the cells are reintroduced into the patient; hopefully, any 
tumor cells in the sample have been killed. 
Autologous bone marrow transplant (ABMT) is an 
example of ex vivo gene therapy. Basically, the notion 
behind ABMT is that the patient will serve as his or her own 
bone marrow donor. Thus, a normally lethal dose of irra 
diation or chemotherapeutic may be delivered to the patient 
to kill tumor cells, and the bone marrow repopulated with 
the patients own cells that have been maintained (and 
perhaps expanded) ex vivo. Because, bone marrow often is 
contaminated with tumor cells, it is desirable to purge the 
bone marrow of these cells. Use of gene therapy to accom 
plish this goal is yet another way WWOX-based geneth 
erapy may be utilized according to the present invention. 
In some embodiments of the present invention a subject is 
exposed to a viral vector and the subject is then monitored 
for expression construct-based toxicity, where Such toxicity 
may include, among other things, causing a condition that is 
injurious to the Subject. 
c. Pharmaceutical Formulations and Delivery 
In a preferred embodiment of the present invention, a 
method of treatment for a cancer by the delivery of an 
expression construct encoding a WWOX polypeptide is 
contemplated. Cancers that are most likely to be treated in 
the present invention are those that result from mutations in 
the WWOX gene and/or the altered expression of the 
WWOX gene products in the cancer cells. Examples of 
cancers contemplated for treatment include lung cancer, 
head and neck cancer, breast cancer, pancreatic cancer, 
prostate cancer, renal cancer, bone cancer, testicular cancer, 
cervical cancer, gastrointestinal cancer, lymphomas, pre 
neoplastic lesions in the lung, colon cancer, melanoma or 
bladder cancer. 
Additionally, the invention also provides WWOX-based 
therapies for hyperproliferative conditions such as but not 
limited to restenosis, primary psoriasis, angiogenesis, rheu 
matoid arthritis, inflammatory bowel disease, psoriasis, 
eczema, secondary cataracts, or bronchial dysplasia. 
An effective amount of the pharmaceutical composition, 
generally, is defined as that amount Sufficient to detectably 
and repeatedly to ameliorate, reduce, minimize or limit the 
extent of the disease or its symptoms. More rigorous defi 
nitions may apply, including elimination, eradication or cure 
of disease. 
Preferably, patients will have adequate bone marrow 













of >2,000/mm and a platelet count of 100,000/mm), 
adequate liver function (bilirubin <1.5 mg/dl) and adequate 
renal function (creatinine <1.5 mg/dl). 
(i) Administration 
To kill cells, inhibit cell growth, inhibit metastasis, 
decrease tumor or tissue size and otherwise reverse or 
reduce the malignant phenotype of tumor cells, using the 
methods and compositions of the present invention, one 
would generally contact a hyperproliferative cell with the 
therapeutic expression construct. The routes of administra 
tion will vary, naturally, with the location and nature of the 
lesion, and include, e.g., intradermal, transdermal, 
parenteral, intravenous, intramuscular, intranasal, Subcuta 
neous, percutaneous, intratracheal, intraperitoneal, intratu 
moral, perfusion, lavage, direct injection, and oral adminis 
tration and formulation. 
Intratumoral injection, or injection into the tumor vascu 
lature is specifically contemplated for discrete, Solid, acces 
sible tumors. Local, regional or systemic administration also 
may be appropriate. For tumors of>4 cm, the Volume to be 
administered will be about 4–10 ml (preferably 10 ml), 
while for tumors of <4 cm, a volume of about 1–3 ml will 
be used (preferably 3 ml). Multiple injections delivered as 
single dose comprise about 0.1 to about 0.5 ml volumes. The 
viral particles may advantageously be contacted by admin 
istering multiple injections to the tumor, spaced at approxi 
mately 1 cm intervals. 
In the case of Surgical intervention, the present invention 
may be used preoperatively, to render an inoperable tumor 
Subject to resection. Alternatively, the present invention may 
be used at the time of surgery, and/or thereafter, to treat 
residual or metastatic disease. For example, a resected tumor 
bed may be injected or perfused with a formulation com 
prising a WWOX polypeptide or an WWOX-polypeptide 
encoding nucleic acid construct. The perfusion may be 
continued post-resection, for example, by leaving a catheter 
implanted at the site of the Surgery. Periodic post-Surgical 
treatment also is envisioned. 
Continuous administration also may be applied where 
appropriate, for example, where a tumor is excised and the 
tumor bed is treated to eliminate residual, microscopic 
disease. Delivery via Syringe or catherization is preferred. 
Such continuous perfusion may take place for a period from 
about 1–2 hours, to about 2–6 hours, to about 6–12 hours, to 
about 12–24 hours, to about 1–2 days, to about 1–2 wk or 
longer following the initiation of treatment. Generally, the 
dose of the therapeutic composition via continuous perfu 
sion will be equivalent to that given by a single or multiple 
injections, adjusted over a period of time during which the 
perfusion occurs. It is further contemplated that limb per 
fusion may be used to administer therapeutic compositions 
of the present invention, particularly in the treatment of 
melanomas and sarcomas. 
Treatment regimens may vary as well, and often depend 
on tumor type, tumor location, disease progression, and 
health and age of the patient. Obviously, certain types of 
tumor will require more aggressive treatment, while at the 
same time, certain patients cannot tolerate more taxing 
protocols. The clinician will be best suited to make such 
decisions based on the known efficacy and toxicity (if any) 
of the therapeutic formulations. 
In certain embodiments, the tumor being treated may not, 
at least initially, be resectable. Treatments with therapeutic 
viral constructs may increase the resectability of the tumor 
due to shrinkage at the margins or by elimination of certain 
particularly invasive portions. Following treatments, resec 
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tion may be possible. Additional treatments Subsequent to 
resection will serve to eliminate microscopic residual dis 
ease at the tumor site. 
A typical course of treatment, for a primary tumor or a 
post-excision tumor bed, will involve multiple doses. Typi 
cal primary tumor treatment involves a 6 dose application 
over a two-week period. The two-week regimen may be 
repeated one, two, three, four, five, six or more times. During 
a course of treatment, the need to complete the planned 
dosings may be re-evaluated. 
The treatments may include various “unit doses.” Unit 
dose is defined as containing a predetermined-quantity of the 
therapeutic composition. The quantity to be administered, 
and the particular route and formulation, are within the skill 
of those in the clinical arts. A unit dose need not be 
administered as a single injection but may comprise con 
tinuous infusion over a set period of time. Unit dose of the 
present invention may conveniently be described in terms of 
plaque forming units (pfu) for a viral construct. Unit doses 
range from 10, 10, 10, 10°, 107, 10, 10, 10", 10'', 10", 
10' pfu and higher. Alternatively, depending on the kind of 
virus and the titer attainable, one will deliver 1 to 100, 10 to 
50, 100-1000, or up to about 1x10, 1x10, 1x10, 1x107, 
1x10, 1x10, 1x10", 1x10'', 1x10", 1x10", 1x10', or 
1x10 or higher infectious viral particles (vp) to the patient 
or to the patients cells. 
(ii) Injectable Compositions and Formulations 
One method for the delivery of an expression construct 
encoding a WWOX polypeptide to hyperproliferative cells 
in the present invention is via intratumoral injection. How 
ever, the pharmaceutical compositions disclosed herein may 
alternatively be administered parenterally, intravenously, 
intradermally, intramuscularly, transdermally or even intra 
peritoneally as described in U.S. Pat. No. 5,543,158; U.S. 
Pat. No. 5,641,515 and U.S. Pat. No. 5,399,363 (each 
specifically incorporated herein by reference in its entirety). 
Injection of nucleic acid constructs may be delivered by 
Syringe or any other method used for injection of a solution, 
as long as the expression construct can pass through the 
particular gauge of needle required for injection. A novel 
needleless injection system has recently been described 
(U.S. Pat. No. 5,846,233) having a nozzle defining an 
ampule chamber for holding the solution and an energy 
device for pushing the solution out of the nozzle to the site 
of delivery. A syringe system has also been described for use 
in gene therapy that permits multiple injections of predeter 
mined quantities of a solution precisely at any depth (U.S. 
Pat. No. 5,846,225). 
Solutions of the active compounds as free base or phar 
macologically acceptable salts may be prepared in water 
Suitably mixed with a surfactant, Such as hydroxypropylcel 
lulose. Dispersions may also be prepared in glycerol, liquid 
polyethylene glycols, and mixtures thereof and in oils. 
Under ordinary conditions of storage and use, these prepa 
rations contain a preservative to prevent the growth of 
microorganisms. The pharmaceutical forms suitable for 
injectable use include sterile aqueous Solutions or disper 
sions and sterile powders for the extemporaneous prepara 
tion of sterile injectable solutions or dispersions (U.S. Pat. 
No. 5,466,468, specifically incorporated herein by reference 
in its entirety). In all cases the form must be sterile and must 
be fluid to the extent that easy syringability exists. It must be 
stable under the conditions of manufacture and storage and 
must be preserved against the contaminating action of 
microorganisms, such as bacteria and fungi. The carrier can 
be a solvent or dispersion medium containing, for example, 













liquid polyethylene glycol, and the like), Suitable mixtures 
thereof, and/or vegetable oils. Proper fluidity may be main 
tained, for example, by the use of a coating, such as lecithin, 
by the maintenance of the required particle size in the case 
of dispersion and by the use of surfactants. The prevention 
of the action of microorganisms can be brought about by 
various antibacterial and antifungal agents, for example, 
parabens, chlorobutanol, phenol, Sorbic acid, thimerosal, 
and the like. In many cases, it will be preferable to include 
isotonic agents, for example, Sugars or sodium chloride. 
Prolonged absorption of the injectable compositions can be 
brought about by the use in the compositions of agents 
delaying absorption, for example, aluminum monostearate 
and gelatin. 
For parenteral administration in an aqueous solution, for 
example, the solution should be suitably buffered if neces 
sary and the liquid diluent first rendered isotonic with 
Sufficient saline or glucose. These particular aqueous solu 
tions are especially suitable for intravenous, intramuscular, 
Subcutaneous, intratumoral and intraperitoneal administra 
tion. In this connection, sterile aqueous media that can be 
employed will be known to those of skill in the art in light 
of the present disclosure. For example, one dosage may be 
dissolved in 1 ml of isotonic NaCl solution and either added 
to 1000 ml of hypodermoclysis fluid or injected at the 
proposed site of infusion, (see for example, "Remington's 
Pharmaceutical Sciences' 15th Edition, pages 1035–1038 
and 1570–1580). Some variation in dosage will necessarily 
occur depending on the condition of the Subject being 
treated. The person responsible for administration will, in 
any event, determine the appropriate dose for the individual 
subject. Moreover, for human administration, preparations 
should meet sterility, pyrogenicity, general safety and purity 
standards as required by FDA Office of Biologics standards. 
Sterile injectable solutions are prepared by incorporating 
the active compounds in the required amount in the appro 
priate solvent with various of the other ingredients enumer 
ated above, as required, followed by filtered sterilization. 
Generally, dispersions are prepared by incorporating the 
various sterilized active ingredients into a sterile vehicle 
which contains the basic dispersion medium and the 
required other ingredients from those enumerated above. In 
the case of sterile powders for the preparation of sterile 
injectable solutions, the preferred methods of preparation 
are vaccuum-drying and freeze-drying techniques which 
yield a powder of the active ingredient plus any additional 
desired ingredient from a previously sterile-filtered solution 
thereof. 
The compositions disclosed herein may be formulated in 
a neutral or salt form. Pharmaceutically-acceptable salts, 
include the acid addition salts (formed with the free amino 
groups of the protein) and which are formed with inorganic 
acids such as, for example, hydrochloric or phosphoric 
acids, or Such organic acids as acetic, oxalic, tartaric, man 
delic, and the like. Salts formed with the free carboxyl 
groups can also be derived from inorganic bases such as, for 
example, sodium, potassium, ammonium, calcium, or ferric 
hydroxides, and Such organic bases as isopropylamine, 
trimethylamine, histidine, procaine and the like. Upon for 
mulation, Solutions will be administered in a manner com 
patible with the dosage formulation and in Such amount as 
is therapeutically effective. The formulations are easily 
administered in a variety of dosage forms such as injectable 
Solutions, drug release capsules and the like. 
As used herein, “carrier includes any and all solvents, 
dispersion media, vehicles, coatings, diluents, antibacterial 
and antifungal agents, isotonic and absorption delaying 
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agents, buffers, carrier Solutions, Suspensions, colloids, and 
the like. The use of Such media and agents for pharmaceu 
tical active substances is well known in the art. Except 
insofar as any conventional media or agent is incompatible 
with the active ingredient, its use in the therapeutic compo 
sitions is contemplated. Supplementary active ingredients 
can also be incorporated into the compositions. 
The phrase “pharmaceutically-acceptable' or “pharmaco 
logically-acceptable' refers to molecular entities and com 
positions that do not produce an allergic or similar untoward 
reaction when administered to a human. The preparation of 
an aqueous composition that contains a protein as an active 
ingredient is well understood in the art. Typically, Such 
compositions are prepared as injectables, either as liquid 
Solutions or Suspensions; solid forms suitable for solution in, 
or Suspension in, liquid prior to injection can also be 
prepared. 
The terms “contacted” and “exposed,” when applied to a 
cell, are used herein to describe the process by which a 
therapeutic construct and a chemotherapeutic or radiothera 
peutic agent are delivered to a target cell or are placed in 
direct juxtaposition with the target cell. To achieve cell 
killing or stasis, both agents are delivered to a cell in a 
combined amount effective to kill the cell or prevent it from 
dividing. 
J. Detection of WWOX 
In some embodiments of the present invention, the detec 
tion of WWOX polynucleotides or polypeptides is desirable, 
for example, to determine the level of expression from an 
expression construct that contains an WWOX polynucle 
otide encoding an WWOX polypeptide and/or for detecting 
which truncated WWOX products are expressed in a cancer 
cell. Methods of detecting polynucleotides, such as the 
mRNA transcripts encoded by the WWOX polynucleotide 
of the expression construct, include Northern detection 
methods and nucleic acid amplification methods, such as the 
polymerase chain reaction (PCR) described in detail in U.S. 
Pat. Nos. 4,683,195, 4,683.202 and 4,800,159. Such tech 
niques are known to those of ordinary skill in the art. Various 
methods of detecting polypeptides are also within the ordi 
nary skill of those in the art. Immunoassays encompassed by 
the present invention include, but are not limited to, those 
described in U.S. Pat. No. 4,367,110 (double monoclonal 
antibody sandwich assay) and U.S. Pat. No. 4,452,901 
(western blot). Other assays include immunoprecipitation of 
labeled ligands and immunocytochemistry, both in vitro and 
in vivo. 
Immunoassays generally are binding assays. Certain pre 
ferred immunoassays are the various types of enzyme linked 
immunosorbent assays (ELISAS) and radioimmunoassays 
(RIA) known in the art. Immunohistochemical detection 
using tissue sections is also particularly useful. The basic 
ELISA technique and its variations are known to those of 
skill in the art. Assays for the presence of expression of 
WWOX may be performed directly on tissue samples. 
Methods for in vitro situ analysis are well known and 
involve assessing binding of antigen-specific antibodies to 
tissues, cells, or cell extracts. These are conventional tech 
niques well within the grasp of those skilled in the art. 
K. Kits 
The materials and reagents required for detecting a cancer 
cell based on the expression of WWOX gene products may 
be assembled together in a kit. In one embodiment, Such a 
kit generally will comprise anti-WWOX antibodies; and 











complex. In one embodiment, the anti-WWOX antibodies 
may be antibodies to mutated versions of the WWOX 
protein. 
The materials and reagents required for detecting an 
individual prone to certain cancer types, based on mutations 
of the WWOX, may also be assembled together in a kit. 
Such a kit will generally comprise reagents to isolate chro 
mosomal DNA from cells; a set of fluorescent probes 
spanning the WWOX gene locus; and reagents to detect the 
binding of these probes to mutated regions of the genome. 
The fluorophore may comprise: Alexa 350, Alexa 430, 
AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY 
FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cas 
cade Blue, Cy3, Cy5,6-FAM, Fluorescein, HEX, 6-JOE, 
Oregon Green 488, Oregon Green 500, Oregon Green 514, 
Pacific Blue, REG, Rhodamine Green, Rhodamine Red, 
ROX, TAMRA, TET. Tetramethylrhodamine, and Texas 
Red. 
In each case, the kits will preferably comprise distinct 
containers for each individual reagent, antibody type; and 
probe. Each biological agent will generally be suitable 
aliquoted in their respective containers. The container means 
of the kits will generally include at least one vial or test tube. 
Flasks, bottles and other container means into which the 
reagents are placed and aliquoted are also possible. The 
individual containers of the kit will preferably be maintained 
in close confinement for commercial sale. Suitable larger 
containers may include injection or blow-molded plastic 
containers into which the desired vials are retained. Instruc 
tions may be provided with the kit. 
In further embodiments, the invention provides immuno 
logical kits for use in detecting cancer cells, e.g., in biologi 
cal samples. Such kits will generally comprise one or more 
antibodies that have immunospecificity for the mutated and 
abnormal proteins or peptides encoded by the WWOX gene 
in cancer cells. The antibodies will be specific for the 
abnormal versions of WWOX such as, the A5-8 form of 
WWOX, which is a frameshifted version that expresses a 
different protein from the normal WWOX. Thus, such 
antibodies can be used to identify cancer cells by using 
immunohistochemical methods such as ELISA’s. 
As the anti-WWOX proteins or peptide antibodies may be 
employed to detect cancer cells either or both of such 
components may be provided in the kit. The immunodetec 
tion kits will thus comprise, in Suitable container means, a 
WWOX polypeptide?protein, a first antibody that binds to 
Such a protein or peptide, and an immunodetection reagent. 
In certain embodiments, the abnormal WWOX proteins or 
peptides, or the first antibody that binds to the protein or 
peptide, such as an anti-WWOX antibody as described 
above, may be bound to a solid Support, Such as a column 
matrix or well of a microtitre plate. 
The immunodetection reagents of the kit may take any 
one of a variety of forms, including those detectable labels 
that are associated with, or linked to, the given antibody or 
antigen itself. Detectable labels that are associated with or 
attached to a secondary binding ligand are also contem 
plated. Exemplary secondary ligands are those secondary 
antibodies that have binding affinity for the first antibody or 
antigen. 
Further suitable immunodetection reagents for use in the 
present kits include the two-component reagent that com 
prises a secondary antibody that has binding affinity for the 
first antibody or antigen (generally a anti-WWOX or a 
WWOX antigen), along with a third antibody that has 
binding affinity for the second antibody, wherein the third 
antibody is linked to a detectable label. 
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As noted above in the discussion of antibody conjugates, 
a number of exemplary labels are known in the art and all 
Such labels may be employed in connection with the present 
invention. Radiolabels, nuclear magnetic spin-resonance 
isotopes, fluorescent labels and enzyme tags capable of 
generating a colored product upon contact with an appro 
priate Substrate are suitable examples. 
The kits may contain antibody-label conjugates either in 
fully conjugated form, in the form of intermediates, or as 
separate moieties to be conjugated by the user of the kit. 
The kits may further comprise a suitably aliquoted com 
position of a WWOX protein or polypeptide, whether 
labeled or unlabeled, as may be used to prepare a standard 
curve for a detection assay. 
The kits of the invention, regardless of type, will gener 
ally comprise one or more containers into which the bio 
logical agents are placed and, preferably, Suitable aliquoted. 
The components of the kits may be packaged either in 
aqueous media or in lyophilized form. 
Additional embodiments provide RT-PCR-based kits 
which utilize primers specific for the tumor specific abnor 
mal transcripts. As abnormally and/or alternatively spliced 
transcripts of WWOX are expressed in tumor cells detection 
of these abnormal transcripts is indicative of the presence of 
cancer. It is envisioned that human tissue samples will be 
screened for the presence of abnormal WWOX gene prod 
ucts to identify the cancer. Such samples could consist of 
cells, cellular fluid, needle biopsy cores, Surgical resection 
samples, lymph node tissue, serum/plasma or any biological 
fluid. 
In one example of Such a kit a common 5' primer Such as, 
5'-AGGCAGTGCGCAGGCGTGAGC-3' (SEQID NO:14) 
and 3' specific primers spanning the new exon-exonjunc 
tions found only in the abnormal alternatively spliced forms 
such as, the abnormal or truncated forms of WWOX, will be 





A 4-8: 5'-TGGTGGCAGCTCCCTGTTGTCAACAAAAAACAC-3' 
A3-8: 5'-ACGGTGGTGGCAGCTCCCTGTTGCTCC-3' 
Thus, the RT-PCR-based kits will contain in suitable 
containers the appropriate primers, the enzymes required for 
reverse transcription and PCR, and other suitable buffers and 
reagents. 
L. Prognostic Applications 
Mutations and overexpression of the WWOX gene and its 
products was identified in a variety of cancer cells and cell 
lines. Thus, the WWOX encoded gene products are useful as 
markers for a cancer phenotype. Evaluation of the expres 
sion of WWOX in the cancer tissues of a patient will be 
useful in determining whether that patient’s cancer will 
progress and, therefore, will allow a proper determination of 
the need for additional therapy to be made. 
The expression levels of WWOX as well as the type of 


















useful in monitoring the effectiveness of a treatment regi 
men. In any event, the methods of the present invention will 
assist physicians in diagnosing cancer and in determining 
optimal treatment courses for individuals with tumors of 
Varying malignancy. 
In other embodiments the prognosis comprises determin 
ing the susceptibility of individuals to certain WWOX 
dependent cancers. In one aspect this comprises 1) gener 
ating fluorescent probes spanning the WWOX chromosomal 
locus; 2) obtaining chromosomal DNA samples from indi 
viduals and 3) identifying different mutations of the WWOX 
gene, thereby identifying individuals susceptible to a par 
ticular cancer types. 
As described herein in detail, the amount of a WWOX 
transcript and/or protein and/or polypeptide present within a 
biological sample, such as a tissue, blood or serum sample, 
may be determined by means of a molecular biological assay 
to determine the level of a nucleic acid that encodes such a 
polypeptide, or by means of an immunoassay to determine 
the level of the polypeptide itself. 
It is envisioned that in clinical applications, human tissue 
samples will be screened for the presence of the WWOX 
gene products identified as markers of cancer herein. Such 
samples could consist of needle biopsy cores, Surgical 
resection samples, lymph node tissue, or serum/plasma. 
In certain embodiments, nucleic acids would be extracted 
from these samples and amplified as described above. Some 
embodiments would utilize kits containing pre-selected 
primer pairs or hybridization probes. The amplified nucleic 
acids would be tested for the markers by any of the detection 
methods described herein or other suitable methods known 
in the art. 
In other embodiments, tissue extracts containing marker 
proteins would be extracted from a sample and Subjected to 
an immunoassay as described herein. Immunoassays of 
tissue sections are also possible. Kits containing the anti 
bodies of the invention would be useful. 
ID NO : 4) 
ID NO. 5) 
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M. Screening for Modulators of WWOX 
As the WWOX polypeptides are mainly implicated in 
protein protein interactions, either via the WW domain, 
and/or the SDR domain, and/or via other domains, another 
objective of the present invention is to provide methods for 
identifying molecules that interact with WWOX polypep 
tides. These molecules include proteins, peptides, polypep 
tides, oligopeptides, and/or any other molecule that can bind 
to and modulate the function and/or localization of a 
WWOX polypeptide. 
The screening assays may comprise random screening of 
large libraries of candidate Substances; alternatively, the 
assays may be used to focus on particular classes of com 
pounds selected with an eye towards structural attributes that 
are believed to make them more likely to modulate the 
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function and/or localization of WWOX. Modulators of 
WWOX polypeptides are also referred to as binding part 
ners in this specification. 
By function, it is meant that one may assay for a change 
in the tumor suppressive ability of a WWOX polypeptide. 
For example, binding to or interaction with a modulator may 
inhibit the tumor suppressive ability of WWOX. Alterna 
tively, modulators that increase the tumor Suppressive prop 
erties of WWOX may be identified by the screening methods 
provided herein. 
By localization, it is meant that one may assay for the 
cellular localization of WWOX. Normal wild-type WWOX 
localizes in the cytoplasm. However, the present inventors 
have shown that some aberrant or alternatively spliced 
WWOX polypeptides that are expressed in cancer cells 
localize to the Golgi bodies. WWOX-localization assays are 
described later in the section entitled Examples and utilize 
WWOX proteins fused with fluorescent proteins such as the 
green fluorescent protein (GFP). 
In some embodiments, the present inventors have identi 
fies several binding partners of WWOX using far-Western 
blot analysis in conjunction with GST-fusion constructs of 
the WW domains of WWOX polypeptides. Some of the 
binding partners identified include proline rich oligopeptides 
such as Ld10, P3, CDC25 and WBP1 which have the proline 
rich motifs PPLP, PPR, PLTP and PPPY respectively. 
Other methods may also be used to identify a WWOX 
modulator. These methods will generally comprise deter 
mining the function of WWOX in the presence and absence 
of the candidate Substance. A modulator is defined as any 
Substance that alters function. For example, a method gen 
erally comprises: 
(a) providing a candidate modulator, 
(b) admixing the candidate modulator to a cell expressing 
WWOX or a suitable experimental animal expressing 
WWOX; 
(c) measuring one or more characteristics cell or animal in 
step (c); and 
(d) comparing the characteristic measured in step (c) with 
the characteristic of the cell or animal in the absence of 
said candidate modulator, 
wherein a difference between the measured characteristics 
indicates that said candidate modulator is, indeed, a 
modulator of WWOX. 
Assays may be conducted in cell free systems, in isolated 
cells, or in organisms including transgenic animals. 
It will, of course, be understood that all the screening 
methods of the present invention are useful in themselves 
notwithstanding the fact that effective candidates may not be 
found. The invention provides methods for screening for 
Such candidates, not solely methods of finding them. 
1. Modulators 
As used herein the term “candidate substance” refers to 
any molecule that may potentially inhibit or enhance 
WWOX activity or cause a change in the cellular localiza 
tion of a WWOX polypeptide. The candidate substance may 
be a protein or fragment thereof, a small molecule, or even 
a nucleic acid molecule. It may prove to be the case that the 
most useful pharmacological compounds will be compounds 
that can bind to domains of WWOX polypeptides. This 
includes molecules with proline rich motifs which are 
known to interact with WW domains as well as other smaller 
ligands and/or co-factors that may bind to the SDR domain 
of WWOX polypeptides. Using lead compounds to help 













design' and includes not only comparisons with know 
inhibitors and activators, but predictions relating to the 
structure of target molecules. 
The goal of rational drug design is to produce structural 
analogs of biologically active polypeptides or target com 
pounds. By creating such analogs, it is possible to fashion 
drugs, which are more active or stable than the natural 
molecules, which have different susceptibility to alteration 
or which may affect the function of various other molecules. 
In one approach, one would generate a three-dimensional 
structure for a target molecule, or a fragment thereof. This 
could be accomplished by X-ray crystallography, computer 
modeling or by a combination of both approaches. 
It also is possible to use antibodies to ascertain the 
structure of a target compound activator or inhibitor. In 
principle, this approach yields a pharmacore upon which 
Subsequent drug design can be based. It is possible to bypass 
protein crystallography altogether by generating anti-idio 
typic antibodies to a functional, pharmacologically active 
antibody. As a mirror image of a mirror image, the binding 
site of anti-idiotype would be expected to be an analog of the 
original antigen. The anti-idiotype could then be used to 
identify and isolate peptides from banks of chemically- or 
biologically-produced peptides. Selected peptides would 
then serve as the pharmacore. Anti-idiotypes may be gen 
erated using the methods described herein for producing 
antibodies, using an antibody as the antigen. 
On the other hand, one may simply acquire, from various 
commercial sources, Small molecule libraries that are 
believed to meet the basic criteria for useful drugs in an 
effort to "brute force' the identification of useful com 
pounds. Screening of Such libraries, including combinatori 
ally generated libraries (e.g., peptide libraries), is a rapid and 
efficient way to Screen large number of related (and unre 
lated) compounds for activity. Combinatorial approaches 
also lend themselves to rapid evolution of potential drugs by 
the creation of second, third and fourth generation com 
pounds modeled of active, but otherwise undesirable com 
pounds. 
Candidate compounds may include fragments or parts of 
naturally-occurring compounds, or may be found as active 
combinations of known compounds, which are otherwise 
inactive. It is proposed that compounds isolated from natural 
Sources, such as animals, bacteria, fungi, plant sources, 
including leaves and bark, and marine samples may be 
assayed as candidates for the presence of potentially useful 
pharmaceutical agents. It will be understood that the phar 
maceutical agents to be screened could also be derived or 
synthesized from chemical compositions or man-made com 
pounds. Thus, it is understood that the candidate Substance 
identified by the present invention may be peptide, polypep 
tide, polynucleotide, small molecule inhibitors or any other 
compounds that may be designed through rational drug 
design starting from known inhibitors or stimulators. 
Other suitable modulators include antisense molecules, 
ribozymes, and antibodies (including single chain antibod 
ies), each of which would be specific for the target molecule. 
Such compounds are described in greater detail elsewhere in 
this document. For example, an antisense molecule that 
bound to a translational or transcriptional start site, or splice 
junctions, would be ideal candidate inhibitors. 
In addition to the modulating compounds initially iden 
tified, the inventors also contemplate that other sterically 
similar compounds may be formulated to mimic the key 
portions of the structure of the modulators. Such com 
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pounds, which may include peptidomimetics of peptide 
modulators, may be used in the same manner as the initial 
modulators. 
An inhibitor according to the present invention may be 
one which exerts its inhibitory or activating effect upstream, 5 
downstream or directly on a WWOX polypeptide. Regard 
less of the type of inhibitor or activator identified by the 
present screening methods, the effect of the inhibition or 
activation results in a change in the activity or localization 
of WWOX as compared to that observed in the absence of 10 
the added candidate Substance. 
2. In Vitro Assays 
A quick, inexpensive and easy assay to run is an in vitro 
assay. Such assays generally use isolated molecules, can be 
run quickly and in large numbers, thereby increasing the 15 
amount of information obtainable in a short period of time. 
A variety of vessels may be used to run the assays, including 
test tubes, plates, dishes and other Surfaces such as dipsticks 
or beads. 
One example of a cell free assay is a binding assay. While 20 
not directly addressing function, the ability of a modulator 
to bind to a target molecule in a specific fashion is strong 
evidence of a related biological effect. For example, binding 
of a molecule to a target may, in and of itself, be inhibitory, 
due to steric, allosteric or charge—charge interactions. The 25 
target may be either free in solution, fixed to a Support, 
expressed in or on the surface of a cell. Either the target or 
the compound may be labeled, thereby permitting determin 
ing of binding. Usually, the target will be the labeled species, 
decreasing the chance that the labeling will interfere with or 30 
enhance binding. Competitive binding formats can be per 
formed in which one of the agents is labeled, and one may 
measure the amount of free label versus bound label to 
determine the effect on binding. 
A technique for high throughput Screening of compounds 35 
is described in WO 84/03564. Large numbers of small 
peptide test compounds are synthesized on a solid Substrate, 
Such as plastic pins or some other Surface. Bound polypep 
tide is detected by various methods. 
3. In Cyto Assays 40 
The present invention also contemplates the screening of 
compounds for their ability to modulate WWOX function/ 
activity or localization in cells. Various cell lines can be 
utilized for Such screening assays, including cells specifi 
cally engineered for this purpose. For example, one may use 45 
cancer cell lines that express alternatively spliced or aberrant 
WWOX polypeptides to screen for modulators that bind to 
these polypeptides and cause a decrease in the overall tumor 
suppression of WWOX. One can also used normal cells (i.e., 
non-cancerous cells), and screen for molecules that bind and 50 
regulate the function of wild-type WWOX. 
Depending on the assay, a cell culture method may be 
required. The cell or cells are examined using any of a 
number of different physiologic assays. Such assays are 
known to the skilled artisan. Alternatively, molecular analy- 55 
sis may be performed, for example, looking at protein 
expression, mRNA expression (including differential dis 
play of whole cell or polyA RNA) and others. 
4. In Vivo Assays 
In vivo assays involve the use of various animal models, 60 
including transgenic animals that have been engineered to 
have specific defects, or carry markers that can be used to 
measure the ability of a candidate Substance to reach and 
effect different cells within the organism. Due to their size, 
ease of handling, and information on their physiology and 65 
genetic make-up, mice are a preferred embodiment, espe 
cially for transgenics. However, other animals are suitable as 
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well, including rats, rabbits, hamsters, guinea pigs, gerbils, 
Woodchucks, cats, dogs, sheep,goats, pigs, cows, horses and 
monkeys (including chimps, gibbons and baboons). Assays 
for modulators of WWOX may be conducted using an 
animal model derived from any of these species. 
In Such assays, one or more candidate Substances are 
administered to an animal, and the ability of the candidate 
Substance(s) to alter one or more characteristics that relate to 
WWOX function, as compared to a similar animal not 
treated with the candidate Substance(s), identifies a modu 
lator. The characteristics may be any of those discussed 
above with regard to the function of a WWOX polypeptide 
including ability to Suppress tumor formation. 
The present invention provides methods of Screening for 
a candidate substance that modulate the function of WWOX. 
In these embodiments, the present invention is directed to a 
method for determining the ability of a candidate substance 
to modulate the tumor suppressive properties of a WWOX 
polypeptide, generally including the steps of 
a) administering a candidate Substance to the animal; and 
b) determining the ability of the candidate substance to 
reduce one or more characteristics relating to WWOX 
function. 
For example, a animal tumor model of cancer may be 
treated with a candidate Substance in conjunction with a 
WWOX-based nucleic acid or protein therapy as discussed 
in this invention and the ability of the candidate substance to 
modulate the tumor suppressive properties of WWOX may 
be analyzed. Thus, enhancers and inhibitors of WWOX 
function may be identified. 
Treatment of these animals with test compounds will 
involve the administration of the compound, in an appro 
priate form, to the animal. Administration will be by any 
route that could be utilized for clinical or non-clinical 
purposes, including but not limited to oral, nasal, buccal, or 
even topical. Alternatively, administration may be by intra 
tumoral, intratracheal instillation, bronchial instillation, 
intradermal, Subcutaneous, intramuscular, intraperitoneal or 
intravenous injection. Specifically contemplated routes are 
systemic intravenous injection, regional administration via 
blood or lymph Supply, or directly to an tumor site or tumor 
vasculature. 
Determining the effectiveness of a compound in Vivo may 
involve a variety of different criteria. Also, measuring tox 
icity and dose response can be performed in animals in a 
more meaningful fashion than in in vitro or in cyto assays. 
N. Screening for Anti-Tumor Activity. Using Animal 
Models 
Animal models may be used as a screen for tumor 
suppressive effects of the WWOX gene or gene combina 
tions. Preferably, orthotopic animal models will be used so 
as to closely mimic the particular disease type being studied 
and to provide the most relevant results. 
One type of orthotopic model involves the development 
of an animal model for the analysis of microscopic residual 
carcinomas and microscopic seeding of body cavities. "Car 
cinoma, as used herein, may refer to a single cell or a 
multicellular tumor mass. In microscopic disease, the 
“tumor' will consist or one or a few carcinoma cells which 
cannot be observed with the naked eye. The animal model 
described herein is particularly advantageous mimicking (i) 
the post Surgical environment of head and neck cancer 
patients, particularly in advanced stages of disease and (ii) 
the body cavity of an affected subject wherein microscopic 
carcinoma has been established. The model, similar to other 
animal models for cancer, derives from inoculation of tumor 
cells into an animal. A distinction, however, lies in the 
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creation, Subcutaneously, of a pouch that is a physiologic 
equivalent of a natural body cavity or a post-Surgical cavity 
created by the excision of a tumor mass. 
Virtually any animal may be employed, however, for use 
according to the present invention. Particularly preferred 
animals will be small mammals that are routinely used in 
laboratory protocols. Even more preferred animals will be 
those of the rodent group, Such as mice, rats, guinea pigs and 
hamsters. Rabbits also are a preferred species. The criteria 
for choosing an animal will be largely dependent upon the 
particular preference of an investigator. 
The first step is to create a tissue flap in the experimental 
animal. The term “tissue flap' means any incision in the 
flesh of the animal that exposes the target tissue. It is 
generally preferred that an incision be made in the dorsal 
flank of an animal, as this represents a readily accessible site. 
However, it will be understood that an incision could well be 
made at other points on the animal, and the choice of tissue 
sites may be dependent upon various factors such as the 
particular type of therapeutics that are being investigated. 
Once a target tissue site is exposed, carcinoma cells, either 
individually or in microscopic tumors, are contacted with 
the tissue site. The most convenient manner for seeding the 
cancer cells into the tissue site is to apply a suspension of 
tissue culture media containing the cells to the exposed 
tissue. Cancer cell application may be achieved simply using 
a sterile pipette or any other convenient applicator. Natu 
rally, this procedure will be conducted under sterile condi 
tions. 
In a particular example, 2.5x10 cells are inoculated into 
the exposed tissue flap of a nude mouse. Those of skill in the 
art will be able to readily determine, for a given purpose, 
what the appropriate number of cells will be. The number of 
cells will be dependent upon various factors, such as the size 
of the animal, the site of incision, the replicative capacity of 
the tumor cells themselves, the time intended for tumor 
growth, the potential anti-tumor therapeutic to be tested, and 
the like. Although establishing an optimal model system for 
any particular type of tumor may require a certain adjust 
ment in the number of cells administered, this in no way 
represents an undue amount of experimentation. Those 
skilled in the area of animal testing will appreciate that Such 
optimization is required. 
This can be accomplished, for example, by conducting 
preliminary studies in which differing numbers of cells are 
delivered to the animal and the cell growth is monitored 
following resealing of the tissue flap. Naturally, administer 
ing larger numbers of cells will result in a larger population 
of microscopic residual tumor cells. 
However, it is envisioned that persons skilled in the art 
may use any of a variety of methods routinely used to seal 
the incision Such as the use of adhesives, clamps, Stitches, 
Sutures, etc., depending on the particular use contemplated. 
Other orthotopic animal models are well known in the art. 
The orthotopic lung cancer model, for example has been 
described in the literature. This protocol involves injection 
of tumor cells into the bronchus of a mouse wherein tumors 
will form in the bronchus and bronchioles, mimicking 
tumors commonly found in non-small cell lung cancer 
patients. The skilled artisan will readily be able to adapt or 
modify each particular model for his intended purpose 
without undue experimentation. 
O. Examples 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 














discovered by the inventors to function well in the practice 
of the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
EXAMPLE 1. 
Isolation And Cloning of WWOX 
Chromosomal and genomic abnormalities affecting chro 
mosome 16q (ch 16q), have been reported in cytogenetic and 
allelotypic studies of various epithelial tumors. The loss of 
heterozygosity (LOH), affecting the long arm of this auto 
Some is often observed in breast carcinomas and pre 
invasive breast lesions (Sato et al., 1990; Tsuda et al., 1994: 
Cleton-Jansen et al., 1994; Aldaz, et al., 1995; Chen et al., 
1996). Other tumor types, such as prostate and hepatic 
carcinomas also exhibit similar abnormalities (Chen et al., 
1996; Carter et al., 1990). Therefore, identification of puta 
tive tumor suppressor gene(s) that may reside in the distal 
portion of ch 16q has been the subject of several studies 
(Whitmore et al., 1998; Crawford et al., 1999 Savino et al., 
1999). 
One of the most commonly affected areas spans the region 
between STS markers D16S515 and D16S504 with the most 
affected locus D16S518 at 16923.3–24.1 (Chen et al., 1996). 
The high incidence of LOH observed at pre-invasive stages 
of tumor development indicates the possibility of a candi 
date tumor Suppressor gene or genes at location 
16q23.3–24.1 which may play an important role in early 
breast carcinogenesis (Chen et al., 1996). Describe herein 
are the physical mapping of the chromosomal region 
between STS markers D16S518 and D16S516, and the 
cloning of a novel gene from within this area. 
Methods 
BACs Identification and Development of STSs and DNA 
Sequencing. YAC and BAC clones spanning the region of 
interest were identified by PCR screening of STSs. BACs 
were isolated from BAC library CITB-HSP-C (Research 
Genetics, Huntsville, AB). BAC ends were sequenced using 
SP6 and T7 vector primers to generate novel STSs for contig 
building. 
Genomic DNA shotgun sequencing was performed using 
DNAse. BAC DNA digestion and subsequent cloning into 
pZErO-1 vector (Invitrogen). Inserts were amplified with 
vector specific primers. Cycle sequencing reactions were 
performed using ABI PRISM BigDye Terminator cycle 
sequencing chemistry (Perkin Elmer/Applied BioSystems) 
and analyzed on an ABI 377 automated fluorescent 
sequencer (PerkinElmer/Applied Biosystems). Some clones 
were sequenced manually with 'P labeled primers. 
Isolation of Candidate cDNAs. cDNA clones were iso 
lated following a modification of a solution hybrid capture 
method described by Futreal et al., (1994), using BAC 
clones from the region of interest, as selector DNA, and 
isolating cDNA clones from a human mammary gland 
cDNA library (5'-STRECH, Clontech Laboratories, Inc). All 
cloned cDNAS were sequenced and analyzed using the 
BLAST algorithm, searching all available GenBank human 
databases. The isolated cDNA clones were mapped back to 
the corresponding BAC (selector) DNAs and compared with 
the genomic DNA sequence. 
WWOX cDNA Isolation and Exon-Intron Structure 
Determination. A consensus sequence was generated by 
alignment of the primary cloned cDNA sequence and match 
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ing ESTs. From this sequence primers were prepared to 
isolate the full length cDNA. Two independent clones were 
isolated from a placenta cDNA library panel (Rapid Screen, 
OriCiene Technologies, Inc.). Additionally, a second strategy 
was followed using the 5' and 3' RACE PCR method on a 
human mammary gland cDNA library (Marathon-Ready, 
Clontech Laboratories, Inc.) according to the manufacturers 
protocol. The cDNAs isolated by this method were cloned, 
76 
System Promega) with full length WWOX cDNA as tem 
plate. S-methionine labeled products were analyzed by 
SDS-polyacrylamide gel electrophoresis followed by phos 
phorimager detection. 
Mutation Screening. Genomic DNA isolated from a panel 
of 27 breast cancer cell lines was used to resequence each of 
the exons of WWOX. Primers for individual exon amplifi 
cation and sequencing are specified in Table 7. 
TABLE 7 
WWOX intron-exon iunctions and PCR/Sequencing primers 
PCR 
product 
Intronic primers for mutation screening size 
(5'-3') (bp) 
1F-ACTGGATTTCAGCTTCGTGGTCG (SEQ ID 35) 334 
1R-TCCGTGGGCTGTGCAGGGTC (SEQ ID 36) 
2F-TTCCCCCTACTTCCTTCTTATATCTGGC (SEQ ID 37) 373 
2R- ATCCTCACTCCACCCTATGATCTCATC (SEQ ID 38) 
3F-ATGGTCTTTACTTCTCCCTGGCAC (SEQ ID 39) 244 
3R- ACTTCTGCTA AGATTACAGATACACACTG 
(SEQ ID 40) 
4F-AGTTCTTTCAGGTTTAAGGAATAAGC (SEQ ID 41) 370 
4R-TAGATCTAAGTGGATCTCATTATAGCAG 
(SEQ ID 42) 
5F-ACTTGGGGTAATTTAAGTGGTGCTC (SEQ ID 43) 296 
5R- AACTTTACACACTCCACTGAAATCTCC (SEQ ID 44) 
6F-ATTAAACAGGGGAATTCCGAC (SEQ ID 45) 278 
6R-TCTCCCAATTGTGTTCATCTG (SEQ ID 46) 
7F-ACATCCATGGATCCCGAAG (SEQ ID 47) 3.18 
7R-TGGTATGAGAAAGGGGATAAGTG (SEQ ID 48) 
8F-TGCACCCAGCATTCCTTAGATTTCC (SEQ ID 49) 459 
8R-ACCAGACTCATGCCCGCAAG (SEQ ID 50) 
8F-AAATGACGCCATCTCATCACTCC (SEQ ID 51) 1259 
8R-TGTTTTCCTGGCATCTACGAGAAG (SEQ ID 52) 
Starting 
Exon position Exon 
O in length 
Intron cDNA (bp) Acceptor splice site" Donor splice site" 
1 1 232 ACGCCAAgtaagggggc 
(SEQ ID 61) 
2 233 65 tttittaa.cag TCACACC GCAGGAG?gtttgtatgt 
(SEQ ID 53) (SEQ ID 62) 
3 298 58 tgtgttcag/ATTGCC TTGTTGAgtaagtgtct 
(SEQ ID 54) (SEQ ID 63) 
4 356 179 ttittgggcag/CCATATA GGAATAG/gtaggctictt 
(SEQ ID 55) (SEQ ID 64) 
5 535 107 taalaccatag/GGTTCGA AGAATGGigtaag.cgct 
(SEQ ID 56) (SEQ ID 65) 
6 642 90 ctcattgcag/CATAAAG GAATGTGigtaagcgctt 
(SEQ ID 57) (SEQ ID 66) 
7 732 185 tttitttcagg?CCTCTTC CCCATCG/gtgggtttga 
(SEQ ID 58) (SEQ ID 67) 
8 917 265 tatttittaag, ATTTACA GTCCATGigtaagagaac 
(SEQ ID 59) (SEQ ID 68) 
9 1182 1060 ggattitccag?CAACAGG 
(SEQ ID 60) 
"Exonic sequences indicated in upper-case; Intronic sequences indicated in lower-case. 
sequenced, aligned and compared with the clones isolated 
from the placenta library to determine the full-length cDNA. 
Primers for the 5' and 3' ends of WWOX cDNA were used 
as a first step to isolate additional BAC genomic clones. 
After the intron-exon junctions for a specific exon were 
determined, primers for the next exon were designed. The 
whole length cDNA sequence was compared with the 
genomic sequence to determine the genomic structure of 
WWOX. 
Protein Sequence Analysis. The WWOX amino acid 
sequence was analyzed using the BLASTP and PSI-BLAST 
algorithms in search for matches or homologies in the 
GenBank protein databases. The identification of protein 
family domains were determined by using the Pfam domain 
models (PFAM: Multiple alignments and profile HMMs of 
protein domains. Release 4.3. The Pfam Consortium, http:// 
pfam.wustl.edu/). 
Northern Analysis. Northern blots using 2 ug polyA RNA 
from breast cancer cell lines and normal human breast 
epithelium were prepared using standard procedures. The 
multi-tissue Northern blot was purchased from Clontech. A 
1553 bp EcoRI restriction fragment of WWOX clone, span 
ning the 5' end and amino acid coding region, was used as 
probe after labeling with ‘PC-dCTP using random prim 
ing (Prime It II, Stratagene, Calif.). The membranes were 
hybridized in Rapid-hyb buffer (Amersham), followed by 
washing according to the manufacturer's protocol. 
In vitro translation. In vitro translation was performed 
using an in vitro transcription-translation reticulocyte lysate 








General Characterization of the Chromosome 16q Region 
of Interest. The present inventors focused on the 
16q23.3–24.1 chromosome region due to the LOH analyses 
(Chen et al., 1996) and an allelotypic study using a panel of 
27 breast cancer cell lines which revealed a very high 
incidence of hemizygosity within this area affecting 70–80% 
of these cell lines and one primary tumor case with a 
homozygous deletion (Bednarek and Aldaz, 1998). Two 
approaches were used to characterize the chromosomal 
region of interest to isolate the putative tumor suppressor 
gene?s. After building a YAC and BAC contig spanning the 
D16S518-D16S516 region conventional shotgun cloning 
and sequencing and cDNA isolation were performed. Sev 
eral cDNA clones were isolated from the area using a 
solution hybrid cDNA capture method (Futreal et al., 1994). 
A total of 35 cDNAs were isolated and sequenced, of which 
17 matched previously isolated ESTs, and 18 showed no 
matches in any of the GenBank databases. All the isolated 
cDNA clones were mapped back to the corresponding BAC 
DNAs and their sequence compared with the genomic DNA 
sequence in order to identify evidence of exon-intron struc 
ture. Only the cDNA corresponding to the WWOX gene 
showed such features. 
Approximately 400,000 bp of the region covered by the 
overlapping BACs 112B7, 249B4, 286F3 and 36022 was 
sequenced (FIG. 1) including a continuous sequence of 
96371 bp (accession number AF 179633). This genomic 
sequence was also analyzed for matching EST clusters from 
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GenBank databases. Of the numerous ESTs identified and 
analyzed none showed evidence of ORF or exon-intron 
Structure. 
Isolation and Characterization of WWOX. Following 
sequencing the mentioned cDNA two independent full 
length cDNA clones were isolated from a placenta cDNA 
library using specific PCR primers which spanned the tran 
script. These full-length cDNAs showed a consensus 
sequence of 2264 bp long with a predicted ORF of 1245 bp. 
a 125 bp long 5' untranslated region and a 3' untranslated 
region (3'UTR) 870 bp long with a polyadenylation signal 
AATAAA starting at position +2091 (cDNA reported to 
GenBank under accession number AF211943). The putative 
start ATG codon is located within a strong Kozak sequence 
(TCAGCCatgG) which contains a highly conserved G resi 
due (position +4) and purine (G residue at position -3) 
(Kozak, 1996). An in frame stop codon is present -30 bp 
from the predicted translation start site, indicating that the 
whole ORF was cloned. This gene was named WWOX for 
the reasons discussed below. 
WWOX’s exon structure and exon-intron boundaries 
were determined and the chromosomal location of the gene 
was confirmed to the region of interest. To this end various 
combinations of PCR primers were designed based on the 
cDNA sequence and then mapped back to the corresponding 
BACs. Subsequent sequencing of the predicted exons per 
mitted the exon-intron boundaries to be established at the 
genomic DNA level (FIG. 1). 
WWOX is composed of nine exons, ranging in size from 
58 bp to 1060 bp (Table 7). Based on analysis of the 
promoter region (reported to GenBank under accession 
number AF212843) the first exon was localized within a 
CpG island starting at position -660 and extending into the 
first intron at 292 bp from the ATG translation start site. This 
area shows a 63% content of C+G and 8% CpG with the 
highest percentage within the area from -300 bp to ATG 
(68% and 11%, respectively). 
The 3' end of WWOX had high sequence homology to a 
previous GenBank entry of a human putative oxidoreductase 
(U13395, locus ID 9621). Furthermore, the physical map of 
WWOX spanned the whole region of interest. Exon1 
mapped WWOX to the BAC containing D16S518 and 
exon9 and the 3' UTR to the BAC containing D16S516 
(FIG. 1). WWOX spans a large genomic region of approxi 
mately 1 Mb in size. Although the exact lengths of the 
intronic portions of this gene were not determined this 
estimate was based on the known size of the YAC clones, the 
average size of BAC clones (~150 kb) and the shotgun 
sequencing (described above) wherein the approximately 
400,000 bp corresponded to WWOX’s intron 8 area (FIG. 
1). Interestingly, analysis of sequence contigs from this large 
intronic region allowed identification of two previously 
described translocation breakpoints mapping to this same 
area. These translocation breakpoints, MM. 1 and JJN3 have 
been described in multiple myeloma involving chromo 
somes 14 and 16, i.e. t14:16)(q32;q23), (Chesi et al., 1998). 
Further sequence analysis of this area also identified the 
existence of a pseudogene for Ribosomal Protein S3 match 
ing to sequence within this intronic region (AF179633). This 
is the first report of a gene in this chromosomal area (i.e. 
D165518-D165516). 
WWOX protein structure. The 1245 bp WWOX ORF 
encodes for a 414 amino acid protein (FIG. 2). The BLAST 
and PSI-BLAST algorithms were used to search for matches 
in GenBank databases. Interestingly, the N terminus of the 
putative WWOX protein showed homology to ubiquitin 














other WW-domain containing proteins. Further amino acid 
sequence analysis using the PROSITE database identified 
two regions within the putative WWOX protein (amino 
acids 18–47 and 59–88) which have high homology to 
WW-domain sequences. The first motif exhibits typical 
features of a WW domain, is 26 bp long with the two highly 
conserved tryptophan, and one proline, residues. In the 
second WW domain one tryptophan is replaced by a tyrosine 
residue, this is an alternative functional replacement which 
is also found in other WW domain proteins (FIG. 2). 
The amino acid sequence also revealed homology to 
numerous proteins known as members of the short chain 
dehydrogenase/reductase family (SDR). The SDR family 
encompasses a wide variety of enzymes which act on 
diverse hydroxy/keto substrates. The most conserved fea 
tures of SDR proteins are two domains constituting the 
cofactor, GXXXGXG, and substrate, YXXXK, binding sites 
(Jornwall et al., 1995). Further WWOX amino acid sequence 
analysis identified both the coenzyme, NAD(H) or NADP 
(H), binding site GANSGIG at position 131-137, and the 
potential substrate binding site, YNRSK, at positions 
293–297 (FIG. 2). 
Due to the presence of the WW domains and the homol 
ogy to SDR this novel protein was named WWOX. Analysis 
using the PSORT algorithm predicts that WWOX has no N 
terminal signal peptide and its localization is probably in the 
cytoplasm (Nakai and Kanehisa, 1992). 
WWOX expression analysis. Northern blot analysis with 
a probe derived from 5' end of WWOX revealed a 2.2 kb 
mRNA which is in agreement with the length of the cDNA 
clone i.e. 2264 bp. 
Analysis of the WWOX expression pattern in normal 
human tissues showed that expression was highest in testis, 
prostate and ovary, and significantly lower in the other 
examined tissues including bulk breast tissues which 
showed very low levels of expression. 
Analysis of the expression of WWOX in normal mam 
mary epithelial cells in culture and in breast cancer cell lines 
was also performed. All the breast cancer lines analyzed 
showed higher WWOX expression than normal breast tissue 
and normal mammary epithelial cells (HME-87). However, 
amongst the breast cancer lines analyzed, WWOX expres 
sion levels varied from relatively low in T47D and MDA 
MB435 to high overexpression in ZR75-1 and MCF-7 cells. 
Of these cell lines, previous extensive allelotypic analysis 
using highly polymorphic STS markers allowed the deter 
mination that T47D, ZR-75, MDA-MB435, MDA-MB453, 
SKBR3 and UACC812 were amongst the group of breast 
cancer lines with no evidence of STS heterozygosity along 
most or all of 16q (13). This indicated the high likelihood 
that they had lost all or a large portion of one of the original 
parental 16q arms including the region spanned by WWOX. 
However the putative hemizygous status of WWOX did not 
impede expression. No correlation was found between the 
estrogen receptor status of the breast cancer lines and the 
levels of WWOX expression. 
To examine whether the translation of the ORF of 
WWOX produced the predicted protein, an in vitro tran 
scription/translation system was used. SDS PAGE analysis 
of the translated product revealed a single protein product of 
approximately 46 kDa. This agrees with the predicted 
molecular weight of WWOX based on its amino acid 
sequence (i.e. 46676.8 Da). 
Mutation screening in breast cancer cell lines. As men 
tioned above, WWOX spans the whole chromosomal area of 
interest between STS markers D16S518 and D16S516. The 
high incidence of LOH affecting this region suggested the 
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presence of a putative tumor Suppressor gene within this 
area. Thus, in order to investigate whether WWOX is a 
target for mutations in breast cancer, we performed a muta 
tion screening on a panel of 27 breast cancer cell lines. 
This panel of breast cancer cell lines were of particular 
interest because the inventors had previously observed a 
high incidence of hemizygosity within the chromosome 16q 
area of interest (Bednarek and Aldaz, 1998), i.e., cell lines 
in which the majority had already lost one WWOX allele via 
chromosomal rearrangements. Only one breast cancer case 
displayed a homozygous deletion in this region (Bednarek 
and Aldaz, 1998). This deletion spanned part of WWOX’s 
intron 8 region from STS 249B4S to D16S3029 inclusive 
(see FIG. 1). 
Each of the WWOX exons was amplified from each of the 
27 breast cancer lines genomic DNA and the products were 
sequenced. The intronic primers used for amplification and 
sequencing are detailed in Table 7. 
No evidence for point mutations was seen. Two substitu 
tions were found which may be polymorphic rather than a 
mutational. The first, a C/T found at position-5 in the Kozak 
sequence, was observed in 50% of the tumor samples but it 
was also observed that DNA isolated from normal mammary 
gland was polymorphic at this position. The second Substi 
tution, a G/A at position +534, results in an amino acid 
change, alanine/threonine, but because of the approximate 
frequency of 50% for either allele in the samples examined 
and because heterozygosity at this position was also found 
in normal DNA, it may also represents a polymorphism. 
Abnormally spliced WWOX transcripts in tumor cell 
lines. Expression analysis was also performed on a panel of 
multiple myeloma cell lines using Northern blot analysis. 
Multiple myeloma cell lines were of particular interest 
because various myeloma specific chromosomal transloca 
tions breakpoints were identified within the genomic region 
spanned by WWOX. A subset of the cell lines used were 
known to carry a chromosomal translocation involving 
chromosomes 14 and 16, tC 14:16). Northern blot analysis 
identified variable levels of expression among these various 
myeloma cell lines. Two of the myeloma cultures showed 
strong hybridization of the WWOX probe to lower size 
transcripts to that expected for the wild type WWOX 
mRNA. These two cell lines were among those known to 
carry the t014:16) translocation. RT-PCR analysis and 
sequencing of the transcript detected in the KMS 11 cell line 
showed that the shorter transcript represents an abnormally 
spliced version of WWOX in which exons 5 through 8 are 
deleted (WWOX A5–8). The second myeloma cell line, 
JJN3, showed a strong alternative band on the Northern blot. 
This Small transcript comprised exons 1-3. 
As described above Northern hybridization demonstrated 
overexpression of WWOX in several breast cancer cell lines 
when compared to normal breast mRNA. The highest 
expression level was found in cell lines ZR75-1 and MCF-7. 
Interestingly, the MCF-7 cell line also showed a lower size 
transcript in the Northern analysis. An expression analysis 
was performed by RT-PCR on numerous cell lines derived 
from different types of cancer with numerous normal tissue 
samples as controls. This analysis identified the existence of 
several alternatively spliced forms of the WWOX transcript 
which were only observed in the tumor cells and not in the 
normal cells. Sequencing analysis confirmed that these were 
abnormally spliced transcripts of WWOX. For example, in 
cell lines MCF-7 and MDA-MB 453 which are breast cancer 
cell lines; HCT116 a colon adenocarcinoma cell line; and 
AGS a gastric adenocarcinoma cell line have deleted exons 













Scripts detected in other lines appear not to encode func 
tional forms since a translation initiation site was not 
detected in Such transcripts. 
Identification of WWOX binding partners and studies on 
cell localization. Identification of putative binding proteins 
for WWOX were performed by Far-Western blot studies 
employing GST-Fusion constructs of the WW domains of 
WWOX proteins. The present inventors have detected a 
preference of WWOX for binding PPPY motif. In studies 
using protein membrane arrays, a series of potential binding 
partners for WWOX were identified. These include the 
proline rich ligand containing oligopeptides such as, Ld 10 
(PPLP), P3 (PPR), CDC25 (PLT*P) and WBP1 (PPPY). The 
inventors contemplate further experiments to identify 
WWOX binding target proteins. 
The cellular localization of WWOX proteins have been 
studies. A WWOX-GFP fusion protein was generated and 
transfected into normal breast cells. Perinuclear aggregates 
of WWOX were seen inside specific organelles. Double 
labeled studies indicate that WWOX proteins localize to the 
Golgi apparatus and not to the mitochondria. 
Discussion 
The inventors outlined the physical map of a 16q chro 
mosomal region commonly affected by abnormalities in 
breast and other cancers. The area spans from STS marker 
D16S518 to D16S516 in the 16q23.3–24.1 region. A novel 
gene mapping to this area, with unique characteristics was 
cloned. This gene, WWOX, contains two WW-domains on 
the N terminus of the protein and a SDR central domain. By 
analogy to other WW domain containing proteins, the WW 
motifs should play a role in protein protein interactions. 
The SDR domain can bind low molecular weight ligands 
and cofactors and the corresponding putative binding motifs 
have also been identified in WWOX. 
The protein motif called WW or WWP was identified in 
very different types of proteins including peptidyl-prolyl 
isomerases involved in mitosis regulation (Lu et al., 1996; 
Maleszka et al., 1996), the cytoskeletal protein, dystrophin 
(Bork and Sudol, 1994), spliceosome-associated proteins 
(Bedford et al., 1998), the ubiquitin-protein ligase NEDD4 
(Staub et al., 1996), signal transducing protein YAP65 (Chen 
and Sudol, 1995). This domain is characterized by the 
presence of very conserved proline and tryptophan residues 
(Bork and Sudol, 1994; Andre and Springael, 1994; Hof 
mann and Bucher, 1995). WW domains are known to 
interact with the proline rich motifs of other proteins. So far, 
four different WW binding proline rich motifs have been 
identified; PPXY (23), PPLP (Chan et 1996), PGM/PPR 
(Bedford et al., 1998) and phosphoserine/phosphothreonine 
(Lu et al., 1999). 
Short chain dehydrogenases/reductases represent a wide 
spectrum of enzymes. The protein domain database (PROS 
ITE) identifies more than 60 different proteins from bacteria, 
fungi, plants and animals, which belong to this family. These 
are typically enzymes which metabolize different alcohols, 
Sugars, keto-acyls, retinoids, Steroids and other hydroxy/ 
keto Substrates. One important group among the SDR pro 
teins is the family of hydroxysteroid dehydrogenases. The 
average size of SDR enzymes is 250–300 amino acids. 
Even-though overall similarity between the different SDRs 
can be as low as 15–30%, a small conserved substrate 
binding motif, YXXXK, and a coenzyme binding motif, 
GXXXGXG, are characteristic for these proteins (Jornwall et 
al., 1995). Although the 414 amino acids of WWOX make 
it larger than the average SDR enzyme, the WWOX dehy 
drogenase domain exhibits the typical sequence features and 
distances between conserved motifs that are characteristic of 
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SDR enzymes (Duax and Ghosh, 1997). WWOX is, as yet, 
the only protein described which contains both binding 
motifs for low molecular weight ligands/substrates and 
WW-domains. 
WWOX has one additional putative signature, which is a 
serine residue 12 amino acids upstream of the YNRSK 
Substrate binding motif. This serine is at a nearly identical 
location to that observed in steroid dehydrogenases (usually 
position -13 from Y) which is Suggested to play an impor 
82 
Several translocations and deletions affecting ch16q23 
have been described as primary cytogenetic anomalies in 
several breast cancers (Dutrillaux et al., 1990; Pandis et al., 
1992). The inventors found one breast cancer case with a 
homozygous deletion also mapping within the same intron 8 
region in which the translocation breakpoints were mapped. 
Interestingly, the locus for the yet uncharacterized common 
fragile site FRA16D has been cytogenetically mapped to this 
very same chromosome region 16q23.2–23.3. 
tant role in the catalysis of steroid Substrates (Duax and 10 All these evidence Suggest that the whole genomic region 
Ghosh, 1997). spanned by WWOX and in particular the intron 8 region 
Hydroxysteroid dehydrogenases/reductases usually show appear to be an area prone to chromosomal fragility. This 
a wide tissue expression profile. Although some enzymes of indicates that this area could be the same as the mentioned 
this family are tissue specific. Northern analysis has shown common fragile site FRA16D, since it displays features of 
that WWOX transcripts are highly represented in hormon- 15 genomic fragility similar to those observed in other better 
ally active tissues with testis showing the highest expres- characterized common fragile site loci (e.g. FRA3B) (Suth 
sion. This tissue specificity in addition to the SDR domain erland et al., 1998; Smith et al., 1998). 
features, indicates that WWOX’s substrate for dehydroge 
nase/reductase activity is probably a steroid. As WWOX has EXAMPLE 2 
the ability to interact with other proteins via the WW 20 
domains, this protein can participate in steroid-receptor Identification of Abnormal Transcripts 
interaction regulation. Based on amino-acid sequence analy 
sis WWOX localizes to the cytoplasm of cells (Nakai and Abnormal WWOX transcripts, such as the alternatively or 
Kanehisa, 1992). abnormally spliced versions of WWOX, are identified using 
WWOX is overexpressed in breast cancer cells when 25 cDNA samples synthesized from RNA isolated from tumor 
compared with normal tissues. The cell line with the highest samples by means of RT-PCR and employing deletion 
WWOX mRNA expression is the MCF7 line, which is specific primers. 
characterized by its high dependence on estradiol for In one embodiment, a common 5' primer 5'-AGGCAGT 
growth. This indicates that WWOX plays a role in estradiol/ GCGCAGGCGTGAGC-3' (SEQ ID NO:14) was used in 
ER interaction regulation. 30 conjunction with 3' specific primers spanning the new 
As WWOX spans a chromosomal area characterized by a exon-exon junctions found only in these alternatively 
very high incidence of allelic loss and chromosomal rear- spliced forms expressed in tumors: 
rangements. Furthermore, two previously described chro- The 3' specific primers used were: 
A8 (5'-ACGGTGGTGGCAGCTCCCTGTTGCGATGG-3'); (SEQ ID NO: 4) 
A7-8 (5'-ACGGTGGTGGCAGCTCCCTGTTGACATTCTTGG-3"); (SEQ ID NO:5) 
A6-8 (5'-ACGGTGGTGGCAGCTCCCTGTTGCCATTCTTC-3"); (SEQ ID NO : 6) 
A5-8 (5'-ACGGTGGTGGCAGCTCCCTGTTGCTATTCC-3') (SEQ ID NO: 7) 
A 4-8 (5'-TGGTGGCAGCTCCCTGTTGTCAACAAAAAACAC-3') (SEQ ID NO: 8) 
A3-8 (5'-ACGGTGGTGGCAGCTCCCTGTTGCTCC-3') (SEQ ID NO: 9) 
A2-8 (5'-ACGGTGGTGGCAGCTCCCTGTTGTTG-3') (SEQ ID NO:3) 
mosomal breakpoints, MM. 1 and JJN3, were mapped to the Using these methods the inventors have identified trun 
last intron of WWOX (FIG. 1). These specific 16c translo- cated WWOX transcript in cell lines derived from multiple 
cation breakpoints, t(14:16)(q32:q23) were previously 50 myeloma Subtypes, breast cancers, colonic adenocarcinomas 
described in multiple myeloma (Chesi et al., 1998). Conse- and gastric adenocarcinomas. 
quently at least one of the alleles of WWOX is truncated in EXAMPLE 3 
some multiple myeloma lines. Hence, WWOX inactivation 
plays a role in multiple myeloma. In myeloma studies it was ss Fluorescent In Situ Hybridization 
also observed that other additional translocation breakpoints 
such as KMS11 and ANBL6, also map to the same region Metaphase or Interphase cells from normal or tumor 
covered by YACS 933h2 and 972d3 and hence in very close samples Were analyzed with probes spanning the WWOX, 
vicinity of WWOX. Nevertheless, the putative oncogenic fragile site 16 D (FRA16D) genomic region. Induction of 
target for transcriptional dysregulation in the myeloma 60 chromosomal fragility in normal cells such as, peripheral 
translocations was proposed to be c-maf oncogene which is lymphocytes, is achieved by treatment with Aphidicolin (0.4 
located telomeric of WWOX and in the opposite 5'-3'orien- mM) dissolved in DMSO during the last 26 hrs. of culture. 
tation. Hence, the present inventors investigated whether the Spontaneous WWOX FRA16D genomic region breakage in 
c-maf oncogene showed any expression alterations in the tumor cells from diverse origin can also be analyzed. 
breast cancer lines. No abnormalities of c-maf expression 65 Metaphase spreads from normal or tumor cells are pre 
was seen when comparing breast cancer lines with normal 
breast cells and tissues. 
pared after 1 hr. incubation in culture media Colcemid (50 
mg/ml). This is followed by standard KCL hypotonic incu 
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bation and acid-methanol fixation. Samples from the cells 
are then spread onto clean glass slides. YAC or BAC probes 
spanning or flanking the WWOX (FRA16D) genomic region 
are labeled with digoxigenin or biotin or a fluorescent dye 
such as FITC or Texas Red and use for in situ hybridization 
on the cell spreads. Prior to hybridization DNA from the 
samples is denatured using high temperature and Forma 
mide. Hybridization of the labeled probe to the samples is 
conducted at 37° C. overnight following standard in situ 
hybridization procedures. Detection of the signal is per 
formed by multiple procedures depending on the original 
method of labeling the probe. Analysis and digital imaging 
is performed utilizing a CCD cooled camera mounted in a 
conventional fluorescent microscope. 
The signal is detected as two distinctive spots in normal 
interphase cells with no breakage, and is detected as addi 
tional spots when breakage on the region of interest has 
occurred. The frequency of cells with WWOX breakage is 
determined. Individuals at higher risk of cancer will show a 
higher frequency of WWOX FRA16D breakage when cells 
are exposed to Aphidicolin. The same method can be used to 
asses the frequency of spontaneous breakage in individuals 
at risk of cancer, i.e. in untreated normal cells. 
In an alternative method, closely flanking WWOX 
FRA16D probes can be labeled with two different labels 
(e.g. red and green) in interphase cells. When no breakage 
both colors will overlap and be detected as yellow. When 
breakage occurs both colors will be distinctive. These meth 
ods can be used for the analysis of normal and tumor cells. 
EXAMPLE 4 
Suppression of Tumor Growth by WWOX in In 
Vitro and In Vivo Systems 
This example is concerned with evidence demonstrating 
the function of WWOX as a suppressor of tumor growth in 
vivo in a mouse model of tumor. Furthermore, in vitro 
experiments demonstrate that ectopically expressed WWOX 
Supresses tumor cell growth in breast cancer cell lines. Also 
reported herein is the detection of aberrantly spliced 
WWOX mRNA forms with deletion of exons 5-8 or 6–8 in 
cancer cell lines and in primary breast tumors. These aber 
rant mRNA forms were not detected in normal tissues. The 
present inventors have also demonstrated that proteins trans 
lated from such abnormal transcripts have a different cellular 
localization than wild-type WWOX protein. 
Materials and Methods 
Cell Lines, Normal and Tumor Tissues. Cell lines used in 
these experiments were derived from the inventor's collec 
tion or were obtained from ATCC. Normal and breast tumor 
samples were obtained from the Cooperative Human Tissue 
Network. 
Nucleic Acids. RNA was isolated using Trizol reagent 
(Gibco BRL) according to the manufacturer protocol. Iso 
lated RNAs were treated with DNAse I (Promega) prior to 
cDNA synthesis, which was performed using Superscript II 
Reverse Transcriptase (Gibco BRL) according to the manu 
facturer protocol. For the methylation study, MDA-MB-435 
cells were treated in culture with 5-aza-2'-deoxycytidine (3.5 
ug/ml) for 48 hours. 
Real-time and Nested RT-PCR. Real-time RT-PCRs were 
performed with primers for the wild type WWOX transcript 
designed to span intron 8. The primers used were: forward 
primer 5'TCGCAGCTGGTGGGTGTAC3' (SEQ ID 
NO:10) located on exon 8 and reverse primer 5'AGCTC 













Real-time RT-PCR was performed on a Perkin-Elmer Bio 
systems Gene Amp 7700 Sequence Detection System. All 
reaction components were purchased from PE Biosystems. 
Detection of double-stranded PCR products was performed 
with SYBR Green I. All reactions were performed in trip 
licate. Relative levels of expression were normalized using 
as internal reference control the P2-microglobulin gene 
(5"TGAGTGCTGTCTCCATGTTTGA3' (SEQ ID NO:12) 
and 5'TCTGCTCCCCACCTCTAAGTTG3') (SEQ ID 
NO:13) (Mitas et al., 2001). Nested RT-PCR to determine 
the existence of aberrant transcripts of WWOX was per 
formed using primers spanning the whole ORF: forward 
5'AGGCAGTGCGCAGGCGTGAGC3' (SEQ ID NO:14): 
reverse 5"CAGCCCTGGCACTTGCGTGAGG3' (SEQ ID 
NO:15) and nested primer set; forward 5'AGCAGGCGT 
GAGCGGTCGG3' (SEQ ID NO:34); reverse 5"TGCGT 
GAGGGGACACACACAGG3' (SEQ ID NO:16). RT-PCR 
screening for aberrantly spliced WWOXA6–8 mRNA was 
performed using primers: forward 5'GAGTTCCTGAGC 
GAGTGGACCCG3' (SEQ ID NO:17) and reverse primer 
5ACGGTGGTGGCAGCTCCCTGTTGCCATTCTTC3" 
(SEQ ID NO:6) which is positioned on a novel exon exon 
junction between exons 5 and 9 and does not amplify the 
wild-type transcript. These RT-PCR reactions were per 
formed using Expand High Fidelity PCR System (Roche). 
Bisulfite DNA Sequencing. Cell lines DNA was isolated 
using standard methods and bisulfite sequencing was per 
formed as previously described (Clark et al., 1994). Primers 
for amplification of modified DNA for the sense strand; 
5'TAGTTTTTATTATTATTAGTTTTTATTATT3' (SEQ ID 
NO:18) and 5'AATACTACATCCTAAACAACAA3' (SEQ 
ID NO:19) and for nested PCR; 5'AGTTTTTATTATTAT 
GAGTTTTTATTAAAT3' (SEQ ID NO:20) and 5'CCRCR 
CAATACTACATCCTA3' (SEQ ID NO:21). For the anti 
sense strand PCR; 5'GGGATGAGGTYGTTTTGTTT3' 
(SEQ ID NO:22) and 5'TCATAAATCTCTATTAAACAA 
CAA3' (SEQID NO:23) and nested PCR set: 5'GYGTAGT 
GTTGTATTTTGAAT3' (SEQ ID NO. 24) and 5'TCA 
CAATCTCTATTATATATTTTAACTA3' (SEQ ID NO: 25). 
For sequencing nested primers 5'TCCTCCCCRCR 
CAAATAAC3' (SEQ ID NO: 26) and 5'TTATTATTAT 
GAGTTTTTATTAAATAATAG3' (SEQ ID NO:27) for the 
sense Strand and 5'ACCTAAACTACATTTCCCATATCC3' 
(SEQ ID NO:28) and 5'TAGTGTTGTATTTTGAATAG 
TAG3' (SEQID NO:29) for the anti-sense strand were used. 
Vector Construction and Stable Transfection. WWOX 
wild-type cDNA was cloned into the pHOOK3 vector (Invit 
rogen) or the plNCX2 retroviral vector (Clontech). Trans 
fections were performed using a standard calcium phosphate 
precipitation method with 10 ug DNA of vector or WWOX 
cDNA clone. 
For retroviral transduction, WWOX cloned into pILNCX2 
vector was transfected into the PT67 packaging cell line 
(Clontech). Positive transfectants were selected for one 
week with G418 (200 ug/ml). Viruses were produced 
according to the manufacturer protocol. Target cells were 
grown to 30% confluence and infected with viruses (approx. 
10° cfU/ml) mixed with cell specific culture medium with 
polybren as vehicle (8 g/ml). After 24 hrs medium was 
replaced and stable transfectants were selected with 200 
ug/ml of G418 for two weeks. 
Soft agar growth assay. The assay was performed using 
5x10 of MDA-MB-435 cells in 2 ml medium (DMEM+10% 
FBS) supplemented with 0.34% agarose (FMC) and layered 
on 3 ml base of 0.9% agarose with medium. For T47D cells 
5x10" cells and medium containing DMEM+10% FBS+10 
ug/ml insulin was used. Experiments were performed in 
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triplicate in 35 mm 6 well plates. After 4 weeks of growth 
cells were stained by incubation with nitro blue tetrazolium, 
cultures were photographed and colonies with diameter 
larger than 200 um were counted and measured using the 
NIH Image analysis software. 
In vivo tumorigenicity assay. Female BALB/c athymic 
nude mice (NCI) were used. Eight weekold animals (five for 
each construct) were injected bilaterally into the thoracic 
mammary fat pad area with 1x10° cells (per side) MDA 
MB-435/vector or MDA-MB-435/WWOX. Tumor growth 
was monitored for a period of 7 weeks. Tumor diameter was 
determined by caliper measurements once per week and 
tumor Volume was calculated using the formula: "If 6xlarger 
diameterx(smaller diameter). At the end of the experiment 
tumors were dissected and the individual tumor wet weight 
was determined. 
GFP-WWOX fusion and cellular localization. GFP 
WWOX N-terminal fusion proteins were constructed using 
pEGFP-N Vector Systems (Clontech). MCF-10F cells 
(1x10) were electroporated in 400 ul complete medium 
with 20 g of the GFP-WWOX construct DNA. Cells were 
plated into 4-well cover-slip chambers and incubated for 24 
hrs prior to confocal microscopy analysis. Golgi system was 
visualized with the anti-Golgi 58 K monoclonal mouse 
anti-human antibody (Sigma) and Cy5 labeled anti-mouse 
IgG donkey secondary antibody (Jackson ImmunoResearch 
Lab.). Brefeldin A (BFA) (Sigma) treatment was performed 
72 hrs post-electroporation (5 ug/ml) for 45 min. followed 
by 35 min. recovery in BFA free media. Mitochondria were 
visualized using MitoTracker RedCMXRos (Molecular 
Probes). 
Results 
Analysis of WWOX expression in cancer cell lines and 
breast tumors. Northern blot analysis demonstrated that 
breast cancer cell lines express highly variable levels of 
WWOX mRNA with some of these cell lines expressing 
very low to undetectable levels of expression (Bednarek et 
al., 2000). In order to perform a comparative analysis of 
levels of expression of WWOX, a quantitative analysis using 
a real-time RT-PCR was performed. The results on the 
relative expression of WWOX are summarized in FIG. 4. 
Some breast cancer cell lines showed very low or almost 
undetectable levels of WWOX expression as determined by 
this highly sensitive assay, for example, MDA-MB-435, 
MDA-MB-231, BT-549 and T47D. 
Interestingly, several of these breast cancer cell lines, that 
have very low to undetectable WWOX levels, are known to 
be highly tumorigenic as determined by their ability to form 
tumors in nude mice (Price et al., 1990; Xie et al., 2001). In 
contrast, cell lines such as MCF7 and BT-20, which showed 
higher levels of WWOX expression, have a much lower 
tumorigenic potential (Xie et al., 2001). 
Promoter methylation study. Very often silencing of 
expression of a tumor Suppressor gene is the result of 
methylation of cytosine residues in CpG pairs within the 
gene's promoter region. As WWOX is variably expressed in 
breast cancer cells, bisulfite genomic sequencing of the 
WWOX promoter region was performed in several breast 
cancer cell lines. This analysis was performed on cells which 
showed the lowest levels of WWOX mRNA, including, 
BT549, MDA-MB-231, and MDA-MB-435 as well as on 
cells with high level of WWOX transcription such as, 
MCF-7 and SKBr-3. 
A CpG rich area Surrounding the translation start codon 
(from -630 to +280) including a putative TATA box (-301 
to -292) was sequenced. No CpG methylation was seen in 














5-azacytidine, an inhibitor of CpG methylation, also did not 
significantly increase the level of WWOX expression (FIG. 
4). 
Phenotype Analysis of WWOX Transfectants 
In vitro studies. It has been previously demonstrated that 
restoring or increasing the expression of a tumor suppressor 
gene in cancer cell lines negatively affects anchorage inde 
pendent growth and/or tumorigenic potential. To determine 
if increased WWOX expression changes the phenotype of 
cancer cell lines expressing low levels of WWOX mRNA, 
recombinant retroviruses carrying the cloned WWOX cDNA 
were used to transduce the breast cancer cell lines MDA 
MB-435 and T47D. Expression of the ectopic WWOX 
cDNA in transduced cells was confirmed using real-time 
RT-PCR. WWOX vs. empty vector breast cancer lines 
transfectants were compared for their ability to grow in 
monolayer culture and no detectable differences were seen. 
However, dramatic differences were observed, when the 
growth of the cells were compared in Soft agar. Increased 
WWOX expression, as a result of ectopic expression, 
strongly inhibits soft agar growth of MDA-MB-435 cells. 
The average number of colonies formed by MDA-MB-435/ 
vector cells was 236-33 while MDA-MB-435/WWOX cells 
formed only 17+3 colonies (P=0.006). Similarly, T47D cells 
transfected with WWOX showed a dramatic decrease in 
their ability to grow in Soft agar, 14+2 colonies compared to 
243+64 colonies formed by T47D/vector cells (P=0.02) 
(FIG. 5A). In summary, breast cancer cells that ectopically 
express WWOX formed fewer and much smaller colonies 
than control cells transfected with vector alone. 
In vivo studies. The ability to supress the formation of 
tumors was also analyzed by in vivo studies. Intramammary 
fat pad injections were performed in nude mice with the 
MDA-MB-435/WWOX and MDA-MB-435/vector cells to 
compare their tumorigenicity. Tumor growth was monitored 
for 7 weeks and tumor size was measured once per week as 
described above. Tumors generated by the MDA-MB-435/ 
vector cells were palpable already by seven days post 
injection, growing in size rapidly from that point on. On the 
other hand, for the MDA-MB-435/WWOX injected ani 
mals, the first very small tumors were detected by 25 days 
post-injection, but only in some of the mice. FIG. 5B 
illustrates dramatic difference in kinetics of tumor growth as 
determined by caliper size measurements between both 
groups of animals. At termination of the experiment MDA 
MB-435/vector cells formed tumors displaying an average 
weight of 821+295 mg and tumors forming at all the 
injection sites (10 out of 10 sites), whereas MDA-MB-435/ 
WWOX cells formed much smaller tumors with an average 
wet weight of 51+22 mg, with tumors forming at 7 out of 10 
sites (FIG.5C). Such a remarkable difference in the tumor 
growth rate and size (P=0.00001) demonstrates the strong 
tumor growth suppressing ability of WWOX. 
Analysis of aberrantly spliced WWOX mRNAs. Northern 
blot analyses from breast, ovarian cancer and multiple 
myeloma cell lines showed the presence of transcripts of 
Smaller size in Some of the cancer cell lines analyzed, which 
represent abnormal WWOX mRNAs. In order to further 
characterize other aberrant transcripts, a full length mRNA 
nested RT-PCR approach was used. Several cancer cell lines 
showed Smaller size amplification products, in addition to 
the normal PCR product (1422 bp), confirming the northern 
analysis observations. All such RT-PCR products were iso 
lated and sequenced. Sequencing of the shorter transcripts 
further confirmed that these are abnormally spliced versions 
of WWOX. Transcripts displaying deletions of exons 6–8 
(WWOXA6–8) were detected in MDA-MB-453, MCF-7, 
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HCT116 (colonadenocarcinoma) and AGS (gastric adeno 
carcinoma) cancer cell lines. A transcript bearing a deletion 
of exons 5-8 as the highly and only expressed transcript was 
obtained from KMS 11, a multiple myeloma cell line. This 
deletion found in KMS11 also results in a frame shift. The 5 
first 136 out of the 311 amino acids in the new protein are 
conserved but the following 175 are different than in the 
wildtype protein. The cDNA sequence of such aberrant 
transcripts has been reported to GenBank under accession 
numbers AF395123 and AF395124 respectively. Other aber 
rant transcripts, displaying no wild-type translation start 
codon, were found in breast cancer cell lines MDA-MB-157 
and MDA-MB-435. In contrast, RT-PCR analysis of several 
normal breast tissues showed only the wild-type length of 
WWOX mRNA. Due to the finding of WWOXA6–8 aber- 15 
rant transcripts in breast cancer lines, specific primers were 
designed to detect this form. To provide specificity the 
3'RT-PCR primer was designed to span the abnormal exons 
5–9 junction. Using this primer set, cDNAs obtained from a 
panel of 53 fresh breast cancer samples, were screened to 
detect the abnormal WWOXA6–8 product. The 
WWOXA6–8 aberrant transcript was detected in 17 of the 
53 specimens, which represents 32% of the examined 
tumors. In contrast, the WWOXA6–8 transcripts was not 
detected in any from 18 normal breast adjacent tissue 
samples tested. 
Normal and Abnormal WWOX Cellular Localization. To 
determine the normal cellular localization of WWOX and to 
compare this with the localization of proteins resulting from 
the aberrant transcripts detected in cancer cells, WWOX 
proteins fused to the green fluorescence protein (GFP) was 
used. Confocal microscopy analysis of normal breast MCF 
10F cells transiently transfected with GFP-WWOX showed 
that WWOX is cytoplasmic protein localized in distinct 
perinuclear particles. Dual color detection of GFP-WWOX 
and a mitochondria specific staining showed no co-localiza 
tion indicating that WWOX does not localize in the mito 
chondria. The ability of GFP-WWOX to localize to the 
Golgi complex was demonstrated by its co-localization with 
an Golgi specific antibody, the anti-Golgi 58K. This specific 
antibody binds a Golgi protein epitope located on the Golgi 
membrane. In order to confirm this finding, GFP-WWOX 
transfected cells were exposed to Brefeldin A (BFA). BFA is 
known to cause disassembly of the Golgi complex and 
redistribution of its contents to the cytoplasm. After BFA 
treatment, GFP-WWOX was diffusely distributed in the 
cytoplasm confirming the Golgi localization. After removing 
BFA from the culture media and allowing a short time for 
recovery GFP-WWOX again localized within the recovered 
Golgi apparatus. In contrast to the wild-type WWOX protein 
localization within the Golgi complex, GFP-WWOXA6–8 
as well the GFP-WWOXA5–8 forms localize to the cell 
nucleus. These WWOX abnormal proteins display a specific 
pattern in the nucleus, which may be associated with distinct 
nuclear particles and/or putative transcription sites. 
Discussion 
Provided here is evidence demonstrating that WWOX is 
a tumor Suppressor gene when ectopically expressed in 
breast cancer cells with low or undetectable levels of endog 
enous expression. WWOX expression induces strong Sup 
pression of anchorage independent growth of breast cancer 
cell lines T47D and MDA-MB-435. More importantly, 
tumorigenicity of the MDA-MB-435 breast cancer line was 
dramatically reduced by ectopically expressing WWOX. 
In several cancer cell lines and in more than 30% of 65 
primary breast tumors expression of aberrant mRNA tran 











major portions of the enzymatic WWOX domain, for 
example, WWOXA5–8 and WWOXA6–8 were seen. Fur 
thermore, such aberrant transcripts were not detected in any 
normal tested breast tissues obtained either from normal 
mammoplasty specimens or normal samples adjacent to 
tumors. The aberrant proteins resulting from the 
WWOXA5–8 and WWOXA6–8 transcripts were found to 
localize in the cell nucleus in contrast to the normal Golgi 
complex localization of the wild type protein. The resultant 
disruption in the catalytic function of the oxidoreductase 
domain consequential to the deletion of exons 5 or 6 through 
8 in addition to the shift in normal cellular localization is 
believed to dramatically alter the function of WWOX in a 
cancer cell. It is envisioned that different protein partners 
could bind to the WW domains of WWOX in the nucleus 
than in its normal cytoplasmic localization. It is also con 
templated that the WWOXA6–8 and WWOXA5–8 proteins 
may behave in a dominant negative fashion competing with 
wild type WWOX for its normal partners and eventually 
transporting them to the cell nucleus. 
All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the compositions and methods and in the steps or 
in the sequence of steps of the method described herein 
without departing from the concept, spirit and scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be substituted for the agents described herein 
while the same or similar results would be achieved. All 
Such similar Substitutes and modifications apparent to those 
skilled in the art are deemed to be within the spirit, scope and 
concept of the invention as defined by the appended claims. 
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Pro Gly. T 
2O 
rp Glu Glu 
Asn His Thr Glu Glu 
40 
Arg Lys Arg Val Ala 
55 
Asp Glu Asn Gly Glin 
Thr Tyr L 
85 
70 
eu Asp Pro 
Lys Pro Thr Thr Arg 
100 
Ile Leu G 
Ala Asn. S 
Gly Ala H 
1 
Ala Wal S 
1.65 
Met Thr L 
18O 
ln Gly Arg 
120 
er Gly Ile 
135 
is Wal Ile 
50 
er Arg Ile 
eu Asp Lieu 
Ala Phe Lys Ala Lys 
200 
Ala Thr Phe Ala Leu 
Thr Phe G 
2 
Glin Asp V 
245 
Ser Glu S 
260 
Asp Phe S 
215 
lin Wall Asn 
30 
all Lieu. Cys 
er His Arg 
er Arg Lieu 
280 









Lieu. Asp Asp 
10 
Arg Thr Thr 
25 
Lys Thr Glin 
Gly Asp Lieu 
Wall Phe Phe 
75 
Arg Lieu Ala 
90 
Glin Arg Tyr 
105 
Asp Phe Thr 
Gly Phe Glu 
Leu Ala Cys 
155 
Leu Glu Glu 
170 
Ala Leu Lieu 
185 
Asn Wall Pro 
Pro Trp Ser 
His Leu Gly 
235 
Arg Ser Ala 
250 
Phe Thr Asp 
265 
Ser Pro Thr 
Lys Lieu. Cys 









Thr Asp Ser 
Trp Glu His 
45 
Pro Tyr Gly 
60 
Val Asp His 
Phe Thr Wall 
Asp Gly Ser 
110 
Gly Lys Wall 
125 
Thr Ala Lys 
1 4 0 
Arg Asn Met 
Trp His Lys 
Arg Ser Val 
19 O 
Leu. His Wall 
2O5 
Lieu. Thir Lys 
220 
His Phe Tyr 
Pro Ala Arg 
Ile Asn Asp 
27 O 
Lys Asn Asp 
285 











































Asn Glu Lieu. His Arg Arg Lieu Ser Pro 
305 310 
Val His Pro Gly Asn Met Met Tyr Ser 
325 
Val Tyr Thr Leu Leu Phe Thr Leu Ala 
340 345 
Gln Glin Gly Ala Ala Thr Thr Val Tyr 
355 360 
Glu Gly Leu Gly Gly Met Tyr Phe Asn 
370 375 
Ser Pro Glu Ala Glin Ser Glu Glu Thr 
385 390 
Ser Glu Arg Lieu. Ile Glin Glu Arg Lieu 
405 
<210> SEQ ID NO 3 
&2 11s LENGTH 26 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 3 
acggtggtgg cagotc.cctg. ittgttg 
<210> SEQ ID NO 4 
&2 11s LENGTH 29 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 4 
acggtggtgg cagotc.cctg. ittgcgatgg 
<210 SEQ ID NO 5 
&2 11s LENGTH 33 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 5 
acggtggtgg cagotc.cctg. ittgacattct tog 
<210> SEQ ID NO 6 
&2 11s LENGTH 32 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 6 
acggtggtgg cagotc.cctg. ittgcc attct to 
<210 SEQ ID NO 7 
&2 11s LENGTH 30 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 7 
acggtggtgg cagotc.cctg. ittgctattoc 
<210 SEQ ID NO 8 
&2 11s LENGTH 33 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 

















US 7,060,811 B2 
-continued 
Wall Thir Ser Asn Ala 
320 
His Arg Ser Trp Trp 
335 
Phe Thr Lys Ser Met 
35 O 
Ala Wall Pro Glu Lieu 
365 
Cys Arg Cys Met Pro 
38O 
Thr Lieu Trp Ala Lieu 
400 









tgcgtgaggg gaCacacaca gg 
<210 SEQ ID NO 17 
&2 11s LENGTH 23 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 17 
gagttcct ga gcgagtggac cog 
<210> SEQ ID NO 18 
&2 11s LENGTH 30 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 18 
tagtttittat tattattagt titttattatt 
<210 SEQ ID NO 19 
<211& LENGTH 22 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 19 
aatact acat cottaaacaac aa 
<210> SEQ ID NO 20 
&2 11s LENGTH 30 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 20 
agtttittatt attatgagtt tittattaaat 
<210> SEQ ID NO 21 
&2 11s LENGTH 2.0 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
&220s FEATURE 
<221 NAME/KEY: modified base 
<222> LOCATION: (3) . . (5) 
&223> OTHER INFORMATION R = A OR G 
<400 SEQUENCE: 21 
ccrcircaata citacatcc ta. 
<210> SEQ ID NO 22 
&2 11s LENGTH 2.0 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
&220s FEATURE 
<221 NAME/KEY: modified base 
<222> LOCATION: (11) 
<223> OTHER INFORMATION: Y = C OR TWU 
<400 SEQUENCE: 22 
gggatgaggit yottttgttt 
<210> SEQ ID NO 23 
<211& LENGTH 24 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 23 










































































































SEQ ID NO 31 
LENGTH 
TYPE 

























SEQ ID NO 32 
LENGTH 
TYPE 





























Ala Gly Lieu 
Glu Glu Arg 
25 
Glu Glu Lys 
40 
Val Ala Gly 
55 
Gly Glin Val 
Asp Pro Arg 
Thr Arg Glin 
105 
Gly Arg Asp 
120 
Gly Ile Ala 
135 
Arg Thr Gly 
His Ala Lieu 
Gly Ala Glin 
185 
Leu Ser Gly 
200 
Ser Pro His 
215 
Thr Glin Ile 
Lys Asn Lieu 
Ser Leu Phe 
265 
Val Ala Cys 
280 
Ser Leu Glu 
295 
Ala 






















































































































































































































ORGANISM: Homo sapiens 
Leu Arg Tyr Ala Gly 
5 
Pro Gly. T 
2O 
rp Glu Glu 
Asn His Thr Glu Glu 
Asp Glu A 
Thr Tyr L 
85 
40 
rg Val Ala 
55 
sn Gly Glin 
70 
eu Asp Pro 
Lys Pro Thr Thr Arg 
100 
Ile Leu G 
Ala Asn. S 
Gly Ala H 
1 
Ala Wal S 
1.65 
ln Gly Arg 
120 
er Gly Ile 
135 
is Wal Ile 
50 
er Arg Ile 
Val Tyr Cys Ala Ala 
Phe Asn. A 
Glu Thir A 
Arg Lieu G 
2 




agCagg cqtg agcggtcgg 
sn Cys Cys 
200 
la Arg Thr 
215 
ly Ser Glin 
30 
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135 136 
-continued 
<400 SEQUENCE: 66 
gaatgtgttga gtgttcc 17 
<210 SEQ ID NO 67 
&2 11s LENGTH 17 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 67 
cc catcggtg g gtttga 17 
<210 SEQ ID NO 68 
&2 11s LENGTH 17 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 68 
gtocatggta agagaac 17 
<210 SEQ ID NO 69 
&2 11s LENGTH 30 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Peptide 
<400 SEQUENCE: 69 
Leu Pro Pro Gly Trp Glu Glu Arg Thr Thr Lys Asp Gly Trp Val Tyr 
1 5 10 15 
Tyr Ala Asn His Thr Glu Glu Lys Thr Glin Trp Glu His Pro 
2O 25 3O 
<210 SEQ ID NO 70 
&2 11s LENGTH 30 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Peptide 
<400 SEQUENCE: 70 
Leu Pro Tyr Gly Trp Glu Gln Glu Thr Asp Glu Asn Gly Glin Val Phe 
1 5 10 15 
Phe Val Asp His Ile Asn Lys Arg Thr Thr Tyr Leu Asp Pro 
2O 25 3O 
What is claimed is: 7. A method of preparing a recombinant polypeptide 
1. An isolated and purified polynucleotide comprising a comprising: 
nucleic acid sequence encoding SEQ ID NO:2. 2. The polynucleotide of claim 1, comprising SEQ ID ss (a) transfecting a cell with a polynucleotide comprising a 
nucleic acid sequence that encodes SEQ ID NO:2 to NO:1. 
3. An expression vector comprising a nucleic acid produce a transformed host cell; and 
sequence that encodes SEQ ID NO:2. (b) maintaining the transformed host cell under biological 
4. The expression vector of claim 3, wherein the nucleic conditions sufficient for expression of the polypeptide 
acid sequence comprises SEQ ID NO:1. 60 in the host cell. 
5. A The recombinant host cell comprising a nucleic acid 
since encoding a polypeptide that comprises SEQ ID se consiyT Sherein the nucleic acid 
6. The recombinant host cell of claim 5, wherein the 
nucleic acid sequence comprises SEQ ID NO:1. k . . . . 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 7,060,811 B2 Page 1 of 1 
APPLICATIONNO. : 09/978318 
DATED : June 13, 2006 
INVENTOR(S) : Aldaz et al. 
It is certified that error appears in the above-identified patent and that said Letters Patent is 
hereby corrected as shown below: 
In claim 5, column 135, line 61, delete “A The and insert --A-- therefor. 
Signed and Sealed this 
Twelfth Day of September, 2006 
WDJ 
JON. W. DUDAS 
Director of the United States Patent and Trademark Office 
